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Body mass varies considerably between different mammals and this variation is 
largely accounted for by a difference in total cell number rather than individual cell 
size.  Insights into mechanisms regulating growth can therefore be gained by 
understanding what governs total cell number at any one point.  In addition, control 
of cell proliferation and programmed cell death is fundamental to other areas of 
research such as cancer and stem cell research.  Microcephalic Primordial Dwarfism 
(MPD) is a group of rare Mendelian human disorders in which there is an extreme 
global failure of growth with affected individuals often only reaching a height of 
around one metre in adulthood.  To date, all identified disease genes follow an 
autosomal recessive mode of inheritance and encode key regulators of the cell cycle, 
where mutations impact on overall cell number and result in a substantially reduced 
body size.  MPD therefore provides a valuable model for examining genetic and 
cellular mechanisms that impact on growth.  The overall aims of this thesis were to 
identify novel disease causing genes, as well as provide further characterisation of 
known disease causing genes, through the analysis of whole exome sequencing 
(WES) within a large cohort of MPD patients.  Following the design and 
implementation of an analytical bioinformatics pipeline, deleterious mutations were 
identified in multiple disease genes including LIG4 and XRCC4.  Both genes encode 
components of the non-homologous end joining machinery, a DNA repair 
mechanism not previously implicated in MPD.  Additionally, the pathogenicity of 
novel mutations in subunits of a protein complex involved in chromosome 
segregation was assessed using patient-derived cells.  These findings demonstrate 
WES can be successfully implemented to identify known and novel disease causing 
genes within a large heterogeneous cohort of patients, expanding the phenotype of 
known disorders and improving diagnosis as well as providing novel insights into 
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Chapter 1: Introduction 
1.1 Overview of microcephalic primordial dwarfism (MPD) 
1.1.1 Definition 
Primordial dwarfism refers to a group of rare Mendelian disorders characterised by 
an extreme failure of growth of prenatal onset with affected individuals often only 
reaching a height of around one metre in adulthood .  Characteristically growth 
failure is global and so although height is severely reduced body proportions 
generally remain unchanged with a uniform reduction in body size (McKusick, 1955) 
(Figure 1.1).  This distinguishes primordial dwarfism from other, more common 
causes of dwarfism, such as skeletal dysplasias (disorders of bone and cartilage 
growth) which typically result in an isolated reduction of limb length with relative 
preservation of head and torso size (Trotter et al., 2005).  Additionally in primordial 
dwarfism, head size is often severely reduced as a consequence of reduced brain 
growth (microcephalic primordial dwarfism, MPD) (Seckel, 1960).  This can be in 
proportion to body size or disproportionately smaller (Klingseisen et al., 2011).  The 
presence of microcephaly distinguishes MPD from other short stature syndromes 
with relative macrocephaly but with a relative proportionate reduction in limb length 
and body size such as Russell Silver syndrome, SHORT syndrome and 3M syndrome 
(Wakeling et al., 2010, Huber et al., 2011, Dyment et al., 2013). 
Another key feature of MPD is the presence of intrauterine growth restriction 
(IUGR) demonstrating growth failure is prenatal in onset (Seckel, 1960).  This 
differentiates MPD from growth failure in which onset only occurs postnatally.  
Affected patients are therefore much smaller at birth than expected for their 
gestational age.  The exact timing of the onset of growth failure in MPD is unknown 
and likely to be variable but may be evident on antenatal ultrasound scans from as 
early as the first trimester (Mirzaa et al., 2014).  Thus MPD can be defined as a 
severe and global failure in growth occurring prior to birth resulting in a reduction in 




Figure 1.1.  Comparison of body proportions in different disorders of dwarfism 
In MPD there is a global failure in growth resulting in an overall smaller body size with normal 
proportions (proportionate dwarfism).  In achondroplasia (a common skeletal dysplasia), limb length 
is reduced disproportionately compared to head and torso (disproportionate dwarfism).  Average 
height and OFC measurements are shown for an unaffected adult male, an adult male with 
achondroplasia (Horton et al., 1978) and an adult with microcephalic osteodysplastic primordial 
dwarfism type II (MOPDII, the most common form of MPD, see Section 1.1.4.3) (Bober et al., 2012).   
1.1.2 Diagnostic criteria  
Weight, height and head circumference are typical parameters used in the clinical 
setting to determine the general status of growth during childhood (Rogol et al., 
2014).  However, a quantitative definition of MPD is lacking from older studies 
(McKusick, 1955, Seckel, 1960).  Across a healthy population growth parameters 
display a normal distribution with 99.73% of individuals falling within 3 s.d. of the 
population mean (Cole, 2012).  Given that MPD is a disorder of extreme growth 
failure, we have used postnatal growth parameters (OFC and height) of at least 4 s.d. 
below the population mean to classify patients with MPD (Klingseisen et al., 2011).  
This is keeping with the human phenotype ontology database (Kohler et al., 2014) 
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which uses -4 s.d. to define severe short stature with less than 0.1% of the population 
falling into this group.   
1.1.3 Aetiology  
Many factors, both environmental and genetic, impact on growth either in utero or 
postnatally.  These include nutritional deficiencies, metabolic diseases, infection, 
endocrine disorders, emotional neglect, chronic disease and drugs including both 
illegal and prescribed (Rogol et al., 2014).  In fact any disease process can hinder 
growth in childhood by diverting energy to another cause (Hochberg et al., 2008).  
However, the rapidly increasing identification of disease causing genes in patients 
with MPD (O'Driscoll et al., 2003, Rauch et al., 2008, Al-Dosari et al., 2010, 
Bicknell et al., 2011a, Bicknell et al., 2011b, Edery et al., 2011, Guernsey et al., 
2011, He et al., 2011, Kalay et al., 2011, Qvist et al., 2011, Ogi et al., 2012) 
indicates growth impairment to such an extreme degree is primarily of genetic origin, 
most commonly a single gene disorder of autosomal recessive inheritance.   
1.1.4 Spectrum of phenotypes   
Although a diagnosis of MPD can be made based on an individual’s growth 
parameters, a large degree of clinical heterogeneity is still apparent between 
individuals that fall within this group (Figure 1.2) reflecting large underlying genetic 
heterogeneity. Several distinct disease entities have now been described.  
1.1.4.1 Seckel syndrome (MIM 210600) 
In 1960, Seckel described a group of 15 patients with MPD (Seckel, 1960), which he 
then termed as ‘bird headed dwarfism’ or ‘nanocephalic dwarfism’ due to the 
significantly sloping forehead, large beaked nose and micrognathia (small chin) 
observed in these patients (Figure 1.2A).  Growth retardation was prenatal in onset 
presenting with reduced growth parameters at birth.  Postnatal growth continued to 
be poor in affected cases with significant developmental delay.  Seckel’s paper led to 
MPD being initially designated as ‘Seckel syndrome’ which is often still used 
interchangeably with the term ‘MPD’ particularly where a molecular diagnosis has 
not yet been ascertained (Sarici et al., 2012).  Large clinical heterogeneity therefore 
exists between many cases originally designated as Seckel syndrome however with 
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improving knowledge of different clinical phenotypes and corresponding molecular 
defects several cases have since been reclassified (Willems et al., 2010).  Classical 
‘Seckel syndrome’ is now often restricted to cases with severe pre- and post-natal 
microcephaly which is disproportionately more severe than short stature, typical 
facial features as described above and significant cognitive impairment (Faivre et al., 
2002).  
Figure 1.2.  Clinical heterogeneity in MPD 
Clinical photographs of patients with MPD with differing distinctive features.  A) A patient with 
Seckel syndrome demonstrating microcephaly with characteristic sloping forehead and large beaked 
nose (Goodship et al., 2000).  B) Two unrelated patients with MOPDI at i) 6 months (Nagy et al., 
2012) and ii) 3 years (Abdel-Salam et al., 2011) with sparse hair, prominent eyes, cerebral 
malformations, severe developmental delay and joint deformities.  C) A patient with Meier-Gorlin 
syndrome characterised by microtia and patella hypoplasia (de Munnik et al., 2012).  D) i) A patient 
with MOPDII and typical facial features including long nose with overhanging columella, hypoplastic 
alae and micrognathia (Hall et al., 2004), ii) Typically, patients with MOPDII also have severe 
microdontia and abnormally shaped teeth (Kantaputra et al., 2011). iii) Angiogram demonstrating 
aneurysm of the posterior inferior cerebellar artery (black artery) in a patient with MOPDII (Bober et 
al., 2010).  MOPDII patients have an increased risk of cerebral vascular malformations. 
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1.1.4.2 Microcephalic Osteodysplastic Primordial Dwarfism Type I 
(MOPDI, MIM 210710) 
MOPDI was first recognised as a distinct phenotype in 1967 (Taybi H & Linder D, 
1967) and initially designated as Taybi-Linder syndrome.  In an attempt to further 
delineate the phenotypes which were falling under the umbrella of ‘Seckel 
syndrome’, Majewski characterised MPD into three subgroups which he termed as 
Majewski osteodysplastic primordial dwarfism types I, II and III (Majewski et al., 
1982a, Majewski et al., 1982b, Majewski et al., 1982c).  It soon became clear that 
Taybi-Linder syndrome and Majewski’s MOPD type I and type III referred to the 
same disorder (Sigaudy et al., 1998).  For the purposes of this thesis this distinct 
subgroup of MPD will be referred to as MOPD type I.   
MOPDI is characteristically associated with significant neurodisability and many do 
not survive beyond one year of age (Nagy et al., 2012).  Patients exhibit severe 
growth failure at birth with profound microcephaly (average weight and OFC at birth 
is -5 s.d. and -7 s.d. respectively).  Structural brain abnormalities are common, 
especially neuronal migration defects such as agenesis of the corpus callosum, gyral 
abnormalities and heterotopias (Meinecke et al., 1991, Sigaudy et al., 1998, Klinge 
et al., 2002, Pierce et al., 2012).  Consequently, severe developmental delay is 
common with accompanying seizures.  Additionally, hypoplastic optic discs and 
Mondini malformations have also been reported resulting in vision and hearing 
impairment (Pierce et al., 2012).  Typical facial features include prominent eyes and 
an elongated, prominent nose (Figure 1.2B) (Edery et al., 2011, Nagy et al., 2012).  
Dry, aged-appearing skin and sparse hair are also characteristic along with skeletal 
abnormalities including joint dislocations, contractures, horizontal acetabulum, 
abnormal vertebrae, bowed long bones, elongated clavicles and delayed bone age 
(Sigaudy et al., 1998).  Recent identification of the underlying genetic aetiology in 
MOPDI has expanded the clinical spectrum of this disorder (see Section 1.3.4) and 
patients with milder growth and neurodevelopmental phenotypes have also been 
described (Abdel-Salam et al., 2012) (Figure 1.2B). 
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1.1.4.3 Microcephalic Osteodysplastic Primordial Dwarfism Type 
II (MOPDII, MIM 210720) 
Majewski’s MOPD type II represents the most common and well characterised 
subgroup of MPD patients.  MOPDII is characterised by a proportionate reduction in 
both head circumference and height to at least 5 s.d. below the population mean 
(average adult height -10 s.d. and OFC -8.5 s.d.) (Bober et al., 2012).  There is a 
characteristic facial appearance and body habitus with long nose, prominent nasal tip, 
hypoplastic alae, small mandible and mild truncal obesity (Figure 1.2C) (Rauch et 
al., 2008).  Skeletal abnormalities are typical and include gracile long bones, carpal 
fusion, brachydactyly, delayed bone age and hip deformities such as coxa vara and 
slipped epiphysis (Willems et al., 2010, Karatas et al., 2014).  Intelligence is 
predominantly normal with only mild learning difficulties (Hall et al., 2004).  There 
is often severe microdontia with malformed teeth that can lack roots (Kantaputra et 
al., 2011).  There is also an increased incidence of early onset insulin resistance 
(Huang-Doran et al., 2011).   
Of most significance to affected families is the increased incidence of neurovascular 
complications predominantly cerebral aneurysms and vascular stenosis resulting in 
moya moya disease (30-50% of cases) (Brancati et al., 2005, Bober et al., 2010, 
Perry et al., 2013), both of which impact on life expectancy.  Awareness of this has 
led to the recommendation that screening with Magnetic Resonance Angiography 
(MRA) should be undertaken every 1-2 years as early intervention is likely to 
improve function and survival although long term follow up studies are not yet 
available (Perry et al., 2013).   
1.1.4.4 Meier-Gorlin Syndrome 
Meier-Gorlin syndrome (MGS) is characterised by a triad of growth failure, microtia 
and hypoplastic or absent patella (Gorlin et al., 1975).  Other malformations have 
also been described including cortical hypoplasia and lobar congenital emphysema as 
well as musculoskeletal abnormalities (clindactyly, hypermobility, slender long 
bones, dislocated joints, contractures, delayed bone age) and urogenital tract 
anomalies (micropenis, hypospadias, cryptorchidism, hypoplastic labia, 
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clitoromegaly) (Bongers et al., 2001, de Munnik et al., 2012).  Additionally, failure 
of development of secondary sexual characteristics, particularly breast development, 
is often a feature.  Patients also have similar facial characteristics which include 
microstomia and full lips with a prominent narrow convex nose becoming more 
apparent with age (Figure 1.2C) and intellect is usually normal.  Although MGS is 
considered a subgroup of MPD, less severe growth failure has been reported in 
affected patients and growth parameters may even be within normal range (Bicknell 
et al., 2011a). 
1.1.4.5 Other disorders which overlap MPD 
1.1.4.5.1 Syndromic conditions affecting global growth 
A proportionate reduction in growth of prenatal onset is a common observation in 
many genetic disorders (Online Mendelian Inheritance in Man, OMIM®) but few are 
associated with consistent growth failure that falls with the defined range of MPD 
(Figure 1.3).  Therefore many syndromes are predominantly characterised on the 
basis of other, more distinguishing features such as the presence of malformations or 
distinctive dysmorphic features and the degree of growth failure is often poorly 
quantified.  However, patients presenting with microcephaly and short stature within 
the defined MPD range (Section 1.1.2) have been described in several disorders 
including Bloom’s syndrome, Wolf-Hirschhorn syndrome and Cohen syndrome 
(Keller et al., 1999, Hennies et al., 2004, Antonius et al., 2008). 
1.1.4.5.2 Autosomal recessive primary microcephaly (1° MCPH) 
In 1° MCPH there is an isolated reduction in brain volume of prenatal onset to 
around a third of its normal size comparable to that observed in early humans 
(Woods et al., 2005).  Although the brain is small, often with a simplified gyral 
pattern, its structure remains otherwise normal (Mahmood et al., 2011).  Patients 
have a variable degree of intellectual disability but usually no neurological deficit.  
This is very similar to many patients with MPD however height is either within 
normal range or mildly reduced.  The discovery of overlapping genetic aetiologies in 
MPD and 1° MCPH (see Section 1.3) has led to the hypothesis that these two 
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disorders represent opposing ends of the same clinical spectrum (Klingseisen et al., 
2011). 
 
Figure 1.3.  Graphical demonstration of overlapping growth distributions in 
MPD and other developmental disorders 
Growth within a population is normally distributed.  MPD is defined as height and OFC below -4 s.d. 
and therefore growth distribution in patients is below this threshold (red).  However, the growth 
distribution for many other developmental disorders also lies below that of the normal population 
(blue) but is not reduced to the degree seen in MPD.  Although mean height and OFC in many such 
disorders does not fall below -4 s.d., patients at the extreme ends of the corresponding growth 
spectrum can fall into the defined range for MPD (hashed region). 
 
1.2 Mechanisms governing body size  
For many years, there has been much interest in how organism size is determined 
although little is still known as to how this is so accurately regulated.  For example, 
how do different organisms attain reproducible sizes whilst ensuring body 
proportions are consistently maintained?  Body size is a reflection of total cell mass 
which in turn is determined by the number of cells and their individual size (Conlon 
et al., 1999).  A high degree of regulation of both cell growth and division must 
therefore exist in order to achieve a finite and consistent growth of different organs 
as well as the organism as a whole.  Perturbation of any cellular mechanisms 




Variation in body size between different mammals appears to be predominantly 
determined by cell number rather than cell size.  This is illustrated by the 2800 fold 
difference in mass between a 70 kg human and a 25 g mouse which is largely 
accounted for by a similar fold difference in cell number with little variation in cell 
size (Conlon et al., 1999).  Cell size and cell number however, are intrinsically 
linked as proliferating cells are required to grow in mass prior to division in order to 
duplicate their content (Coelho et al., 2000).   In yeast, specific checkpoints through 
the cell cycle ensure that a minimum threshold in size is reached before the cell 
divides (Jorgensen et al., 2004) and a similar mechanism may be in place in 
metazoans (Tzur et al., 2009).  Cells such as muscle and nerve cells can also 
continue to grow after they have ceased proliferating (Conlon et al., 1999) but size 
regulation clearly exists at both organ and global levels ensuring growth does not 
exceed a set point.  A balance must therefore occur between those factors which 
stimulate growth and promote cell survival and those which restrict final cell number 
and size.   
The number of cells at any one point is a product of the rate at which cells are 
dividing minus the rate of cell death (Conlon et al., 1999).  Rate of cell division (or 
cell proliferation) is governed extrinsically by mitogens but also requires the cells 
intrinsic ability to undergo mitotic division and respond to both internal and external 
regulatory factors appropriately.  A similar degree of complexity is also apparent in 
the control of cells undergoing programmed cell death (apoptosis) and those which 
become terminally differentiated having exited the cell cycle (Fuchs et al., 2011). 
1.2.1 Signalling pathways promoting cell growth and 
proliferation 
1.2.1.1 Mitogen activated protein kinase (MAPK) pathways 
Mitogens, which include growth factors, hormones, cytokines and environmental 
stresses, promote cell growth and proliferation by signalling through mitogen 
activated protein kinase (MAPK) pathways (Krishna et al., 2008).   Together these 
pathways coordinate the responses to a wide range of external and internal stimuli 
and can impact on many cellular processes including gene expression, cell 
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metabolism, motility, apoptosis and differentiation.  The mammalian MAPK 
extracellular regulated kinase 1 and 2 pathway (MAPK-ERK1/2) (Figure 1.4) has 
been specifically identified as a central regulator of cell proliferation by promoting 
the progression of the cell cycle from G1 phase to S phase through several 
mechanisms (Meloche et al., 2007).  Over 150 downstream phosphorylation targets 
of ERK have been identified (Krishna et al., 2008).  These include D-type cyclins 
which drives G1/S transition (Liu et al., 1995, Sherr, 1995, Winston et al., 1996) and 
the transcription factor c-myc which up regulates the expression of several genes 
such as translation initiation factors, ribosomal proteins and cyclins (Bouchard et al., 
1999, Hermeking et al., 2000, Sears et al., 2000, Adhikary et al., 2005) promoting 
cell growth and proliferation.  ERK activation also decreases expression of 
antiproliferative genes (Yamamoto et al., 2006) and possibly the cyclin dependent 
kinase inhibitor p27 (Meloche et al., 2007) further contributing to cell cycle 
progression. 
1.2.1.2 Insulin-like growth factor (IGF) signalling   
The IGF system is critical in growth both in utero and throughout childhood.  Two 
insulin-like growth factors exist, IGF-I and IGF-II, which are secreted in an autocrine 
or paracrine fashion from most tissues during fetal life (Han et al., 1988) in response 
to nutritional factors (Hietakangas et al., 2009).  In the postnatal period, production is 
predominantly via the liver (Yakar et al., 1999) and largely under the control of 
growth hormone (GH) (Roberts et al., 1987).  Both IGF-I and -II activate 
Phosphotidyl-inosine-3 kinase (PI3K) signalling via the type 1 IGF receptor (IGF1R) 
present on all cell types (Siddle, 2011).  Downstream targets include the master 
kinase target of rapamycin (TOR) which also integrates with other signalling 
pathways to modulate cell growth (Thomas et al., 1997).  Consequences of TOR 
activation include increased protein synthesis by initiating translation as well as 
preventing protein degradation and promoting ribosome biogenesis.   
Disruption of the IGF system therefore results in a significant reduction in growth.  
Deficiency of growth hormone is characterised by a postnatal failure in growth 
whereas deficiency of IGF1 or IGF-1R results in both pre and post-natal growth 
failure in mice (Liu et al., 1993) and humans (Walenkamp et al., 2013) similar to 
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MPD.  Investigation of IGF function in MPD patients has been advocated as growth 
hormone replacement therapy can improve growth in this patient group (Woods et 
al., 2000).  Interestingly, IGF-2 deficiency also results in growth failure of pre-natal 
onset but with relative preservation of head size (Russell-Silver syndrome) (Netchine 
et al., 2007) possibly reflecting a tissue specific role during fetal development (Han 
et al., 1988).   
Although described separately a large degree of cross talk occurs between these 
signalling pathways (Mendoza et al., 2011).  IGF1R signalling can also activate 
MAPK pathways (King et al., 1997) whereas ERK1/2 can activate TOR through 
phosphorylation (Carriere et al., 2008). 
1.2.2 Signalling pathways negatively regulating proliferation 
In mammals, the Hippo pathway is the least well characterised of the three major 
signalling pathways but plays an important role in the control of organ size through 
the modulation of cell proliferation, migration, differentiation and apoptosis (Pan, 
2007).  Dysregulation of the Hippo pathway results in abnormal growth with organ 
overgrowth and tumorigenesis (Dong et al., 2007).  Core components of the Hippo 
pathway include the STE20 protein family kinases, Mst-1 and -2 (Harvey et al., 
2003) which activate the nuclear Dbf2-related (NDR) family protein kinases, Lats -1 
and -2 (Justice et al., 1995, Xu et al., 1995, Wu et al., 2003).  The major downstream 
effectors of the Hippo pathway are the transcriptional coactivators YAP (Yes-
associated protein) and its paralog TAZ (Lei et al., 2008) which are inhibited through 
their phosphorylation by Lats kinase (Dong et al., 2007).  This prevents their 
accumulation in the nucleus where they associate with the TEAD family of DNA 
binding proteins inducing gene expression and promoting cell proliferation and 
survival (Ota et al., 2008, Zhao et al., 2008).  In Drosophila, two proteins whose 
levels are decreased by Hippo signalling include cyclin E and DIAP1 (Tapon et al., 
2002) which negatively regulate cell cycle exit (Knoblich et al., 1994) and apoptosis 
(Wang et al., 1999) respectively.  Reduced expression of bantam mRNA, another 
regulator of proliferation and apoptosis, has also been shown in Drosophila 
melanogaster (Peng et al., 2009).  Thus the net effect of the Hippo pathway 
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following Mst and Lats kinase activation is suppression of growth by inhibiting 
proliferation and promoting apoptosis and differentiation.   
Upstream regulators of the Hippo pathway so far identified include the cell surface 
protocadherins, Fat and Dachsous (Bennett et al., 2006) and other apical membrane 
proteins including Crumbs (Chen et al., 2010), Merlin, Expanded and Kibra 
(Genevet et al., 2011) indicating that cell to cell interactions and cell polarity are 
important in governing this pathway.  YAP/TAZ activity is also influenced directly 
by changes in mechanical tension through the F-actin cytoskeleton (Aragona et al., 
2013) and recent evidence has also shown Lats activity can either be activated or 
suppressed in response to different extracellular signals through G-protein coupled 
receptors (Yu et al., 2012).  In addition, the Hippo pathway can impact on the 
regulation of other key signalling pathways controlling tissue morphogenesis 
including Wnt, TGF-β, Sonic Hedgehog (Shh) and Notch pathways (Alarcon et al., 
2009, Varelas et al., 2010, Zhao et al., 2010, Heallen et al., 2011).  Changes in levels 
of morphogens which regulate these pathways governing the patterning of tissue 
during development can have large effects on organ size demonstrating such 

















Figure 1.4.  Signalling pathways regulating growth 
1) Mitogens stimulate proliferation through the MAPK-ERK1/2 pathway.  Activation of specific cell 
surface receptors (Goldsmith et al., 2007, McKay et al., 2007) recruit the nucleotide exchange factor, 
SOS (son of sevenless), activating the GTPase, Ras (Thomas et al., 1992, Margarit et al., 2003).  The 
subsequent Raf activation phosphorylates MEK1/2 (Kyriakis et al., 1992) which in turn 
phosphorylates ERK1/2 (Robinson et al., 1996) promoting cell cycle progression through a variety of 
substrates including c-myc and D-cyclins.  2) IGF signalling activates PI3K which results in the 
sequential phosphorylation of AKT and TOR (Burgering et al., 1995, Scott et al., 1998).  TOR 
activation has multiple downstream effects culminating in increased cell growth and proliferation.  
PTEN, whose dysfunction is associated with overgrowth, inhibits AKT activation thus suppressing 
growth (Mester et al., 2013).  3) Activation of the Hippo pathway suppresses growth through 
inhibition of the transcriptional regulator YAP/TAZ (see Section 1.2.2 for details).  As well as cell to 
cell contact, MST1/2 activity can also be modified by signalling induced by various stimuli through G 
protein coupled receptors.  Abbreviations: RTK=receptor tyrosine kinase, GPCR=G protein coupled 
receptor, Dachs=Dachsous.  
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1.2.3 ‘Hypocellular’ hypothesis of MPD 
It has been hypothesised that MPD is a condition of hypocellularity in which there is 
an overall reduction in cell number resulting in a smaller, but still proportionate 
person (Delaval et al., 2008, Rauch et al., 2008, Klingseisen et al., 2011).  In support 
of this hypothesis, the majority of disease genes so far identified in MPD have clear 
roles in cell cycle regulation (Section 1.3).  Typically in affected patients neither 
increased nutritional support nor growth hormone administration have any impact on 
final body mass (Rauch, 2011) suggesting that cell growth is unable to be pushed 
beyond a particular threshold.  Small changes in the rate of cell division can have a 
profound impact on the total cell number, for example, a cell which undergoes five 
rather than seven rounds of division will result in a four fold difference in final cell 
number (Klingseisen et al., 2011) (Figure 1.5).   This difference is then magnified 
with increasing rounds of division.  The impact of altered proliferation and apoptosis 
on size has been demonstrated experimentally in embryonic mouse brains where 
inhibiting cell death or increasing neural progenitor proliferation both resulted in a 
dramatic increase in brain size (Kuida et al., 1998, Chenn et al., 2002).  1° MCPH is 
similarly thought to be due to reduced cell number arising from reduced expansion of 
the neural progenitor pool, either through premature neuronal differentiation or 
increased cell death, resulting in an isolated reduction in brain size (Mochida et al., 
2001).  
1.2.4 Summary 
Growth is controlled by a complex interplay of numerous pathways and mechanisms.  
Abnormalities in growth regulation are critical to many disease processes, most 
notably malignancy, therefore understanding which biological mechanisms govern 
body size and how is important to many areas of research.  In MPD both pre- and 
post-natal growth is globally reduced as the result of a single gene defect.  
Identifying the molecular cause and the resulting impact on cellular processes in 
affected cases will give further insights into mechanisms critical in ensuring normal 
growth from early embryogenesis. Thus MPD provides us with a useful human 
33 
 
model for investigating growth.  The next Section details the disease causing genes 
so far identified in MPD and their associated function.   
 
Figure 1.5.  Impact on cell number by reduction in rate of cell division  
In mammals, difference in body size is largely accounted for by a difference in cell number rather than 
cell size.  Small differences in the number of cell divisions can have large impacts on final cell 
number and consequently body size.  Reproduced from Klingseisen et al., (2011). 
 
1.3 Cellular mechanisms identified in MPD 
Several genes have now been identified in MPD which act downstream of the 
pathways discussed in Section 1.2 and encode proteins integral to the cell cycle 
machinery.  This includes centrosomal proteins with roles in the faithful segregation 
of chromosomes during mitosis (CEP152, CENPJ and PCNT) as well as those 
involved in DNA damage response and repair (ATR and RBBP8) which regulate cell 
cycle progression in order to maintain genomic integrity.  Others are required for 
DNA replication (ORC1, ORC4, ORC6, CDC6 and CDT1) and mRNA splicing 
(RNU4ATAC) although it is still currently unclear exactly how the latter impacts on 
cell cycle dynamics.   
34 
 
1.3.1 Centrosomal proteins 
1.3.1.1 Centrosome structure and replication 
The centrosome is a key organiser of the microtubule cytoskeleton integral to cell 
motility, adhesion, polarity and organelle transport as well as mitotic spindle poles 
(Badano et al., 2005).  Centrosomes are composed of two centrioles surrounded by a 
matrix of pericentriolar material (PCM) (Figure 1.6A) (Paintrand et al., 1992).  The 
two centrioles each consist of a barrel of nine microtubule triplets and are linked by 
fibres with one daughter (younger) centriole sitting in perpendicular orientation to 
the mother centriole.  The older, mother centriole has subdistal and distal appendages 
to which microtubules are anchored (Piel et al., 2000).  During each cell cycle, the 
centrosome is replicated through the duplication of the centrioles, a process that only 
occurs once and is intricately linked to cell cycle progression (Figure 1.6B) (Robbins 
et al., 1968).  The process of centriole duplication involves four stages (Azimzadeh 
et al., 2010).  First the two centrioles disengage at the end of mitosis followed by 
nucleation of new daughter centrioles proximal to each mother centriole in G1-S 
phase.  The daughter centrioles then elongate and mature in S-G2 phase before the 
two new centriole pairs separate.  Each pair therefore contains an older ‘mother’ and 
younger ‘daughter’ centriole.  The youngest set of centrioles then moves to the basal 
aspect of the cell where it gathers pericentriolar material forming a second 





Figure 1.6.  Centrosome structure and replication 
A) Each centrosome consists of two centrioles composed of nine microtubule repeats.  Subdistal and 
distal appendages exist on the mother centriole through which microtubules are attached.  The 
centrioles are attached through interlinking fibres and surrounded by the pericentriolar matrix (PCM).  
B) Each cell contains one centrosome which is replicated once each cell cycle.  Initially the two 
centrioles (dark green) disengage on mitotic exit, followed by nucleation of two daughter centrioles 
(light green) in G1 and S phase.  The new procentrioles are then elongated in S and G2 phase followed 
by separation of the two pairs to opposite ends of the cell and formation of the mitotic spindle 






1.3.1.2 Centrosome function in the cell cycle 
During interphase, proteins in the pericentriolar material nucleate a large number of 
surrounding microtubules which contribute to the formation of the mitotic spindle 
apparatus (Luders et al., 2007, O'Connell et al., 2007).  This apparatus consists of a 
system of microtubules attached to the centrosome at one end and the kinetochore, a 
protein structure located at each centromere of centrally aligned chromosomes, at the 
other.  This enables the separation of sister chromatids by forces generated through 
these microtubules which pull the chromosomes to opposite ends of the cell prior to 
cytokinesis.  Centrosomes therefore contribute to the formation, organisation and 
subsequent orientation of the mitotic spindle apparatus (Rebollo et al., 2007, Rusan 
et al., 2007).  The latter determines the plane of cleavage through which the cell 
divides (cytokinesis) which contributes to cell fate determination in certain stem cell 
populations (Yamashita et al., 2007).  Although microtubule arrays can form in the 
absence of centrosomes and cell division can still be completed (Khodjakov et al., 
2001), disrupting centrosome replication has been shown to result in aberrant cell 
divisions.  In Drosophila, failure in centriole duplication results in slower mitotic 
spindle assembly and prolonged mitosis as well as abnormal cytokinesis (Basto et 
al., 2006) whereas centrosome amplification (more than two centrosomes at mitosis) 
results in the formation of multipolar spindles and genome instability (Ko et al., 
2005, Loncarek et al., 2008, Li et al., 2014a). 
Experiments in which the centrosome has been excised from the cell altogether 
results in G1 arrest (Hinchcliffe et al., 2001, Khodjakov et al., 2001) indicating 
centrosomes also play a role in cell cycle progression.  In fact, centrosomes act as a 
platform for over 100 regulatory proteins (Doxsey et al., 2005) including cyclin E 
which is required for G1 to S phase transition (Matsumoto et al., 2004) and possibly 
CHK1, a cell cycle checkpoint kinase which inhibits G2 to M transition in response 
to DNA damage signalling (Kramer et al., 2004, Loffler et al., 2007).  Thus 




1.3.1.3 PCNT in MOPDII 
Biallelic truncating mutations in Pericentrin (PCNT) have so far been identified as 
the sole cause of MOPDII with large numbers of patients now reported (Griffith et 
al., 2008, Rauch et al., 2008, Willems et al., 2010).  PCNT is a well conserved large, 
coiled coil protein and a core component of the PCM (Flory et al., 2000).  It acts as a 
multifunctional scaffold protein anchoring other important centrosomal proteins 
including the microtubule nucleating protein γ-tubulin (Doxsey et al., 1994, 
Dictenberg et al., 1998, Zimmerman et al., 2004).  Loss of PCNT therefore results in 
the depletion of such proteins from the centrosome and consequently defects in the 
mitotic spindle apparatus.  In keeping with this role, patient cells lacking PCNT show 
reduced γ-tubulin at spindle poles, disorganised mitotic spindles, chromosome 
misalignment and abnormal cytokinesis (Figure 1.7) (Griffith et al., 2008, Rauch et 
al., 2008).  Additionally, premature sister chromatid separation was observed 
suggesting PCNT also contributes to the spindle assembly checkpoint (SAC) which 
ensures chromosomes are correctly attached to the mitotic microtubules in metaphase 
prior to segregation.  Such mitotic failure is likely to result in reduced cell 
proliferation and/or increased cell death leading to a reduction in overall cell number 
(Delaval et al., 2010).   
PCNT, in combination with microcephalin (MCPH1), is also thought to recruit the 
cell cycle checkpoint kinase, CHK1 to the centrosome (Tibelius et al., 2009).  RNAi 
depletion of PCNT in cells results in loss of CHK1 from the centrosome, premature 
mitotic entry, delayed mitosis and increased cell death.  In keeping with a role in 
CHK1-mediated cell cycle regulation, PCNT-deficient patient cells also show 
defective G2/M checkpoint arrest in response to UV-induced DNA damage and 
therefore ATR-dependent signalling may also contribute to growth failure (Griffith et 
al., 2008, Tibelius et al., 2009).  
Although aberrant mitosis and impaired DNA damage signalling may well be 
responsible for the global growth failure seen in MOPDII patients, mechanisms 
underlying the other associated features in this syndrome (insulin resistance, 
cerebrovascular malformations) are less clear and may indicate additional cellular 






Figure 1.7.  Mitotic abnormalities in patient fibroblasts lacking PCNT 
Immunofluorescence images of mitotic cells.  PCNT stained red, microtubules green and 
chromosomes blue.  Mitotic cell from a healthy individual shown in A) interphase, B) metaphase, C) 
anaphase and D) during cytokinesis.  In comparison, E-L represents images of MOPDII patient cells 
in which there is no detectable PCNT at the centrosomes.  Patient cells displayed disorganised mitotic 
microtubules (I, F, J and G), abnormal alignment in metaphase (J) and disorganised cytokinesis (H, K 
and L).  Reproduced from Rauch et al., (2008). 
1.3.1.4 Centriole duplication proteins in Seckel syndrome 
Mutations in two genes encoding proteins essential to centriole duplication have been 
described in Seckel syndrome patients; Centrosomal protein of 152kDa (CEP152) 
and centromere protein J (CENPJ) (Al-Dosari et al., 2010, Kalay et al., 2011).  
Mutations in both genes have also been identified in patients with 1° MCPH (Bond et 
al., 2005, Guernsey et al., 2010).  To date few mutations have been identified in 
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CEP152 in MPD including a founder intronic variant (c.261+1G>C) within several 
families of Turkish ancestry which disrupts transcript splicing (Kalay et al., 2011).  
Patient cells deficient in CEP152 displayed delayed cell cycle progression and 
numerous mitotic abnormalities including multiple and fragmented centrosomes, 
incorrectly aligned chromosomes, premature separation of sister chromatids and 
monopolar spindles (Kalay et al., 2011) .  Only one mutation in CENPJ has been 
reported to date in association with Seckel syndrome, c.3302-1G>C (Al-Dosari et al., 
2010).  This was identified in multiple affected individuals from a Middle-Eastern 
family with anthropometric measurement of -7 s.d. or less in all cases.  The mutation 
was shown to alter mRNA splicing although no further characterisation of patient 
cells was performed.   
CEP152 acts as a centrosomal scaffold for key regulators of centriole biogenesis 
including the polo-like kinase 4 protein (PLK4) and CENPJ (Kim et al., 2013).  
Recently, mutations in PLK4 have been identified in patients with MPD and 
retinopathy (Martin et al., 2014).  The authors also observed a similar phenotype in 
several patients with mutations in the tubulin, gamma complex associated protein 6 
(TUBGCP6) which has previously been associated with microcephaly and 
retinopathy (Puffenberger et al., 2012).  TUBGCP6 is phosphorylated by PLK4 and 
is required for assembly of the γ-tubulin ring complex which nucleates microtubules 
in centriole biogenesis and formation of the mitotic spindle (Bahtz et al., 2012).   
1.3.1.5 Other mitotic spindle proteins implicated in MPD 
Biallelic nonsynonymous mutations have recently been reported in CENPE 
(centromere-associated protein E) in a patient with MPD also exhibiting severe 
developmental delay, neurological abnormalities and congenital restrictive 
cardiomyopathy (OFC -9 s.d., height -7s.d.) (Mirzaa et al., 2014).  A sibling was 
similarly affected however height was less severely reduced (-3 s.d.).  CENPE 
encodes a core component of the kinetochore, stabilizing the attachment of 
chromosomes to the mitotic microtubules (Yao et al., 2000).  Failure in attachment 
of the kinetochore to microtubules results in activation of the SAC preventing mitotic 
progression until all kinetochores are attached (Cleveland et al., 2003).  Patient cells 
showed mitotic spindle defects and impaired mitotic progression similar to those 
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observed in PCNT-negative cells (Mirzaa et al., 2014).  Defects in other kinetochore 
proteins have also previously been associated with growth failure including the SAC 
kinase BUBR1 resulting in Mosaic Variegated Aneuploidy (MVA) characterised by 
growth retardation and cancer predisposition (Hanks et al., 2004).  Mutations in the 
cancer susceptibility candidate 5, CASC5, encoding another member of the 
kinetochore complex have also been identified in 1° MCPH patients (Genin et al., 
2012).   
1.3.1.6 Centrosomal proteins identified in 1° MCPH and stem cell 
fate 
In total nine genetic loci encoding centrosomal proteins have now been identified in 
1° MCPH (Table 1.1); Microcephalin (MCPH1), ASPM, CDK5RAP2, CENPJ, STIL, 
CEP152, WDR62, CEP63 and CEP135 (Bond et al., 2002, Jackson et al., 2002, 
Bond et al., 2005, Kumar et al., 2009, Bilguvar et al., 2010, Guernsey et al., 2010, 
Yu et al., 2010, Sir et al., 2011, Hussain et al., 2012).  All are expressed in the 
neuroepithelium during embryonic neurogenesis and play key roles in neurogenic 
mitosis (Megraw et al., 2011) either through ensuring correct cell cycle check point 
signalling or through correct mitotic spindle organisation and orientation which 
determines cell fate following neural stem cell division.  In early embryogenesis 
neural progenitors undergo symmetric cell division with the plane of division exactly 
perpendicular to the cell surface creating an adequate pool of stem cells from which 
to populate the developing cortex (Noctor et al., 2004).  Later in development, 
oblique cell cleavage of progenitor cells results in asymmetric cell division 
producing only one cell which continues to proliferate and another which is 
committed to become terminally differentiated as a neuron.  In 1°MCPH it is 
postulated that mitotic spindle defects leads to an increase in early asymmetric 
divisions resulting in a reduction in the number of neural progenitors from which to 
populate the developing cortex.  Disrupting asymmetric cell divisions has been 
shown to result in a depletion of progenitors in the proliferating region of the brain 
(ventricular zone, VZ) (Wang et al., 2009).   
As several genes are allelic for both MPD and 1° MCPH it has been hypothesised 
that MPD may arise from a similar cellular mechanism in which multiple stem cell 
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pools are affected resulting in a more global growth failure (Delaval et al., 2010).  
Interestingly, spindle misorientation has also been described in the neural precursors 
of PCNT deficient mice (Chen et al., 2014).  Compound heterozygous 
nonsynonymous mutations in NIN were reported in two siblings with MPD (height 
and OFC <-6 s.d.) (Dauber et al., 2012).  Ninein is another centrosomal protein 
which functions in the anchoring of the centrosome to microtubules (Shinohara et al., 
2013).  Removal of ninein disrupts asymmetric cell division and leads to a reduction 
in neural progenitors in the VZ (Wang et al., 2009).  However, impaired ninein 
function in MPD patients as a direct consequence of NIN mutations has not been 
shown.  
Table 1.1 provides a summary of all the centrosomal genes identified in MPD and 1° 
MCPH to date and their associated function (reviewed in Megraw et al., (2011)).  It 
is unclear, however, why some mutations result in MPD as opposed to 1° MCPH.  
The presence of other genetic modifiers in MPD patients or that some mutations only 



















Table 1.1.  Summary of genes encoding centrosomal proteins in MPD and 1° 
MCPH 















Centrosomal protein of 152 
kDa 
1° MCPH & 
MPD 
614852 
CENPJ Centromeric protein J 
1° MCPH & 
MPD 
609393 





Tubulin, gamma complex 







1° MCPH 612703 
CEP63 
Centrosomal protein of 63 
kDa 
1° MCPH 614728 
CEP135 
Centrosomal protein of 135 
kDa 








1° MCPH 608716 
CDK5RAP2 
Cyclin dependent kinase 5 
regulatory subunit-
associated protein 2 








1° MCPH 604317 
Abbreviations: PCM=pericentriolar matrix, MT=microtubules, JNK= c-Jun N-terminal kinase. 
1.3.2 DNA damage response and repair proteins 
DNA is under constant attack by both endogenous and exogenous reactive molecules 
with approximately 105 DNA lesions occurring per mammalian genome per day 
(Hoeijmakers, 2009).  As well as promoting cell death and threatening organism 
viability, incorrect or ineffective repair can introduce genomic instability and 
predispose to cancer development with the introduction of mutations or larger 
structural rearrangements (Bender et al., 1974, Frank et al., 2000).  Maintaining 
genomic integrity through effective DNA repair mechanisms is therefore integral to 
cell cycle control and survival.   
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1.3.2.1 Mechanisms of DNA damage  
DNA damage can occur endogenously during physiological processes such as 
incorrectly incorporated nucleotides during DNA replication (DNA mismatch) as 
well as following abortive topoisomerase I and II activity resulting in single or 
double DNA strand breaks (Wang, 2002).  Reactive oxygen compounds (ROS) can 
also induce DNA base lesions and are a by-product of several cellular processes 
including oxidative respiration and immune activation in response to inflammation 
and infection (Finkel et al., 2000).  In addition, exogenous agents capable of 
inducing DNA damage include ionising radiation, ultraviolet radiation, chemicals 
found in tobacco products and medication used in the treatment of cancer (Doll et al., 
1981, Ward, 1988, Espinosa et al., 2003).  Such extrinsic damage can block or 
impair DNA replication and transcription, resulting in nucleotide loss or induce 
single- or double-strand DNA breaks (SSB, DSB).   
Of all possible DNA damage lesions that can occur, DSBs are the most deleterious 
and it is estimated that 10-20 DSBs occur in each cell every day (Martin et al., 1985).  
The majority are pathologic occurring during replicative stress, mechanical stress, 
exposure to ionising radiation, ROS or the inadvertent action of nuclear enzymes 
(McClintock, 1941, Lea, 1946, Karanjawala et al., 2002, Adachi et al., 2003, 
Mahowald et al., 2008, Ozeri-Galai et al., 2011).  Unrepaired SSBs can also become 
DSBs when encountered during replication (Kuzminov, 2001).  Repair is important 
as DSBs promote cell death and impede proliferation (Frank et al., 2000) whilst 
defective repair can lead to genomic rearrangements (Bender et al., 1974) and 
telomere instability (Bailey et al., 1999) which can promote the development of 
malignancy and contribute to ageing (Chang et al., 2001, Schuler et al., 2013).   
Although DSBs can clearly be deleterious to a somatic cell they also have an 
important role in ensuring genetic diversity.  Firstly, in the adaptive immune system 
by enabling variable (diversity) joining (V(D)J) recombination (Tonegawa, 1983, 
Taccioli et al., 1993) and class switch recombination (CSR) (Casellas et al., 1998, 
Pan-Hammarstrom et al., 2005) in B and T lymphocyte maturation.  Secondly, in 
germ cells DSBs are required to generate cross overs between homologous 
chromosomes during meiosis (Zickler et al., 1999).   
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1.3.2.2 Mechanisms of DNA damage repair 
Different repair mechanisms are present in the cell to deal with the diverse range of 
possible lesions and cells defective in certain repair mechanisms show increased 
sensitivity towards specific DNA damaging agents (Table 1.2).   
1.3.2.2.1 Repair of aberrant nucleotides 
Mismatch repair (MMR) machinery recognises and repairs incorrectly incorporated 
nucleotides during replication as well as DNA loops which have occurred during 
slippage of the replication machinery at repeat sequence motifs know as 
microsatellites (Strand et al., 1993).  The process involves endonucleolytic 
degradation of the error-containing strand to the site of the mismatch with removal of 
the incorrect base(s) followed by DNA resynthesis and ligation of the remaining nick 
(Jiricny, 2006).  Damaged bases such as those induced by ROS can be corrected by 
base-excision repair (BER) in which the defect is recognised by a DNA glycosylase 
enzyme, followed by removal, infilling and ligation (David et al., 2007).  Base-
lesions such as UV-induced pyrimidine photodimers which distort the DNA helix are 
removed by the nucleotide excision repair (NER) machinery which can also target 
lesions specifically blocking transcription (transcription-coupled NER).  NER results 
in the excision of a 22-30 bp oligonucleotide removing the obstructive lesion and 
generating single-stranded DNA which is then recognised and repaired accordingly 
(Melis et al., 2013).     
1.3.2.2.2 Single-strand break (SSB) repair  
SSBs occur as a direct consequence of damage by agents such as endogenous ROS 
and UV radiation as well as indirectly following nucleotide resection by MMR, BER 
or NER (Caldecott, 2008).  SSBs also arise from abortive TOPI activity and 
decoupling of the replication machinery in stalled replication forks (Wang, 2002).  
SSBs are initially detected by poly (ADP-ribose) polymerase 1, PARP1 (D'Amours 
et al., 1999).  This is followed by the recruitment and activation of various end 
processing factors depending on the damage incurred.  Such factors include X-ray 
repair cross-complementing protein 1 (XRCC1), polynucleotide kinase 3’-
phosphatase (PNKP), tyrosyl-DNA phosphodiesterase 1 (TDP1) and Aprataxin 
(APTX) to resect and repair the damaged ends as well as polymerases to infill any 
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remaining gap (Jilani et al., 1999, Pouliot et al., 1999, Whitehouse et al., 2001, Liu 
et al., 2005, Ahel et al., 2006).  This ensures the two ends are then compatible for 
final ligation by DNA ligases (LIG1 or LIG3) (Timson et al., 2000).  
1.3.2.2.3 Double-strand break (DSB) repair  
In eukaryotic cells, there are two main DSB repair pathways; non-homologous end 
joining (NHEJ) and homologous recombination (HR).  In NHEJ the broken ends of 
the DSB are ligated back together regardless of whether the DNA sequence remains 
intact (Roth et al., 1985).  This can be beneficial in promoting immune 
diversification in lymphocytes (Gerstein et al., 1993) but can also introduce 
deleterious mutations and lead to genome instability with the generation of 
chromosomal rearrangements (Bender et al., 1974).  HR ensures the genomic 
sequence is preserved by using the alternative sister chromatid as a template for 
repair (Howard-Flanders, 1975).  Due to their different mechanisms NHEJ can be 
active at any point in the cell cycle whereas HR is restricted to the late S and G2 
phases of the cell cycle when there is a sister chromatid within close proximity 
(Rothkamm et al., 2003).  HR is therefore largely responsible for the repair of DSBs 
occurring during replication as well as those formed in meiosis whereas NHEJ has 
more impact on the repair of DSBs occurring as a consequence of DNA damage in 
G1-phase and non-cycling cells. 
Although individual repair mechanisms have been described distinctly, marked 
overlap exists between these different processes.  For example, HR and NER 
involves the generation of single-stranded DNA which then recruits factors required 
for SSB repair (Melis et al., 2013).  SSBs are also generated following the removal 
and correction of base lesions in BER and MMR and require components of the SSB 
repair machinery (Jiricny, 2006, David et al., 2007).  Some proteins also have roles 
in more than one mechanism, for example PNKP and APTX are often required for 
SSB repair but can also be utilised for DNA end-processing in NHEJ (Clements et 
al., 2004, Koch et al., 2004).   
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1.3.2.2.4 DNA repair mechanisms and human disease 
Defects in many of these mechanisms are associated with human disease including 
cancer predisposition, neurodegeneration and developmental disorders in which 
growth is often affected (Table 1.2).  The latter is illustrated by disorders such as 
Cockayne syndrome (impaired transcription-coupled NER) and Bloom syndrome 
(impaired HR), both associated with severe growth impairment which can fall into 
the defined range for MPD (Nance et al., 1992, Keller et al., 1999).  However, the 
prominence of other features such as premature aging, immunodeficiency and cancer 
predisposition often distinguishes these syndromes from other MPD disorders. 
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Table 1.2.  DNA damage repair mechanisms and associated disease 
DNA repair 
mechanism 
Type of lesion 
repaired 
Associated disorder OMIM Genes mutated Associated phenotype Cellular phenotype 
1 Mismatch repair 
(MMR) 
Replication errors: 















2 Base excision repair 
(BER) 
Abnormal DNA 
bases arising from 





























MPCH, growth delay, cataracts, 
arthrogryposis, photosensitivity, 
hearing loss, severe 
developmental delay, premature 
ageing 
↑ sensitivity to 
UV 




Acute sun sensitivity, cancer 
predisposition (skin) 
Trichothiodystrophy 601675 ERCC2 
ERCC3 
Brittle hair, growth delay, 
congenital icthyosis, 
photosensitivity 





failure plus BER, 
MMR & NER/TCR 
induced SSB 
Microcephaly with early 
onset, intractable seizures 
and developmental delay 
613402 PNKP MCPH, seizures, developmental 
delay 
↑ sensitivity to 
camptothecin, UV 
& hydrogen 
peroxide Spinocerebellar ataxia with 
axonal neuropathy 1 
607250 TDP1 Cerebellar atrophy, peripheral 
neuropathy 
Ataxia oculomotor apraxia 
1 





Mechanisms reviewed in the following articles; 1) Jiricny, (2006), 2) David et al., (2007), 3) Melis et al., (2013), 4) Caldecott, (2008), 5) Lieber, (2008) , 6) San 
Filippo et al., (2008), 7) Su et al., (2011).  Disease associations reviewed in the following articles: O'Driscoll, (2012), Suhasini et al., (2013).  Abbreviations: 
COFS=cerebroocularfacioskeletal, SCID=severe combined immunodeficiency.   
5 Non-homologous 
end joining (NHEJ) 
DSB Ligase IV syndrome  
 











SCID +/- growth delay 
6 Homologous 
recombination (HR) 
DSB Nijmegen breakage 
syndrome (NBS) 
251260 NBN MCPH, growth delay, immune-
deficiency, cancer predisposition 




NBS-like syndrome 613078 RAD50, MRE11A MCPH, growth delay 




Werner syndrome 277700 WRN Premature aging, cataracts, 









RECQL4 Poikiloderma, growth delay, 
sparse hair, radial ray defects, 
cancer predisposition, cataracts. 
Familial breast cancer 604370 
612555 
BRCA1, BRCA2,  Cancer predisposition 




Fanconi Anaemia 227650 FANCA, FANCC, 
FANCG most 
common (15 
genes in total) 
Progressive bone marrow failure, 
skeletal abnormalities, congenital 
malformations, growth delay, 
cancer predisposition 






1.3.2.3 Cellular responses to DNA damage 
To ensure repair occurs effectively and efficiently, signalling pathways are present to 
respond to DNA damage.  Two main DNA damage response (DDR) pathways exist 
in the cell, one initiated by ATR (Ataxia Telangiectasia and Rad3-related) and the 
other by ATM (Ataxia Telangiectasia Mutated), both members of the 
phosphatidylinositol-3-kinase-like kinase (PIKKs) family (Marechal et al., 2013).  
Following initial sensing of DNA damage, ATM/ATR activation results in the 
phosphorylation of hundreds of downstream effector proteins, many of which are 
common to both pathways (Shiloh, 2006).  As well as recruiting relevant repair 
proteins to lesions, DDR pathways activate cell cycle checkpoints.  Additionally 
DDR pathways regulate cell fate by inducing apoptosis or senescence to prevent the 
propagation of DNA damage and maintain genomic integrity.  Checkpoint arrest of 
the cell cycle can occur at G1-S phase, intra-S-phase and G2-M phase postponing 
cell cycle progression until the lesion(s) is repaired (Lukas et al., 2004).   
1.3.2.3.1 ATR-mediated DNA damage signalling 
ATR is recruited and activated by replication protein A (RPA) which coats single 
stranded DNA through obligatory binding to the ATR-interacting protein, ATRIP 
(Zou et al., 2003) (Figure 1.8).  Important downstream targets of ATR activation 
include CHK1 (Liu et al., 2000) and the tumour suppressor protein p53 which can 
induce apoptosis (Tibbetts et al., 1999).  ATR is essential for development and 
complete absence leads to early embryonic lethality in mice (Brown et al., 2000).  
ATR also plays an important role in the regulation of DNA replication in response to 
DNA damage by altering the distribution of active replication origins (Ge et al., 
2010).   
1.3.2.3.1 ATM-mediated DNA damage signalling 
ATM is activated in response to DSBs (Figure 1.8) interacting with NBS1 of the 
MRN (MRE11-RAD50-NBS1) complex at the site of a DSB (You et al., 2005).   
Downstream targets of ATM include the checkpoint kinase CHK2, p53 and BRCA1 
mediating cell cycle arrest, apoptosis and HR respectively (Matsuoka et al., 1998, 
Fernandes et al., 2005, Cheng et al., 2010).  This differs from DSB repair by NHEJ 
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in which DSBs are detected by the KU70-80 complex (Mimori et al., 1986, Walker 
et al., 2001) and repair is initiated by the recruitment and activation of another PIKK, 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) (Gottlieb et al., 1993).  
In contrast to ATR, ATM is non-essential for development.  Mutations in ATM cause 
ataxia-telangiectasia characterised by neurodegeneration, immunodeficiency and 
cancer predisposition (Savitsky et al., 1995).   
 
Figure 1.8.  DNA damage response (DDR) pathways 
ATR and ATM are both protein kinases central to the two main DDR signalling pathways.  ATR is 
recruited to RPA-coated single-stranded DNA in association with ATRIP whereas ATM is activated 
by the MRN complex at sites of DSBs.  Both activate downstream checkpoint kinases (CHK1 and 
CHK2 respectively) which phosphorylate a large number of downstream targets with a range of 
consequences all with the purpose of maintaining genomic integrity.  Proteins encoded by genes 
mutated in MPD are highlighted in red and those which cause other disorders associated with 
impaired growth are shown in dark blue.  Abbreviations:  ROS=reactive oxygen species, 
ssDNA=single-stranded DNA, DSB=DNA double strand break. 
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1.3.2.4 ATR and ATRIP in Seckel syndrome 
ATR was the first MPD disease gene to be identified.  A homozygous synonymous 
mutation (c.2101A>G) that altered splicing resulting in partial loss of ATR function 
was identified in two related consanguineous families with Seckel syndrome through 
linkage studies (O'Driscoll et al., 2003).  Patient cells showed increased sensitivity to 
UV radiation and mitomycin C with impaired phosphorylation of downstream ATR 
DDR targets including p53.  No impairment was seen in response to ionising 
radiation reflecting intact ATM-dependent signalling and repair.  The patients were 
diagnosed with Seckel syndrome on the basis of microcephaly, receding forehead, 
prominent nose, micrognathia and developmental delay.  In one patient severe 
growth retardation of prenatal onset was documented (OFC -12 s.d., height -4.8 at 9 
years) (Goodship et al., 2000).  Three further cases have since been reported carrying 
compound heterozygous mutations in ATR.  Two apparently unrelated patients have 
the same variants, a nonsense mutation in combination with a non-synonymous 
mutation (Ogi et al., 2012).  Both patients showed severe pre- and post-natal growth 
failure with severe microcephaly (average OFC -10 s.d., height -8 s.d.).  The most 
recent patient reported carried a nonsynonymous coding variant which disrupted 
splicing in combination with a 540 kb deletion encompassing four genes including 
ATR (Mokrani-Benhelli et al., 2013).  This patient exhibited a less severe growth 
phenotype (OFC -5 s.d., height -1 s.d.) along with severe learning disability, 
epilepsy, a profound episode of bone marrow hypoplasia shortly after birth and mild 
immune abnormalities.  
One patient has also been described with a heterozygous nonsense mutation 
(c.2278C>T, p.Arg760*) in ATRIP in combination with altered splicing of the other 
allele (Ogi et al., 2012).  ATRIP binding confers stability to ATR and assists in the 
localisation of ATR to single stranded DNA (Cortez et al., 2001).  This patient also 
had severe pre- and post-natal global growth failure (OFC -10 s.d., height -6.5 s.d.) 
as well as microtia, micrognathia, and dental crowding.  Similar features were also 
described in the ATR patients, interestingly displaying some overlap with Meier-
Gorlin Syndrome (Ogi et al., 2012).  Markedly reduced expression of both ATRIP 
and ATR was observed in both ATR and ATRIP patient cells along with reduced 
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activation of downstream targets including CHK1 and FANCD2, reduced formation 
of 53BP1 foci and impaired G2/M checkpoint arrest in response to UV radiation 
consistent with impaired ATR DDR signalling.  As so few cases have been reported 
to date, despite identification of ATR as a cause of MPD over a decade ago, this 
suggests ATR/ATRIP mutations are a relatively rare cause of MPD.  An autosomal 
dominant nonsynonymous coding variant in ATR affecting p53 activation has also 
been reported in a large family with an oropharyngeal cancer syndrome (Tanaka et 
al., 2012b) however additional families have yet to be reported.  Furthermore, cancer 
predisposition has not yet been reported in association with MPD and autosomal 
recessive ATR mutations or in any of the parents carrying heterozygous mutations.  
1.3.2.5 RBBP8 in Seckel syndrome 
Two independent families with multiple affected individuals homozygous for 
nonsense mutations in the retinoblastoma binding protein 8 gene, RBBP8 (also 
known as CTIP), have been reported (Qvist et al., 2011).  RBBP8 acts in 
combination with the MRE11-RAD50-NBS1 (MRN) complex in the end processing 
of DSBs during homologous recombination (Sartori et al., 2007).  The 
phosphorylation of RBBP8, a 5'-3' exonuclease, is required for the initiation of DNA 
end resection generating single-stranded DNA which consequently activates ATR 
signalling (Sartori et al., 2007).  RBBP8 has also been shown to be required for 
sustained ATR signalling and checkpoint activation ensuring complete repair occurs 
(Kousholt et al., 2012).    
In one family, aberrant splicing as the consequence of a new intronic splice site 
resulted in a truncated but stabilised protein, while in the second a homozygous 2 bp 
deletion in exon 11 was detected.  In the former family, a diagnosis of Seckel 
syndrome had been made due to low birth weight and proportionate growth failure 
(height -3.5 to -5.5 s.d., OFC -4.7 s.d. to -5 s.d.) whereas affected cases in the second 
family showed a similar degree of microcephaly but with normal height (OFC -5 s.d. 
to -7 s.d.).  Affected cases from both families had a characteristic ‘Seckel syndrome’ 
appearance with receding forehead and prominent nose, developmental delay, café 
au lait spots and digital abnormalities including phalangeal joint swelling, 
clinodactyly, polydactyly, syndactyly and absent nails.  RBBP8 patient cells had 
53 
 
increased sensitivity to ionising radiation demonstrating impaired DSB repair along 
with reduced CHK1 activation (Qvist et al., 2011).  This also reflects how different 
DNA damage response and repair mechanisms function cooperatively in the repair of 
certain lesions.  Of note, mutations in all three genes encoding the MRN complex 
have also been associated with microcephaly and reduced growth (Matsuura et al., 
1998, Waltes et al., 2009, Matsumoto et al., 2011) (Table 1.2).   
1.3.3 DNA replication proteins in Meier-Gorlin Syndrome 
The discovery of mutations within components of the origin of replication complex 
(ORC1, ORC4, ORC6, CDT1 and CDC6) in patients with Meier-Gorlin syndrome 
(Bicknell et al., 2011a, Bicknell et al., 2011b, Guernsey et al., 2011) extended 
insights into cell cycle processes impacting on growth.   
During S phase of the cell cycle, DNA replication is initiated at specific genomic 
sites referred to as origins of replication.  Licensing of such origins at the end of M 
and during G1-phase requires the loading of a hexameric complex consisting of 
ORC1-ORC6 onto chromatin (Bell et al., 1992, Gavin et al., 1995) (Figure 1.9).  
This is followed by the recruitment of CDC6 (cell division cycle 6), CDT1 
(chromatin licensing and DNA replication factor 1) and MCM (mini-chromosome 
maintenance) 2-7 helicase complex (Mendez et al., 2003) forming the pre-replication 
complex (pre-RC).  DNA replication is then initiated at the onset of S-phase by the 
phosphorylation of the pre-RC (Krude et al., 1997, Lei et al., 1997) resulting in 
association of replisomal proteins and activation of the DNA helicase complex 
(MCM2-7) necessary for DNA unwinding to form the replication fork (Moyer et al., 
2006, Ilves et al., 2010).  DNA replication proceeds bidirectionally from each origin 




Figure 1.9. Pre-replication complex assembly and initiation of DNA replication 
in eukaryotes 
During M/G1-phase, the ORC complex consisting of six subunits (ORC1-6) initially binds to 
chromatin, a process predominantly regulated by ORC1.  Recruitment and binding of CDC6 and 
CDT1 follow with subsequent loading of at least 2 MCM helicase (MCM2-7) complexes (Ilves et al., 
2010) to complete the pre-replication complex (preRC) and licencing of the replication origin.  At the 
onset of S-phase, the pre-RC complex is activated by cyclin-dependent kinases, recruiting several 
other proteins to form the pre-initiation complex (preIC), including the cell division cycle protein 45 
(CDC45), the GINS complex, SLD2 and MCM10 (Zegerman et al., 2007, Ilves et al., 2010, van 
Deursen et al., 2012).  DNA topoisomerase 2-binding protein 1 (TOPBP1) and treslin (homologues of 
yeast DPB11 and SLD3 respectively) are also recruited to the preIC (Mueller et al., 2011).  The final 
recruitment of DNA polymerase machinery (Polɛ and Polα) initiates replication in both directions 
from the origin preceded by the MCM2-7 helicase which travels ahead of the polymerase to unwind 
the double stranded DNA.  Reproduced from Aladjem, (2007).     
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To ensure the genome is replicated once and only once during each cell cycle, 
licencing of origins is strictly confined to M/G1 phase (Arias et al., 2007).    Under 
unstressed conditions only approximately 10% of origins licenced for replication are 
activated (Cayrou et al., 2011).  However, as new origins can not be licensed 
following entry into S phase (Wohlschlegel et al., 2000), dormant origins can be 
utilised in the event of stalled replication forks or failed initiation of origins ensuring 
complete replication still occurs (Woodward et al., 2006).  To make certain that an 
adequate number of origins are licenced during G1 prior to progression into S-phase, 
a p53-dependent licencing checkpoint has been proposed to be activated preventing 
G1/S transition until a certain threshold is reached (Nevis et al., 2009).   
Reduction in assembly of the pre-RC reduces capacity to activate replication origins 
may result in slower progression through the cell cycle due to prolonged G1-phase 
and delayed S-phase entry (Noguchi et al., 2006, Bicknell et al., 2011b).  Although a 
large degree of redundancy exists in the number of licenced origins it has been 
hypothesised that reduced licencing capacity may become rate limiting in certain cell 
populations with higher rates of proliferation (Bicknell et al., 2011b, Klingseisen et 
al., 2011), such as neuronal stem cells in which G1-phase is reduced (Takahashi et 
al., 1995).  The failure in growth seen in MGS patients may therefore be the result of 
a slower proliferation rate in specific cell populations critical to ensuring normal 
cellularity during development.  Notably, patients with mutations in ORC1 have a 
greater reduction in growth compared to mutations in other pre-RC genes (de 
Munnik et al., 2012).  The majority of ORC1 mutations in MGS patients lie within 
the BAH chromatin binding domain (Bicknell et al., 2011a).   ORC1 is the only ORC 
protein with a BAH domain and appears to play an important role in the regulation of 
pre-RC loading onto chromatin (Noguchi et al., 2006).  The BAH domain has 
recently been shown to bind to chromatin bound H4K20me2, a modified histone 
enriched at replication origins and disruption of this interaction was found to impair 
normal growth in zebrafish (Kuo et al., 2012).   
Mice with mutations in the MCM subunits also have impaired growth along with 
genome instability and cancer predisposition (Kunnev et al., 2010).   In humans, a 
founder mutation in the MCM4 helicase has been described in the Irish traveller 
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community in association with short stature, adrenal insufficiency and natural killer 
cell deficiency, although OFC was normal or only mildly reduced and additionally 
microtia and patella abnormalities were not noted (Gineau et al., 2012, Hughes et al., 
2012).  Patient cells also exhibited increased chromosomal breakage in response to 
genotoxic agents (Gineau et al., 2012).  In contrast, genome instability and cancer 
predisposition have not been described in patients with MGS. 
1.3.4 Splicing in MOPDI 
Mutations within RNU4ATAC, which encodes a member of the minor spliceosome 
targeting splicing of U12 introns (Edery et al., 2011, He et al., 2011) have recently 
been identified including a founder mutation g.51G>A in several affected cases in 
the Ohio Amish population.  The majority of mutations appear to lie in the 
structurally important 5' stem loop and are predicted to disrupt RNA secondary 
structure (He et al., 2011).  However, the exact mechanism by which RNU4ATAC 
mutations causes MOPDI is not yet understood.  U12 introns are present in 
approximately 700 genes with diverse functions including cell cycle regulation 
(Sheth et al., 2006, Alioto, 2007).  Severe growth failure may therefore result from a 
cumulative effect of the abnormal splicing of several different RNA transcripts or 
even from the effect on just one specific gene transcript. 
1.3.6 Common cellular pathways for MPD genes 
A common feature of all the above genes so far identified in MPD is a disruption in 
cell cycle kinetics either through impaired DNA replication, impaired mitosis or 
failure in adequate DNA damage response.  It is therefore conceivable that such 
defects can lead to a reduction in global cellularity either through reduced 
proliferation or increased cell death.  Notably, there is also significant overlap 
between these different cellular processes.  For example ATR activation alters 
replication origin distribution in response to stalled replication forks (Ge et al., 2010) 
and many components of the ATR signalling pathway localise to the centrosome 
including CHK1 (Kramer et al., 2004).  Furthermore, both PCNT and CEP152 
appear to contribute to the DNA damage response.  CEP152 has been shown to bind 
to CINP, a genome maintenance protein which interacts with ATRIP (Lovejoy et al., 
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2009).  Thus, it is unlikely that each gene described above impacts on growth 
through the disruption of a single pathway.  
At least four genes (CENPJ, CEP152, TUBGCP6, RBBP8) are associated with a 
variable phenotype which ranges from microcephaly and normal stature to MPD 
suggesting the two conditions may represent a single disease spectrum with similar 
underlying pathogenesis (Bond et al., 2005, Al-Dosari et al., 2010, Guernsey et al., 
2010, Kalay et al., 2011, Qvist et al., 2011, Puffenberger et al., 2012, Martin et al., 
2014).  Why some mutations result in primary 1° MCPH and others in MPD is not 
yet fully understood but this suggests other genes implicated in 1° MCPH could also 
cause MPD.   
1.4 Methods of Gene discovery 
The previous Section highlighted that MPD is a highly heterogeneous disorder.  
Recent developments in sequencing technology may therefore be beneficial to 
further gene discovery in this group of conditions, particularly given the rarity of 
MPD and that patients are predominantly single cases from non-consanguineous 
families.  This combined with genetic heterogeneity in an extremely rare disorder 
makes gene discovery difficult by traditional methods. 
Prior to the advent of next generation sequencing technology, Sanger sequencing 
(Sanger et al., 1977) was the most efficient method available by which to sequence 
DNA and identify causative mutations.  In this method, a DNA polymerase replicates 
DNA from a primer bound to the single stranded template under investigation.  
Chain-terminating dideoxyribonucleotides (ddNTPs), along with unmodified dNTPs, 
are added to the sequencing reaction.  ddNTPs lack the 3’-OH group required to form 
a phosphodiester bond thus terminating further synthesis once incorporated into the 
newly synthesised strand.  The sequence can then be deduced using capillary 
electrophoresis to determine the different fragment lengths produced following 
addition of each of the four ddNTPs.  In modern methods, the ddNTPs are 
fluorescently labelled to allow automated detection (dye-terminator sequencing) 
(Smith et al., 1986).   
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Advantages of Sanger sequencing include a low error rate and the ability to produce 
reasonably long sequencing reads (up to 900 bp) in a single reaction (Liu et al., 
2012).  Although automated capillary sequencing machines can analyse multiple 
sequencing reactions at one time (up to 384), only one DNA template can be 
sequenced per reaction.  Therefore sequencing large numbers of genes by this 
method is not feasible for most researchers and diagnostic services.  Genetic 
mapping techniques such as linkage analysis including homozygosity mapping 
(Lander et al., 1987, Kerem et al., 1989), karyotyping to detect translocations 
(Kurotaki et al., 2002) and detection of  duplications and deletions (Vissers et al., 
2005) can assist in limiting the genomic region in which the causative mutation 
might reside.  Candidate genes within this region can then be prioritised and 
sequenced although the region may still be too large to sequence every gene.  
Methods utilising genetic linkage are also often only successful in homogeneous 
disorders with multiple affected individuals or where DNA from several family 
members is available to inform on commonly inherited regions.  
1.4.1 Next Generation Sequencing (NGS) Technology  
Mass paralleled sequencing technologies have revolutionised DNA sequencing.  
Sequencing the entire genome is now possible in under a day and costs are rapidly 
reducing as technology continues to advance.  This has resulted in the rapid 
identification of a large number of new disease causing genes in recent years and 
provided valuable information on the degree of normal variation within the human 
genome (Genomes Project et al., 2012).  However, this technology is not without 
disadvantages with higher error rates and often limited read length compared to 
traditional Sanger sequencing methods (Metzker, 2010).   
In NGS technologies numerous unique template fragments can be spatially separated 
on a single stage enabling vast numbers of sequencing reactions to be performed 
simultaneously.  Each template is clonally amplified via emulsion PCR (Dressman et 
al., 2003) or solid-phase amplification (Fedurco et al., 2006) to enable detection of 
the fluorescent signal during DNA synthesis (Figure 1.10).  Methods using single 
molecule templates are also employed by some systems (Harris et al., 2008) and 
have the advantage of requiring lower input DNA, generally more straightforward 
59 
 
preparation protocols and the potential to produce longer read lengths (Metzker, 
2010).  Ligating a short unique identifying sequence (barcode) onto each template 
fragment also allows multiple samples to be sequenced in one reaction (Meyer et al., 
2007, Parameswaran et al., 2007).    
  
Figure 1.10.  Methods of template immobilisation and amplification in Next 
Generation Sequencing Technologies 
In NGS technology millions of template fragments can be separated and sequenced in a single 
reaction.  The most commonly used technologies require clonal amplification of each fragment prior 
to sequencing in order for the fluorescent signal to be detected.  Prior to this stage adapters containing 
universal primer sequences (blue and red) are ligated onto the ends of each fragment (Orange in A, 
grey in B).  A) In emulsion PCR (e.g. used by Roche) one DNA fragment is hybridised to a single 
bead (yellow) in solution.  The fragment is then repeatedly amplified so each bead holds several 
thousand copies of the same fragment.  The beads can then be evenly distributed and immobilised on a 
solid platform prior to sequencing.   B) In solid-phase amplification (e.g. used by Illumina) each 
fragment is hybridised to a solid platform containing millions of universal forward and reverse 
primers prior to amplification.  Initial extension of each primer allows the fragment to form a bridge 





Currently five different sequencing methods are used by commercially available 
NGS systems; pyrosequencing, ion semi-conductor sequencing, sequencing by 
ligation (SBL), cyclic reversible termination (CRT) and real-time sequencing (Figure 
1.11).  In CRT, one terminating fluorescent nucleotide is added at a time followed by 
imaging which detects where they have been incorporated (Ju et al., 2006).  The 
terminating group and dye is then cleaved allowing further synthesis on addition of 
the next nucleotide.  SBL involves the use of DNA ligase to join cyclically 
introduced dye-labelled probes (Landegren et al., 1988).  The two base pair probe 
hybridises to the complimentary sequence on the template and is then ligated to the 
adjacent probe/primer by DNA ligase.  Unligated probes are washed away prior to 
imaging to identify only those that have been incorporated.  Pyrosequencing and ion 
semi-conductor sequencing differs from the other two methods in that they do not 
involve the cyclical termination of DNA synthesis.  Pyrosequencing measures the 
release of inorganic pyrophosphate on incorporation of a complimentary nucleotide 
by converting it to a light signal.  The intensity (proportional to the amount of 
nucleotide incorporated) and order of the light signal following sequential addition of 
each dNTP is then used to determine the sequence.  Ion semi-conductor technology 
is similar except the voltage produced from emitted hydrogen ions following 
incorporation of nucleotides is measured (Rothberg et al., 2011).  However, runs of 
identical nucleotides in the sequence (homopolymer runs) are more prone to error in 
these latter two methods due to difficulties in accurately relating the intensity of the 
emitted signal to the number of bases incorporated (Harris et al., 2008, Liu et al., 
2012).   
Finally, and most recently available, is the real time imaging of incorporated dye-
labelled nucleotides during uninterrupted template-directed synthesis using a zero-
mode waveguide detector (real-time sequencing) (Eid et al., 2009).  This allows the 
sequencing of longer reads compared to other methods and improved sequencing of 
GC rich regions (Shin et al., 2013).  As single molecule templates are used, this 
method avoids errors which can potentially be introduced during clonal amplification 
(Metzker, 2010).  Advantages and disadvantages of each method are highlighted in 
Table 1.3 which shows the most popular sequencing platforms commercially 






















































































All data obtained from Liu et al., (2012) except Ion proton specifications obtained from company 
website (www.lifetechnologies.com, accessed 07.07.14).  Abbreviations: EmPCR=emulsion PCR, 
CRT=cyclic reversible termination, SBL=sequencing by ligation, prepn=preparation. 
1.4.1 Whole Exome Sequencing (WES) 
Sequencing a human genome requires the analysis of 6 Gb of DNA which can 
contain over three million variants (Wheeler et al., 2008).  Not only is this a large 
volume of data to analyse and store but identifying one or two causal pathogenic 
variants from such a large dataset is very challenging.  As approximately 85% of 
pathogenic mutations lie in protein coding regions of the human genome (Botstein et 
al., 2003), limiting sequencing to these regions drastically reduces the volume of data 
produced (300 fold reduction in  variant number; Wheeler et al., 2008) whilst still 
capturing the majority of disease causing mutations.  Also the 20-fold reduction in 
sequencing required (Ng et al., 2009) allows more samples to be analysed within the 
confines of available resources such as additional patients or family members.  
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Including more samples in the experimental design could also potentially increase 
the chances of identifying causative variants.  
In WES, the desired genomic regions are captured by the hybridisation of sheared 
DNA to probes complimentary to the sequence of interest, the exons.  Sequence 
probes may be fixed to a solid platform such as a microarray (Hodges et al., 2007) or 
filter (Herman et al., 2009) (solid-phase hybridization) or in suspension and 
biotinylated (liquid-phase hybridization) allowing them to bind to magnetic 
streptavidin beads (Gnirke et al., 2009).  Following hybridisation and capture of 
target regions, fragments containing non-coding sequences can be washed away and 
the remaining library enriched prior to sequencing.  A range of different exome 
capture kits are now commercially available.  Those based on liquid-phase 
hybridisation (Agilent and NimbleGen) have the advantage of being more amenable 
to automation and thus potentially have a higher throughput capacity.    
Initially, proof of principle experiments successfully identified known disease 
causing mutations by using targeted capture methods and NGS in several patient 
groups (Ng et al., 2009, Chou et al., 2010, Hoischen et al., 2010, Raca et al., 2010).  
WES was then successfully employed to identify novel disease causing genes in 
2010 where patients with Miller syndrome were found to share deleterious, 
autosomal recessive variants in the DHODH gene (Ng et al., 2010b).  This was 
shortly followed by the identification of de novo variants in MLL2 in patients with 
Kabuki syndrome (Ng et al., 2010a).  Both discoveries, and many more since, have 
established WES as a useful and powerful diagnostic tool for isolated, unrelated 






Figure 1.11.  Different methods of exome capture  
In both methods illustrated DNA fragments containing the sequence of interest (light blue) are 
captured by hybridisation to a set of complimentary probes (dark blue/black hashed).  In A) Solid-
phase hybridisation probes are fixed to a microarray whereas in B) Liquid-phase hybridisation probes 
are biotinylated (black) and in suspension which can then bind to streptavidin beads.  Following 
capture, unwanted DNA fragments (red) are removed by washing and the desired fragments eluted 
from the probes.  Reproduced from Teer et al., (2010). 
1.4.3 Summary 
WES is now a commonly used research technique in gene discovery in a wide 
variety of both common and rare disease (Majewski et al., 2011) and with decreasing 
costs the possible applications of NGS technologies has expanded (for example, 
detection of copy number variation, homozygosity mapping and RNA sequencing) 
(Medvedev et al., 2009, Ku et al., 2012, Seelow et al., 2012).  Given the large 
number of mechanisms that regulate growth (Conlon et al., 1999, Klingseisen et al., 
2011), the number of potential candidate genes for MPD is extensive.  It is therefore 
not feasible to sequence large numbers of genes in every patient by conventional 
capillary based sequencing methods.  This is not only due to time and cost but also 
the large quantity of DNA required may not be realistic to obtain in young patients 
with a small body mass.  Also many of these patients are single cases in non-
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consanguineous families and therefore are not suitable for gene discovery by genetic 
mapping methods.  NGS affords the ability to perform massive parallel sequencing 
providing an attractive, and now cost effective, method for screening a large number 
of genes.  WES has already led to the identification of novel disease causing genes in 
MPD including the centrosomal genes, CEP152 (Kalay et al., 2011) and PLK4 
(Martin et al., 2014).  As well as identifying disease genes in known pathways and 
mechanisms affecting growth, WES will also facilitate the discovery of unanticipated 
disease causing genes.  These may be functionally different to those previously 
discovered giving new insights into growth regulation. 
 
1.5 Thesis aims and objectives 
1.5.1 Hypothesis: MPD is a heterogeneous genetic disorder 
resulting from defects in a number of cellular pathways and 
mechanisms that reduce global cellularity  
Recent advances in DNA sequencing has led to a rapid increase in the discovery of 
novel disease causing genes in Mendelian disorders.  Despite this, many MPD 
patients still remain without a molecular diagnosis.  Within this patient group, 
marked clinical heterogeneity has been described suggesting a large degree of 
underlying genetic heterogeneity.  This is supported by the multiple disease causing 
genes identified in MPD to date (Section 1.3).  In addition, reduced growth is a 
common finding in many different developmental disorders, several of which may 
overlap with MPD further adding to the genetic diversity of this group of conditions.  
It is likely that genetic heterogeneity combined with the rarity of MPD has hindered 
gene discovery to date.  For many disease causing genes in MPD, mutations have 
only been reported in a small number of families (often only one) preventing detailed 
characterisation of distinct phenotypes (Section 1.3).  Identifying other possible cases 
with mutations in the same gene has therefore been difficult on a phenotypic basis.        
To date, almost all disease causing genes identified in MPD encode proteins that 
operate in different but overlapping mechanisms which alter cell cycle kinetics and 
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survival, including DNA replication, mitosis and DNA damage response and repair.  
Such processes involve many different proteins, regulated by complex signalling 
pathways.  Therefore, any gene encoding proteins involved in such processes and 
pathways could be considered a possible candidate for MPD.  The diversity of 
potentially affected processes is further illustrated by genome wide association 
studies in which a large number of genetic loci have been link to both height and 
head circumference (Weedon et al., 2008, Ikram et al., 2012b, Taal et al., 2012a).  In 
addition, growth retardation is a commonly reported finding in many knockout 
mouse strains (Reed et al., 2008).   
1.5.2 Thesis aims 
The objective of this thesis was to define the molecular basis for profound growth 
impairment in patients for whom a recognisable syndrome is not apparent and a 
molecular diagnosis has not yet been determined in order to identify novel disease 
genes.  Secondly, I aimed to characterise associated phenotypes, with a view to 
improving clinical diagnosis, management and outcomes.  Finally, identifying novel 
genetic causes of MPD may provide new insights into physiological growth 
regulation. 
I plan to address this with the following aims:-   
1. Design and implement an analytical pipeline for the analysis of WES in a large 
cohort of clinically diverse MPD patients. 
 
2. Identify novel candidate disease causing genes in MPD through the analysis of 
WES. 
 
3.  Establish the impact of mutations in novel disease genes on protein function and 
investigate the mechanism by which protein dysfunction impairs growth. 
 




Chapter 2: Materials & Methods 
2.1 Patient recruitment  
Patients were recruited to research studies at the MRC Human Genetics Unit in 
Edinburgh, UK, the Institute of Human Genetics at the University of Cologne, 
Germany and the Nemours Foundation, Delaware, USA by their local physician.   
2.1.1 Ethical consent  
This study was approved by the multi-centre research ethics committee for Scotland 
(04:MRE00/19).  Collaborative studies, from which results in this thesis are also 
obtained, were approved by the Cologne hospitals ethics board or the Nemours 
Office of Human Subject Protection (NOHSP) and Institutional Review Board.  
Informed consent was obtained from all families.   
2.1.1 Inclusion criteria 
All patients selected into the study had a clinical diagnosis of MPD based on head 
(occipital-frontal) circumference (OFC) and height being more than 4 standard 
deviations (s.d.) below the population mean at the time of recruitment.  Standard 
deviations for height, weight, and OFC normalized for age and sex were calculated 
using Cole's LMS method using UK 1990 cohort data (Freeman et al., 1995).  Age at 
examination was corrected for prematurity where birth was before 37 weeks 
gestation and age <2 years.  Age was rounded to the nearest month prior to s.d. 
calculation. 
2.1.3 Clinical data collection 
Medical history, anthropometric data, examination findings and clinical laboratory 
results were obtained by questionnaire from the referring physician.   
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2.2 Chemical reagents and buffers 
2.2.1 Sources of reagents 
All chemicals were purchased from Sigma-Aldrich, Fisher Scientific or Amersham 
Biosciences (GE Healthcare Life Sciences).  Enzymes were from New England 
Biolabs, Promega and Roche and cell culture materials from Gibco (Life 
Technologies). 
2.2.2 Buffer solutions 
All buffers listed were prepared with dH2O (Elix® essential 5 water purification 
system, EMD Millipore). 
10 X TBE:  0.89 M Tris base, 0.89 M boric acid, 20 mM EDTA 
TE: 10 mM Tris-HCl and 1 mM EDTA (autoclaved at 121oC for 15 minutes to 
sterilise) 
Low TE: 10 mM Tris-HCl and 0.1 mM EDTA (pH8, autoclaved at 121oC for 15 
minutes to sterilise) 
WCE Buffer: 50 mM Tris-HCl pH8, 280 mM NaCl, 0.5% NP40, 0.2 mM EDTA, 
0.2 mM EGTA, 10% glycerol and EDTA-free protease inhibitor tablet (Roche) 
1 X Western transfer buffer: 25 mM Tris base, 192 mM glycine, 0.1% (w/v) SDS, 
20% (v/v) methanol 
1 X TBST: 0.05 M Tris base, 0.15 M NaCl, 2% (v/v) Tween-20 (pH 7.5)   
PHEM: 25 mM Hepes-NaOH pH 6.8, 100 mM EGTA, 60 mM PIPES, 2 mM MgCl2 
Hypotonic Buffer:  0.56% (w/v) KCl, 1% (w/v) Na3C6H5O7 
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2.3 Cell culture methods 
2.3.1 Preparation and growth of human cell lines 
2.3.1.1 Lymphoblastoid cells (LBCs) 
Lymphocytes were isolated from fresh blood samples and transformed with Epstein 
Barr virus by Sean O’Neil (MRC HGU, IGMM, Edinburgh).  LBCs were cultured in 
suspension in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco) 
supplemented with 10% fetal calf serum (FCS, HyClone™), 100 U/ml penicillin and 
100 µg/ml streptomycin.  Cells were maintained at 37oC with 5% CO2 and at a 
density of 2-10 x 105cells/ml.     
2.3.1.2 Fibroblast cells 
Fibroblasts were cultured from a 3x3 mm punch skin biopsy taken from an affected 
MPD patient and two healthy control individuals.  Skin biopsies were performed by a 
local physician under aseptic technique (iodine and mercurochrome based antiseptics 
were avoided).  The biopsy was transported in PBS or culture media.  On arrival the 
sample was dissected into smaller segments using a scalpel and placed in a sterile 16 
mm laten tube (Nunc™ cell culture tube, Thermo Scientific) under a glass coverslip 
(Nunc™ Thermanox™ coverslip, Thermo Scientific).  These were cultured in pre-
warmed AmnioMax™ C-100 basal media plus AmnioMax™ C-100 supplement 
(Gibco) at 37oC with 3% O2  and 5% CO2.  Initial skin biopsy samples were cultured 
for a minimum of 2 weeks prior to first passage.  When confluent, cells were 
passaged by the removal of media and washed twice with pre-warmed PBS.  Cells 
were detached from the vessel surface by the addition of trypsin:versene (1:1, v:v) 
and incubated at 37oC for 5 minutes.  Cells were re-suspended in fresh media and 
split 1:2-1:6 of their original density.  Cells were maintained in the same culture 
medium at 37oC with 3% O2 and 5% CO2. 
2.3.1.3 Cell preservation 
Initially cells were stored at -80oC in 2ml cryostat tubes re-suspended in 1ml FCS 
and 10% DMSO prior to transfer to liquid nitrogen for longer term storage.  Cell 
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pellets for nucleic acid and protein extraction were obtained by centrifugation of re-
suspended cells at 1200 rpm (Allegra™ X-22 centrifuge, Beckman Coulter) for 4 
minutes followed by removal of supernatant and stored until required at -80oC.  Prior 
to use, cell pellets were thawed and washed in PBS by centrifugation at 6,000 rpm 
for 10 minutes (Heraeus Megafuge 1.0R centrifuge, Thermo Scientific).   
2.3.2 Transfection with short interfering RNA (siRNA) 
NCAPD3 and Luciferase control siRNA oligonucleotides were designed using the 
Whitehead Institute siRNA design tool (http://jura.wi.mit.edu/bioc/siRNA) (Yuan et 
al., 2004) by Carol-Anne Martin (MRC HGU, IGMM, Edinburgh). 
NCAPD3 siRNA: 5´CAU GGA UCU AUG GAG AGU AUU-3´      
Luciferase control siRNA: 5´-CUU ACG CUG AGU ACU UCG AUU-3´      
siRNA oligonucleotides were transfected into monolayer primary fibroblasts at 40-
50% confluency using DharmaFect transfection reagent (Thermo Scientific) 
according to manufacturers’ instructions.  Each well of a 6-well plate was transfected 
with 25 nM siRNA.  Two solutions were prepared, one containing 50 nmol siRNA in 
200 µl of Opti-MEM I Medium (Life Technologies) and the second contained 5 µl of 
DharmaFect in 195 µl of Opti-MEM.  Both solutions were incubated at RT for 5 
minutes prior to combining and then incubated for a further 20 minutes before adding 
to the cells.  Following addition of the transfection solution, a further 800 µl Opti-
MEM was added and cells were incubated for 8 hours at 37oC with 3% O2 and 5% 
CO2.  The transfection media was then removed by aspiration and replaced with 
AmnioMax™ C-100 media plus supplement.   
2.4 Nucleic acid methods  
2.4.1 Nucleic acid extraction from human cells 
2.4.1.1 Genomic DNA 
Genomic DNA was extracted from whole blood using the Genomic DNA extraction 
kit (Illustra) or saliva samples using ORAgene® collection kits according to 
manufacturer’s instructions.  This was performed by Sean O’Neil (MRC HGU, 
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IGMM, Edinburgh).  Genomic DNA was extracted from ~1 x 106 primary fibroblasts 
using the DNeasy blood and tissue kit (Qiagen) following the manufacturers’ 
instructions and eluted in 100 µl of elution buffer. 
2.4.1.2 RNA and generation of cDNA 
RNA was extracted from human LBCs and primary fibroblasts using the RNeasy 
Mini Kit (Qiagen) as per manufacturers’ instructions.  Approximately 1 x 106 cells 
were homogenised using a Qiashredder column (Qiagen) by centrifugation at 16000 
g for 2 minutes.  An on-column treatment was then performed with 30 U RNase-free 
DNase I (Qiagen) for 15 minutes to remove genomic DNA.  RNA was eluted in 30 
µl of RNase-free H2O (Qiagen) and stored until required at -80
oC.   
Complimentary DNA (cDNA) was then generated from template RNA by reverse 
transcription.  Each reaction contained 400 ng to 1 µg of RNA, 100 pmol random 
primers (Promega), 5 mM Dithiothreitol (DTT) and 40 U Protector RHase Inhibitor 
(Roche) made up to a total volume of 14µl with RNase-free H2O.  The reaction was 
initially heated to 70oC for 5 minutes followed by incubation for 5 minutes on ice to 
denature RNA secondary structures.  The reverse transcriptase (RT) enzyme (20 U 
AMV RT, Roche) and buffer (1 X AMV RT buffer, Roche) were then added along 
with 1 µM dNTPs in 6 µl of RNase-free H2O.  The 20 µl reaction was incubated at 
42oC for 60 minutes followed by incubation at 75oC for 8 minutes to inactivate the 
RT enzyme.  For each RNA sample the reaction was also performed in the absence 
of RT (substituted with RNase-free H2O) to ensure contamination with genomic 
DNA had not occurred during the generation of cDNA.  Samples of cDNA were 
stored at -20oC.     
2.4.2 Polymerase chain reaction (PCR) 
2.4.2.1 Primer design 
Primers were designed to amplify specific exons and intron-exon boundaries using 
the ExonPrimer tool (http://ihg.gsf.de/ihg/ExonPrimer.html) which utilises the 
Primer3 tool (v.0.4.0) (Untergasser et al., 2012).  Primers ranged from 17 to 27 bp in 
length with a melting temperature (Tm) of 57
oC to 63oC.   This script utilises a 
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nearest neighbour formula to calculate the Tm of individual primers which did not 
differ by more than 4oC between forward and reverse primer pairs (SantaLucia, 
1998).  Primers designed and used in this thesis are listed in Appendix I.  
2.4.2.2 Amplification of genomic DNA and cDNA 
Regions of interest were amplified by polymerase chain reaction (PCR) using the 
relevant primers pairs designed as described in Section 2.4.2.1.  PCR reactions were 
performed using Taq polymerase (Thermo Scientific).  Each reaction contained 10 
ng of genomic DNA, 1 X Reddymix PCR mastermix (Thermo Scientific) and 0.5 
µM of both forward and reverse primers in a final reaction volume of 10 µl made up 
with dH2O.   
Prior to amplification of cDNA, each sample generated in Section 2.4.1.2 was diluted 
5 fold and 1 µl used in each 10 µl reaction volume.  For regions with a high GC 
content, 5% (v/v) DMSO was added to the PCR reaction to inhibit secondary 
structure formation.          
A touchdown PCR programme was used to permit efficient amplification of different 
primer sets with a range of annealing temperatures to allow for variation in Tm 
between different primer pairs.  This allowed multiple PCR targets to be routinely 
amplified on the same PCR plate, increasing throughput of samples.  PCRs were 
performed using a DNA Engine Tetrad 2 thermal cycler (MJ research/Bio-Rad) using 
the following programme;  
1. Denaturation: 94oC for 4 minutes  
2. Cycle 1 (x3); 
Denaturation: 94oC for 30 sec  
Annealing:  65oC for 30 sec 
Extension:  72oC for 45 sec 
3. Cycle 2 (x3); 
Denaturation: 94oC for 30 sec  
Annealing:  62oC for 30 sec 
Extension:  72oC for 45 sec 
4. Cycle 3 (x3); 
Denaturation: 94oC for 30 sec  
Annealing:  59oC for 30 sec 
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Extension:  72oC for 45 sec 
5. Cycle 4 (x35); 
Denaturation: 94oC for 30 sec  
Annealing:  56oC for 30 sec 
Extension:  72oC for 45 sec 
6. Extension: 72oC for 10 minutes 
7. Hold: 10oC for 15 minutes 
Amplification of cDNA with primers complimentary to CENPJ was performed using 
the following PCR programme; 
1. Denaturation: 94oC for 4 minutes  
2. Cycle 1 (x35); 
Denaturation: 94oC for 30 sec  
Annealing:  63oC for 30 sec 
Extension:  72oC for 90 sec 
3. Extension: 72oC for 10 minutes 
4. Hold: 10oC for 15 minutes 
2.4.3 Agarose gel electrophoresis  
Gels were cast by dissolving 1% (w/v) agarose (Hi-Pure Low EEO agarose, Biogene) 
in 1 X TBE buffer (Section 2.2.2) by heating the solution to boiling in a conventional 
microwave for 1-2 minutes.  To visualise nucleic acids, ethidium bromide (0.5 
µg/ml), SYBR® gold (1 in 10,000 dilution) (Life Technologies) or SYBR® Safe (1 
in 10,000 dilution) (Life Technologies) was added to the liquid gel (v/v) during 
cooling.  If required, samples were mixed with 1x blue/orange loading dye 
(Promega) prior to loading.  Samples were then loaded into the gel alongside a 
reference DNA marker containing fragments of known sizes (1 kb plus DNA ladder, 
Life Technologies and 100 bp ladder, Promega).  A constant voltage of 60-120 volts 
(depending on gel volume) was applied to resolve DNA fragments of different sizes.  
Nucleic acids were then visualised using a UV (U:Genius3) or LED transilluminator 
(Syngene) to determine the presence and size of nucleic acid fragments.   
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2.4.4 PCR purification from agarose gel 
Where multiple PCR products were resolved by electrophoresis, each band was 
excised from the gel using a scalpel.  The PCR product was then purified from the 
gel using the QiaQuick Gel Extraction Kit (Qiagen) according to the manufacturers’ 
instructions.  DNA was finally eluted in 30µl of elution buffer.  
2.4.5 Ligation of DNA into plasmids and transformation of 
chemically-competent cells 
20 ng of gel-extracted PCR product was ligated into pGEM®-T Easy Vector 
(Promega) at a 3:1 insert:vector molar ratio as per manufacturers’ instructions.  The 
ligation reaction was incubated for 6 hours at RT prior to transformation of 
chemically competent cells. 
Chemically competent DH5α E. coli was prepared by Martin Reijns (MRC HGU, 
IGMM, Edinburgh) (Reijns, 2006) and stored in 200 µl aliquots at -80oC until 
required for transformation.  Cells were thawed on ice and transformed by the 
addition of 1 µl of ligation reaction to 50 µl of DH5α cells and incubated on ice for 
30 minutes.  Cells were then heat-shocked at 42oC for exactly 45 seconds and placed 
on ice for 2 minutes to recover.  Cells were re-suspended in 500 µl Luria-Bertani 
(LB) broth medium and incubated for 60 minutes with shaking.  500 µl of cells were 
then evenly distributed over a pre-warmed LB-agar plate with ampicillin (0.1%, v/v) 
and incubated overnight at 37oC following which discrete colonies were visible.  
Individual colonies were then harvested and grown for a further 24 hours in 5 ml LB 
broth with 50µg/ml ampicillin at 37oC with constant agitation.  Cells were pelleted 
by centrifugation 4000 rpm for 4 minutes (Allegra X-12R centrifuge, Beckman 
Coulter) and the residual broth discarded prior to DNA extraction (Section 2.4.6).    
2.4.6 Purification of plasmid DNA from E.coli cells    
DNA was extracted from transformed DH5α E.coli using the QIAprep Spin Miniprep 
Kit (Qiagen) following manufacturers’ guidelines and eluted in 50 µl elution buffer. 
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2.4.7 Quantification and quality assessment of nucleic acids 
Nucleic acid concentration was determined in 1.5µl of sample using a NanoDrop 
1000 UV-Vis Spectrophotometer (Thermo Scientific) by measuring the sample 
absorbance at 260 nM.  Purity was also assessed by measuring the absorbance at 230 
nM and 280 nM.  A 260/280 ratio and 230/260 ratio of greater than 1.8 indicates 
minimal protein, carbohydrate and lipid contamination.    
Genomic DNA was additionally quantified by IGMM technical services using the 
QuantiFluor® dsDNA system (Promega).  Double-stranded DNA in each sample 
was stained with QuantiFluor® dye (Promega) (504nmEx/531nmEm) and the emitted 
wavelength measured using a 1420 Victor2 microplate reader (Perkin Elmer).  DNA 
concentration was calculated based on a standard curve (0 - 100 ng/ml) plotted from 
measurements of Lambda DNA at a known concentration after serial dilutions.  As 
many of the DNA samples had been stored for several years and obtained from 
multiple samples worldwide, each sample was also assessed for evidence of 
degradation by agarose gel electrophoresis.  Over time DNA can fragment following 
exposure to various environmental insults including UV radiation and variations in 
temperature which will occur through repeated freeze-thaw of samples (Dean et al., 
2001) (Figure 2.1).   
Samples which appeared severely degraded or those of low concentration (less than 
30 ng/µl) were amplified using GenomiPhi V2 DNA amplification kit (Illustra™) as 
per manufacturers’ instructions.  The amplification reaction was incubated at 30oC 
for 17 hours using a DNA Engine Tetrad 2 thermal cycler.  The enzyme was then 
inactivated by heating to 65oC for 10 minutes.  Samples were then purified by 
ethanol precipitation.  Absolute ethanol was added to each sample at a 2:1 ratio 
(EtOH:DNA, v/v) with 0.1 M NaOAc (pH 5.2) and incubated on ice for 40 minutes.  
DNA was collected by centrifugation at 2800 g for 15 minutes and then washed in 
70% ethanol (EtOH:dH2O, v/v).  The DNA pellet was left to air dry for 5 minutes 
before resuspension in 20 µl low TE buffer (Section 2.2.2).  The quantity and quality 
of DNA were then reassessed as prior to amplification.  DNA yield ranged from 2 
ng/µl to 7.7 µg/µl.  Following the two methods of quantification, the concentration 
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most consistent with the intensity of DNA visualised following gel electrophoresis 
was subsequently used.   
 
Figure 2.1. Agarose gel electrophoresis of genomic DNA  
Example of resolution of different DNA samples following gel electrophoresis.  A) Poor quality 
sample in which the DNA has degraded into multiple fragments of various sizes appearing as a large 
smear.  B and C) Two samples show some evidence of degradation although the majority of DNA 
remains intact at 12 kb.  D and E) Good quality samples with minimal degradation demonstrated by 
only fragments with a high molecular weight.  
 
2.4.6 DNA methods 
2.4.6.1 Whole exome capture 
Samples were selected on the availability of DNA of adequate quantity and quality 
and also prioritised on whether parental DNA samples were available.  To maximise 
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the chances of identifying pathogenic variants, as many affected cases as possible 
were selected whilst also including samples from unaffected and affected parents and 
siblings where possible.  In families with a strong degree of consanguinity 
(relationship between parents at least third cousins), only the affected case was 
sequenced as it was anticipated that the pathogenic variant would most likely be 
homozygous in these cases and thus sequencing parental DNA would be less 
informative compared to non-consanguineous families.  In total, DNA samples from 
166 individuals were prepared and sequenced, 154 of which were performed 
elsewhere (45 were prepared at the Wellcome Trust Sanger Institute (WTSI, 
Cambridge, UK) and 109 by Oxford Gene Technology (OGT, Oxfordshire, UK)).             
Preparation of whole exome libraries from 12 samples was performed by myself 
using the SureSelectXT target enrichment system for Illumina paired-end sequencing 
library (Agilent Technologies) as per manufacturers’ instructions (Protocol version 
1.3).  All DNA quantification steps and assessment of library fragment size were 
performed using a 2100 Bioanalyzer with high sensitivity DNA kit (Agilent 
Technologies) unless otherwise stated.  All purification steps were performed using 
Solid Phase Reversible Immobilization (SPRI) (Agencourt AMPure XP, Beckman 
Coulter) as per manufacturers’ instructions, in DNA LoBind 1.5ml tubes (Eppendorf) 
using a Dynal DynaMag™-2 magnetic stand (Life Technologies).  Beads were 
washed in freshly prepared 70% ethanol (EtOH:nuclease-free H20, v/v) and DNA 
fragments eluted in nuclease-free H20 (Life Technologies).   
For each sample, 3 µg of genomic DNA was fragmented to approximately 200 bp 
(range 50 to 500 bp) by sonication using a Bioruptor® Plus (Diagenode) as per 
manufacturers’ instructions.  Genomic DNA was diluted to 0.01 µg/µl in TE buffer 
(Section 2.2.2) and sonication was performed in 30 second cycles for 2 to 3.5 hours 
at 4oC.  Size of fragments was initially assessed by agarose gel electrophoresis prior 
to SPRI bead purification at a 1:5 ratio (DNA:beads) to select 100-200 bp fragments.  
End repair and adapter ligation were performed using the Agilent SureSelectXT 
reagent kit for Illumina HiSeq as per manufacturers’ instructions.  Libraries were 
amplified prior to exome capture by high fidelity PCR.  Each reaction contained 15 
µl of adapter ligated DNA library, 1 X KAPA HiFi™ HotStart ReadyMix (Kapa 
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BioSystems), 2.5 µl of PE 1.0 primer and indexing reverse primer (SureSelectXT 
reagent kit) made up to 50 µl volume with nuclease-free H20.  Libraries were 
amplified using the following PCR programme: 
1. Denaturation: 98oC for 2 minutes  
2. Cycle 1 (x5); 
Denaturation: 98oC for 30 sec  
Annealing:  65oC for 30 sec 
Extension:  72oC for 60 sec 
3. Extension: 72oC for 10 minutes 
4. Hold: 10oC for 10 minutes 
500 ng of each amplified library was concentrated by dehydrating samples in a 
centrifugal vacuum concentrator (DNA 120 SpeedVac®, Thermo Scientific) at RT 
for 30 minutes at 300 g and re-suspended in 3.4 µl nuclease-free H2O.  Exome 
capture was performed using the Agilent SureSelectXT Human All Exon V4 kit.  This 
exome capture kit was used in the library preparation of all 166 samples.  Block, 
hybridisation and bait solutions (SureSelectXT reagent kit) were prepared as per 
manufacturers’ instructions.  Libraries were denatured after addition of 5.6 µl of 
blocking solution by heating to 95oC for 5 minutes using a DNA Engine Tetrad 2 
thermal cycler followed by incubation at 65oC for 5 minutes.  Immediately after, 13 
µl of hybridisation solution was combined with 7 µl of bait solution and added to 
each library maintained at 65oC followed by incubation at the same temperature for 
24 hours.  Hybridised fragments were isolated using Streptavidin-coated magnetic 
beads (Dynabeads® MyOne™ Streptavidin T1, Life Technologies) prepared as per 
manufacturers’ instructions.  Finally, the captured library was amplified indexing 
each library with a unique index sequence (SureSelectXT reagent kit) to allow 
sequencing of multiple libraries in a single run.  Each reaction contained 15 µl of 
captured DNA library, 1 X KAPA HiFi™ HotStart ReadyMix (Kapa BioSystems), 
1µl each of post-capture forward and reverse primer with index (SureSelectXT reagent 
kit) made up to 50 µl volume with nuclease-free H20.  Post-captured libraries were 
amplified using the following PCR programme: 
1. Denaturation: 98oC for 2 minutes  
2. Cycle 1 (x12); 
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Denaturation: 98oC for 30 sec  
Annealing:  57oC for 30 sec 
Extension:  72oC for 60 sec 
3. Extension: 72oC for 10 minutes 
4. Hold: 10oC for 10 minutes 
Following final quantification, each library was dehydrated by centrifugation at 300 
g in a vacuum concentrator at 43oC for 30 minutes followed by reconstitution in low 
TE buffer to a concentration of 10 nM.  Libraries were then combined in equimolar 
amounts into two pools.  Libraries with similar average fragment length were pooled 
together and a 25% representation of A and C or T and G at each site in the unique 
index sequence were ensured in each pool.   
2.4.6.2 Preparation of custom designed AmpliSeq™ libraries 
An Ion AmpliSeq™ primer panel was custom designed using the online web tool 
(https://www.ampliseq.com, Life Technologies).  All coding exons plus 25 bp into 
flanking introns of 20 genes were specified.  The designed panel, based on the hg19 
reference sequence, contained 686 amplicons in three pools with 98.5% coverage of 
the desired sequence.  Genes (relevant to this thesis) included in the panel are listed 
in Table 2.1. 
Table 2.1. Genes and their associated coverage in the custom designed 
AmpliSeq™ primer panel  
Gene Coverage % Gene Coverage % 
SMC2 99.21 NCAPD3 99.78 
SMC4 95.97 XRCC4 100 
NCAPH 99.94 PLK1 100 
NCAPH2 100 AURKB 100 
NCAPG 96.24 KIF4A  100 
NCAPG2 99.98 USP2 97.58 
NCAPD2 99.38 FAT1 99.77 
 
Libraries were prepared using the Ion AmpliSeq™ library kit 2.0 (Life Technologies) 
as per manufacturers’ instructions (Ion AmpliSeq™ library preparation, v5.0).  For 
each DNA sample, three individual PCR reactions were performed with each primer 
pool.  Each PCR reaction consisted of 5 ng genomic DNA with 1 X primer pool and 
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1 X HiFi master mix in a 3.4 µl volume performed over 19 cycles.  To prevent 
evaporation each reaction was performed in a 384-well plate (Roche) heat sealed 
with a foil lid (ALPS™ 35 manual heat sealer, Thermo Scientific).  The three 
amplified primer pools were then combined prior to digestion of primer sequences.  
Reagent volumes in subsequent steps were scaled down according to the initial PCR 
reaction volume (1/6th of recommended reaction volumes used).  Primer digest was 
performed at the following incubations; 50oC for 10 minutes, 55oC for 10 minutes 
and 65oC for 20 minutes.  Unique Ion Xpress™ barcode adapters (Life 
Technologies), numbers 1-96, were ligated onto individual libraries to allow 
multiplexing of samples during sequencing.  SPRI bead purifications were performed 
as described in Section 2.4.6.1 with the exception that bead immobilization was 
performed in a U-bottom 96-well plate (Greiner Bio-One) using a corresponding 
magnetic stand (DynaMag™-96 side magnet, Life technologies) and DNA eluted in 
low TE buffer.  Following adapter ligation and purification, libraries were amplified 
as per manufacturers’ instructions using the following PCR Programme; 
1. Denaturation: 95oC for 5 minutes  
2. Cycle 1 (x8); 
Denaturation: 95oC for 15 sec  
Annealing:  58oC for 15 sec 
Extension:  70oC for 60 sec 
3. Hold: 10oC for 10 minutes 
Amplified libraries were then purified as per manufacturers’ instructions and 
quantified as per Section 2.4.6.1.  Serial dilutions of individual libraries was 
performed in low TE buffer (Section 2.2.2) to achieve a final concentration of 100 
pM.     
2.4.6.3 Array comparative genomic hybridisation (array-CGH) 
Genomic DNA from six unaffected individuals (three males and three females) was 
combined in equi-molar amounts to create two reference pools of DNA, one for each 
sex.  500 ng of test sample and sex-matched reference genomic DNA was labelled 
with Cyanine-3 (Cy3) and Cyanine-5 (Cy5) dyes respectively using the NimbleGen 
Dual-Colour DNA labelling kit (Roche) as per manufacturers’ instructions 
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(NimbleGen arrays user’s guide: CGH and CNV arrays v8.1).  The labelling was 
performed at half reaction volumes and samples were protected from the light where 
possible.  Following denaturation, the labelling reaction was incubated overnight at 
37oC before addition of the stop solution.  Precipitated DNA was washed with 
freshly prepared 80% ethanol (EtOH:dH2O, v/v) at 4oC and dried by centrifugation 
at 300 g in a vacuum concentrator (DNA 120 SpeedVac®, Thermo Scientific) at 
43oC for 5 minutes.  DNA was rehydrated in 25 µl dH2O for 20 minutes at RT prior 
to quantification using a NanoDrop 1000 UV-Vis Spectrophotometer (Thermo 
Scientific, Section 2.4.7).  20 µg of the labelled test sample was then combined with 
an equal amount of labelled (sex-matched) reference DNA and dehydrated as above 
for 15-20 minutes prior to re-suspending in 3.3 µl of a unique NimbleGen sample 
tracking control (Roche).  Hybridisation solutions (NimbleGen hybridisation kit) 
were prepared and added to the sample as per manufacturers’ instructions prior to 
loading onto a 12 x 135 K array slide (v3.1, Roche).  Hybridisation was then carried 
out by incubation at 42oC for 72 hours using a NimbleGen hybridisation system 4 
(Roche).  Array slides were washed (NimbleGen wash buffer kit) and dried as per 
manufacturers’ instructions and then immediately scanned using laser emission 
wavelengths of 532 nm and 635 nm (NimbleGen MS200 scanner).  NimbleScan 
software (v1.2) was used to calculate the relative intensity at each probe.  The CGH-
segMNT module of NimbleScan was used for the analysis with a minimum segment 
length of 5 probes and averaging window of 130 kb.  Regions of copy number 
variation were identified using SignalMap software (v1.9, NimbleGen) and 
compared to the Database of Genomic Variants (http://projects.tcag.ca/variations) to 
exclude polymorphic CNVs.  SignalMap assigns the probe position to the hg18 
reference genome.  For the purposes of this thesis, genomic coordinates have been 
translated to the hg19 reference to maintain consistency in results.  
2.5 Sequencing methods and variant detection 
2.5.1 ABI dye-terminator sequencing 
ABI sequencing was undertaken by the Institute of Genetics and Molecular Medicine 
(IGMM) sequencing service.  Purification of PCR products was performed using 
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1.2X SPRI beads (Agencourt AMPure XP, Beckman Coulter) as per manufacturers’ 
instructions.  Beads were washed as described in Section 2.4.6.1 and PCR product 
eluted in 15 µl dH2O.  Dye termination cycle sequencing reactions were performed 
using BigDye® Terminator v3.1 cycle sequencing kit (Life Technologies) as per 
manufacturers’ instructions.  A standard reaction contained 0.0625 X BigDye® ready 
reaction premix, 1 X BigDye® sequencing buffer, 0.165 µM of both forward and 
reverse primers and 2 µl of purified PCR product made up to 10 µl volume with 
dH2O.  For sequencing reactions, either gene specific or N13 primers were used 
(Appendix I).  For sequencing plasmids, 150 ng of plasmid plus 0.34 µM of both 
forward and reverse M13 primers (Appendix I) were heated to 96oC for 2 minutes in 
5 µl dH2O followed by addition of 0.125 X BigDye® ready reaction premix, 0.65 X 
BigDye® sequencing buffer made up to a final volume of 10 µl dH2O.  Cycle 
sequencing reactions of both PCR products and plasmids were then performed under 
the following conditions: 25 cycles of 96oC for 30 seconds, 50oC for 15 seconds and 
60oC for 4 minutes. 
Samples were precipitated in 24 µl 95% ethanol (EtOH:dH2O, v/v) with 0.23 M 
NaOAc (pH 4.8) and washed twice with 100 µl of 70% ethanol (EtOH:dH2O, v/v).  
DNA was precipitated by centrifugation at 3000 rpm for 30 minutes (Allegra™ X-12 
centrifuge, Beckman Coulter) and the pelleted DNA left to air dry for 5 minutes prior 
to resuspension in 15 µl Hi-Di formamide (Life Technologies).  Samples were then 
denatured by heating to 95oC for 5 minutes and immediately cooled on ice.   
Products were capillary-sequenced using an ABI 3730 (48 capillary) or 3130xl (16 
capillary) Genetic Analyzer.  Alignment of sequencing reads and detection of 
variants was performed using Mutation Surveyor® software (v3.30) (Softgenetics) or 
Sequencher 4.10.1 (Gene Codes Corp) with default settings.  Reference sequences 
for individual genes are listed in Appendix II. 
2.5.2 Illumina  
2.5.2.1 Sequencing  
100 bp paired-end sequencing of pooled whole exome libraries (166 in total) was 
performed using the Illumina® HiSeq 2000 sequencing system.  7-8 pooled libraries 
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were sequenced on an individual lane.  This was conducted at three different centres: 
OGT (n = 109), WTSI (n = 45) and the National High-throughput DNA sequencing 
centre in Denmark (University of Copenhagen) (n = 12). 
2.5.2.2 Alignment and variant calling  
FASTQ files containing sequencing reads for 158 libraries were aligned and 
recalibrated using a pipeline designed by Alison Meynert, James Prendergast and 
Martin Taylor (MRC HGU, IGMM, Edinburgh).  This is based on a previously 
established method (DePristo et al., 2011), an overview of which is shown in Figure 
2.2.  I performed alignment and recalibration of the remaining eight samples (all 
sequenced in Denmark) using the same tools to ensure consistency in analysis (script 
supplied in Appendix III).  Sequencing reads were initially aligned to the hg19 
reference genome (ftp://hgdownload.cse.ucsc.edu, 11.04.12) using the Burrows-
Wheeler Alignment tool (BWA, v6.2) (Li et al., 2009), a high speed, short read 
aligner algorithm.  Bases with a quality (PHRED) score of less than 10 were trimmed 
from the 3' end of each read prior to alignment.  Unmapped reads were then further 
aligned with the Stampy alignment tool (v1.0.21) (Lunter et al., 2011), a hybrid 
mapping algorithm with higher sensitivity.  Any reads mapping to identical positions 
in the genome (duplicates) were marked using Picard tools (v1.79) 
(http://picard.sourceforge.net/) and ignored in downstream variant detection to 
reduce errors from PCR amplification (Meynert et al., 2013).  Coverage of target 
exons was determined using the GATK DepthOfCoverage tool (Genome Analysis 
Toolkit v2.4.9) (https://www.broadinstitute.org/gatk/) and a BED file format listing 
the genomic coordinates of designed baits supplied by the manufacturer.  
Realignment around known and suspected indels was performed using the GATK 
RealignerTargetCreator and IndelRealigner using the following reference data sets 
for known indels: Single Nucleotide Polymorphism Database (dbSNP) version 137 
(Smigielski et al., 2000), Phase I release of indels from the 1000 Genomes Project 
(1KG) (Clarke et al., 2012), and a high confidence combined set of indels from Mills 
et al., (2011a) and the 1KG project (ftp://gsapubftp-
anonymous@ftp.broadinstitute.org/bundle/2.5/hg19/). Recalibration of base quality 
scores was performed using the GATK BaseRecalibrator and PrintReads tools.  
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Variant calling and recalibration was then performed on all 166 BAM (Binary 
Alignment Map) files by Alison Meynert using the GATK Unified Genotyper, 
VariantAnnotator and VariantRecalibrator tools (Figure 2.2).  Recalibration of called 
variants was performed using reference datasets of validated variants obtained from 
the 1KG (1000G_omni2.5) and HapMap (HapMap_3.3) sequencing projects (Frazer 
et al., 2007).  
All variants were initially annotated with predicted protein consequence using 
SnpEff (v3.2a) with the Ensembl 70 human annotations (Cingolani et al., 2012) and 
all variants not occurring in a gene were removed (Alison Meynert).  SnpEff also 
annotates variants with the corresponding ‘rs#’ identifier (if present) in dbSNP.  All 
remaining variants were then compiled into an SQL database and non-synonymous 
coding variants were additionally annotated using dbNSFP v2.0 (Alison Meynert) 
(Liu et al, 2013) which details the predictions from a further seven different 
programmes (see Chapter 3, Table 3.3).  All variants were additionally annotated 
using the Alamut-HT (Interactive Biosoftware, Rouen, France) programme 
(performed by Louise Bicknell, MRC HGU, IGMM, Edinburgh) which allows batch 
processing of large datasets through five splice prediction programmes (further 
details provided in Section 3.3.2).  Variants were then annotated with corresponding 
minor allele frequencies in the 1KG (Clarke et al., 2012) and NHLBI GO Exome 
Sequencing Project (ESP) databases (Seattle, WA: 
http://evs.gs.washington.edu/EVS/) (Alison Meynert) and finally, with the full gene 
name and any associated disease (OMIM morbid) acquired from the Ensembl 
database (http://www.ensembl.org/biomart/martview/).  I then performed all 
downstream filtering of variants using SQL scripts (Appendix IV) and the SQLyog 




Figure 2.2.  In-house alignment and variant calling pipeline for Illumina data.  
Samtools (v1.16) (http://samtools.sourceforge.net/). 
2.5.2.3 Copy number variation (CNV) analysis  
CNV analysis was performed in-house on all exome datasets of affected individuals 
by Mihail Halachev (MRC HGU, IGMM, Edinburgh) using ExomeCNV 
(Sathirapongsasuti et al., 2011).  ExomeCNV creates a reference read depth across 
each exon (as set by the bed file of designed capture baits obtained from the 
manufacturer) by either using a single reference sample or by pooling multiple 
samples that have been prepared and sequenced in a similar manner to the test 
sample.  The presence of a CNV may then be identified by detecting a deviation in 
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the depth of coverage in the test sample from the paired reference.  This is initially 
performed on a per exon basis and then across widening chromosome segments with 
sequential merging using the circular binary segmentation algorithm (Olshen et al., 
2004).  The latter improves power in CNV detection by combining depth of coverage 
over consecutive exons.  Minimum specificity and sensitivity were set at 0.999 in 
exon-wise calling and 0.99 in segment-wise calling with an admixture rate of 0.  The 
smallest region that has sufficient coverage to create enough power to detect a CNV 
is called and thus single exon CNVs will not be rejected if surrounded by copy 
neutral exons.    
Two reference datasets were created by pooling the depth of coverage obtained at 
each exon in five parental samples prepared and sequenced at WTSI and 55 parental 
samples prepared and sequenced at OGT.  The median read depth for each exon was 
then used as the reference to compare with each affected sample generating a log2 
ratio for each exon.  All singleton samples were matched according to where they 
were sequenced except for those samples prepared in Edinburgh and sequenced in 
Denmark which were matched to the OGT reference dataset.  For all samples in 
which parents were additionally sequenced, the analysis was performed twice 
comparing the read depth at each exon to that of each parent.  I then compiled all 
deleted regions into an SQL database and performed downstream filtering using SQL 
scripts (Appendix IV).     
2.5.3 Ion Proton™ and Ion Torrent™ 
Two pools containing 96 uniquely barcoded libraries (Ion Xpress™ barcode adapters 
1-96, Life Technologies) in equal concentrations were prepared (192 individual 
samples in total).  Libraries were then combined in equal volumes and quantified 
using a 2100 Bioanalyzer.  Each pool was sequenced at the Wellcome Trust Clinical 
Research Facility (WTCRF, Edinburgh) using an Ion P1™ chip kit (v2) and an Ion 
Proton™ semiconductor sequencing system (Life Technologies).   Sequencing reads 
were aligned to the hg19 reference genome and variants called using the Ion 
Torrent™ Suite Software (v4.0.2) (also performed at the WTCRF).  Variants were 
then annotated as per Illumina data by Mihail Halachev (MRC HGU, IGMM, 
Edinburgh).  Equal volumes of the remaining 6 Ampliseq libraries were pooled and 
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sequenced using an Ion 316™ chip kit (v2) and Ion Torrent™ semiconductor 
sequencing system (Life Technologies) performed by IGMM technical services 
(University of Edinburgh).  FASTQ files generated from the Ion Torrent™ sequencer 
were aligned and analysed by myself using NextGENe (v2.2.0) (Softgenetics) with 
the following alignment settings: matching requirements ≤ 12 bp and ≥ 65%, filter 
out variants with mutation percentage ≤ 20, SNP allele ≤ 3 counts and total coverage 
≤ 5 X except for homozygous variants, balance ratios ≤ 0.1 and frequency ≤ 80%.  
Reference sequences for individual genes are listed in Appendix II. 
 
2.6 Protein Methods 
2.6.1 Whole cell protein extraction 
Protein was extracted from cultured primary fibroblasts by detergent mediated cell 
lysis.  Harvested cell pellets were re-suspended in whole cell extract (WCE) buffer 
(Section 2.2.2) with 0.025 U benzinase nuclease (Novogen) and incubated on ice for 
30 minutes.  WCE buffer volume was matched to the number of harvested cells, for 
example, 3 x 106 fibroblasts were re-suspended in 200 µl of buffer.  Cellular debris 
was pelleted by centrifugation at 16000 g for 10 minutes at 4oC and the supernatant 
collected and stored until required at -80oC.         
2.6.2 Protein quantification 
A Bradford assay was performed to determine the protein concentration in whole cell 
extracts using the Bio-Rad protein assay kit (Bio-Rad laboratories Ltd).  2 µl of 
sample was added to 1 ml of 1 X dye reagent and incubated for 5 minutes at RT.  
The A595 was measured using a WPA* UV1101 Biotech Spectrophotometer 
(Colonial Scientific) and the protein concentration calculated from the absorbance 
reading using a standard curve (prepared by Margaret Harley, MRC HGU, IGMM, 
Edinburgh) generated from BSA standards (concentration range 0.2-1.5 mg/ml) 
provided by the manufacturer.  Three measurements were taken for each sample and 
the average used for quantification.   
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2.6.3 SDS-PAGE and Western immunoblotting 
Sodium dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE) was 
performed to separate proteins according to size using the NuPage®Novex gel 
system (Life Technologies) and pre-cast 4-12% Bis-tris 1 mm gels (Life 
Technologies).  30 µg of protein from each sample was denatured in 1 X sample 
loading buffer (Life Technologies) with 0.05 M DTT by heating to a minimum 
temperature of 70oC for 20 minutes.  Denatured samples were then loaded onto the 
gel (maximum 40 µl per well) alongside the precision plus protein standard (Life 
Technologies).  Electrophoresis was performed in 1 X MOPs SDS running buffer 
(Life Technologies) with 0.25% (v/v) NuPAGE antioxidant at 200 volts for 60 
minutes.       
Following separation, electrophoretic transfer of proteins to a nitrocellulose blotting 
membrane (Amersham) was performed using a Mini-PROTEAN® 3 Cell system 
(Bio-Rad).  The transfer was performed in 1 X western transfer buffer (Section 2.2.2) 
at 100 V for 60 minutes.  The membrane was then blocked in 5% Marvel (Premier 
foods) in 1 X TBST for 1 hour at RT with constant agitation.  Primary antibodies 
(Table 2.2) were diluted in fresh blocking solution at the relevant concentration.  
Following overnight incubation at 4oC with the primary antibody, the membrane was 
washed three times in 1 X TBST for 5 minutes.  A second incubation was then 
performed with the appropriate HRP-labelled secondary antibody (Table 2.2) also 
diluted in fresh blocking solution for 1 hour at RT with constant agitation.   
Table 2.2.  Details of antibodies used in western immunoblotting   
Antibody Dilution Species Catalogue No Company 
Primary 
NCAPD3 1:250 Rabbit A300-604A Bethyl labs 
NCAPG2 1:500 Rabbit A300-605A Bethyl labs 
NCAPH2 1:500 Rabbit A302-276A Bethyl labs 
NCAPH 1:500 Rabbit A300-603A Bethyl labs 








HRP was detected using an ECL detection kit (Amersham Biosciences) according to 
the manufacturers’ instructions.  ECL solutions A and B were combined in equal 
volumes (2 ml total volume for a 20 cm2 membrane) and mixed vigorously prior to 
adding to the membrane ensuring complete coverage of the membrane surface.  The 
membrane was incubated in the ECL detection solution for 1 minute at RT.  Excess 
solution was then removed and the membrane placed between two acetate sheets in a 
Hypercassette™ (Amersham).  In the absence of light, the membrane was exposed to 
photographic film (Kodak Biomax XAR film) and developed using a Konika SRX-
101A Developer.  The developed film was scanned and the image uploaded into 
Adobe Photoshop CS6 for presentation.        
2.7 Microscopy Methods 
2.7.1 Fixation of cells 
To visualise mitosis, primary fibroblasts were cultured on 16 mm glass coverslips 
(thickness 0.13 - 0.17 mm, Thermo Scientific) and fixed at 60-80% confluency.  
0.5% Triton™ X-100 (Sigma-Aldrich) in PHEM buffer (Section 2.2.2) was pre-
warmed to 37oC prior to the addition of 4% paraformaldehyde (Thermo Scientific).  
The fixative solution was then immediately added to the cells and incubated for 10 
minutes at RT followed by removal of the fixative and 2 x 5 minute washes in PBS.  
Fixed cells were stored until required at 4oC.         
To examine chromosome morphology, primary fibroblasts were cultured to 80% 
confluency in a 25cc flask (CELLSTAR®, Sigma-Aldrich).  Prior to fixation cells 
were incubated at 37oC at 3% O2 and 5% CO2 for 30 minutes with 70 ng/ml 
colcemid (Sigma-Aldrich) in culture media to disrupt microtubules.  Cells were 
washed in PBS and detached by trypsinisation followed by resuspension in culture 
media and centrifugation at 1200 rpm (Allegra™ X-22 centrifuge, Beckman Coulter) 
for 5 minutes to pellet the cells.  Cells were gradually re-suspended in 5mls of 
hypotonic buffer (Section 2.2.2) added in a drop-wise manner with gentle flicking of 
the tube and incubated for 10 minutes at RT.  Centrifugation was repeated as 
previously and supernatant removed.  Cells were then fixed by the addition of 5 ml 
of freshly prepared methanol:acetic acid, 3:1 (v/v), at 4oC in a drop-wise manner.  
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Centrifugation and re-suspension in fixative was repeated a further two times 
reducing the volume of methanol fixative each time to achieve a final suspension 
volume of 1 ml.     
2.7.2 Immunostaining 
PFA fixed cells on coverslips were blocked by incubation in 1% (v/v) bovine serum 
albumin (Sigma-Aldrich) in PBS at 37oC in a humidity chamber for 30 minutes.  
Incubations with primary and secondary antibodies at the following dilutions were 
performed under the same conditions in fresh blocking solution; 
Primary antibody: α-tubulin (B512) antibody (Cat. Number T6074, Sigma-Aldrich) 
diluted to 1:1000.   
Secondary antibodies: Alexa Fluor 488-linked anti-mouse antibody at 1:500 
dilution (Cat. Number A11029, Life Technologies) and 4´6-diamidino-2-
phenylindole (DAPI) (Fisher Scientific) at 1 µg/ml.   
Stained cells were washed three times in PBS for 5 minutes after incubation with 
primary and secondary antibodies.  Coverslips were mounted in Vectorshield® 
mounting medium (Vector Laboratories).  Methanol fixed cells were dropped onto a 
microscopy slide from a minimum height of 0.25 m.  Following evaporation of 
methanol cells were mounted in Vectorshield® mounting medium with DAPI.  All 
stained slides were stored at 4oC protected from light prior to microscopy.   
2.7.3 Microscopy  
Imaging of fixed cells was performed using a Zeiss Axioplan 2 widefield 
fluorescence microscope with an objective lens mounted PIFOC collar.  Images were 
obtained in multiple Z planes using a 63 X 1.4 plan apochromat objective (Zeiss) and 
fluorescence filters for DAPI (359 nm excitation, 461 nm emission) and FITC (489 
nm excitation and 508 nm emission).  Image capture and acquisition was performed 
with an ORCA-ER camera (Hamamatsu) using Volocity software (PerkinElmer).  To 
improve resolution, images were deconvolved using constrained iterative restoration 
with Volocity software.  Metaphase chromosomes were imaged in a single Z plane 
using a 100 X 1.4 plan apochromat objective (Zeiss) and DAPI filter.  Image capture 
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and acquisition was obtained using a CoolSnap HQ2 camera (Roper Scientific) and 
iVision software.  Scale of images in iVision software (IPLab) was determined using 
a script designed by Matt Pearson (MRC HGU, IGMM, Edinburgh) in Volocity 
software.   
2.7.4 Flow cytometry  
3 x 106 cells were harvested by trypsinisation and then washed by the addition of 10 
mls PBS added in a drop-wise manner.  Cells were pelleted by centrifugation at 1200 
rpm (Allegra™ X-22 centrifuge, Beckman Coulter) for 10 minutes and supernatant 
gently removed followed by fixation of cells in 900 µl 70% EtOH/dH2O at 4
oC 
added in a drop-wise manner.  Fixed cells were stored at -20oC.  At least 60 minutes 
prior to flow cytometry, cells were thawed and washed twice in PBS before being re-
suspended in 100µg/ml RNase A and 50 µg/ml propidium iodide.  Stained cells were 
incubated on ice and protected from light.  Flow cytometry was performed by 
Elizabeth Freyer (MRC HGU, IGMM, Edinburgh) using a FACScalibur (BD 
Biosciences).  Subsequent data analysis was performed using FlowJo software 
(v7.6.5, Tree Star). 
2.8 Data Analysis 
Graphs were generated and statistical analysis performed using GraphPad Prism v6 
(GraphPad Software).  Statistical comparisons of normally distributed continuous 
data were performed using the two tailed Students unpaired t-test and comparisons of 
categorical data performed using the Fisher’s exact test or Chi squared test with 
Yates correction.  Statistical comparison of three or more groups of non-normally 
distributed data was performed using the non-parametric Kruskal-Wallis test 








Chapter 3:   Diagnosis and gene discovery in MPD by 
whole exome sequencing (WES) 
 
3.1 Introduction 
In this Chapter, the development of a filtering workflow for the identification of 
pathological mutations in this cohort of MPD patients is described.  The pipeline 
integrates many of the filtering strategies previously employed by other sequencing 
projects as well as incorporating new methods to remove sequencing errors and 
prioritise candidate disease genes.  This led to an increase in diagnosis within this 
diverse patient group as well as the identification of novel disease genes.    
 
3.2 Description of samples and sequencing data 
3.2.1 Samples selected for WES 
Analysis of WES was performed in 95 out of a possible 114 families within the MPD 
cohort who did not yet have a molecular diagnosis.  166 individuals were sequenced 
of which 102 were affected (Table 3.1).  In 57 families only the affected case was 
sequenced due to the presence of consanguinity or lack of adequate DNA available 
from other family members.  Families were then categorised as singletons, pairs, 
trios or quads depending on which additional family members’ were also sequenced 
(Table 3.1).  Data from eight families in which the causative variant(s) had already 






   
92 
 
Table 3.1. Family relationships of WES samples 
 Number of samples 
Individuals sequenced 
Affected individuals sequenced 
Singletons without any additional family samples  
Pairs: Singleton with affected sibling (pairs)  
Trios: Singleton with both parental samples (trios) 
Trios(m): Singleton with sample from mother & unaffected sibling  
Quads: Affected sibling pairs with parental samples (quads) 
Affected cases from consanguineous families* 










* Relationship between parents 3rd cousin or closer. 
3.2.2 Quality analysis of sequencing data 
Overall, a mean of 82,370,661 sequencing reads (range 34,961,608 to 203,909,410) 
was generated per sample, of which an average of 92% uniquely mapped to the 
reference genome (range 74-98%).  On-target coverage with a read depth of at least 
15X ranged from 79% to 96% (mean=89%), with average on-target read depth 
ranging from 37 to 119 (mean=72) per sample.   
Comparison between samples prepared and sequenced in the three different locations 
(Table 3.2) identified significant differences in the number of sequencing reads, 
mean read depth and on-target coverage between each group indicating technical 
variation in the efficiency in both library capture and sequencing (Table 3.2).  WTSI 
samples were the earliest libraries prepared and showed the lowest capture efficiency 
with less on-target coverage indicating a less efficient protocol was used at this time.  
To compensate for early inadequacies in capture methods, these libraries were 
sequenced to a much higher read depth.  In contrast, libraries prepared and sequenced 
a year later at OGT showed significantly improved on-target coverage and a higher 
proportion of useable reads.  This likely reflects a lower number of duplicate reads 
arising from bias in PCR amplification and an increase in the number of mappable 
reads indicating a higher quality of sequencing was achieved.  Improved uniformity 
in flowcell loading as well as sequencing software is likely to have contributed to the 
latter.  Notably, those libraries prepared manually by myself in Edinburgh followed 
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by sequencing in Denmark were comparable to OGT samples in terms of capture 
efficiency although read depth was higher in this group as one less sample was 
present in each sequencing run.   
Table 3.2. Quality metrics on sequencing output  
Per sample 
WTSI 
Mean (+/- s.d.) 
OGT 
Mean (+/- s.d.) 
Edinburgh/Denmark 
Mean (+/- s.d.) 
Statistical 
significance 






































On-target coverage indicates percentage of targets sequenced to a depth of at least 15X.  Each 
subgroup was compared to all others using a non-parametric Kruskal-Wallis test followed by a 
Dunn’s multiple comparison test.  P value indicates results for all three comparisons performed for 
that parameter except where stated.  Abbreviations: WTSI=Wellcome Trust Sanger Institute, 
OGT=Oxford Gene Technology.  
3.3 Description of filtering pipeline 
In total, 11,540,535 variants were identified in the 102 affected individuals 
sequenced following the variant calling process described in Chapter 2.  Therefore to 
identify pathogenic variants, I devised and implemented a filtering pipeline using 
SQL scripts (Appendix IV).  An overview of this pipeline is shown in Figure 3.1 and 










Figure 3.1.  Overview of variant filtering pipeline.   
List of known MPD & 1o MCPH genes provided in Appendix V.   
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3.3.1 Stage 1 Filter: Excluding common variants and likely 
sequencing errors 
Prior to filtering, all variants not occurring within a gene were removed from the 
SQL database (Alison Meynert, MRC HGU, IGMM, Edinburgh).  This included all 
variants annotated as `intergenic` by SnpEff or those which were not annotated with 
a corresponding gene name removing many off target reads which are likely to have 
low read depth and therefore a higher false positive variant rate adding to variant 
‘noise’ (Hoischen et al., 2010, Meynert et al., 2013).  This resulted in an initial 
starting list of over 600,000 variants in more than 30,000 candidate genes across all 
samples corresponding to approximately 100,000-150,000 variants per family.  I then 
performed all downstream filtering of variants using SQL scripts (Appendix IV).     
To select for rare variants, those annotated with a minor allele frequency of 0.005 or 
less in either the 1KG or the EVS databases were filtered out.  MPD is a very rare 
disorder likely to occur in around 1 in every million people therefore any pathogenic 
variant, assuming Hardy–Weinberg equilibrium (Stern, 1943) and a recessive model, 
would be expected at an allele frequency of 0.001 or less.  However, a less stringent 
threshold was used in order not to miss a more common causative variant occurring 
in combination with another exceedingly rare pathogenic variant as the alternate 
allele.  An extreme example of this is TAR syndrome (Albers et al., 2012) which 
results from a deletion on one allele in combination with a SNP on the other allele.  
Additionally, allele frequency for rare variants have wide confidence intervals given 
current sample size in the 1KG and EVS cohorts leading to inaccuracies in the 
reported minor allele frequency.  
 
As all samples were sequenced on the same Illumina HiSeq platform it was 
anticipated that false positive variants arising through sequencing errors, such as 
homopolymer runs, will likely occur at similar sites across multiple samples.  To 
remove such technical artefacts, filtering was performed to exclude variants that 
occurred recurrently in those sequenced.  It was reasoned that as the MPD cohort is 
clinically heterogeneous and from a wide range of ethnic backgrounds it was 
unlikely that the majority of families would share the exact same pathogenic variant.  
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Mutations in PCNT (MOPDII) are the most common cause of MPD occurring in 
approximately 20% of patients in this cohort.  This is followed by mutations in 
RNU4ATAC (MOPDI) occurring in less than 3% of cases.  Furthermore, recurrent 
mutations are rare in both disorders.  It was therefore anticipated that further disease 
causing variants in novel genes were likely to be present at low frequency in the 
patients sequenced, therefore variants occurring in 6 families (5%) or more were 
excluded.  Assuming a model of full penetrance, variants also highly unlikely to be 
pathogenic were those occurring in the homozygous state in unaffected individuals 
and therefore such variants were also removed on filtering.  
This first stage of filtering removed 68% of variants (approximately 400,000 in total) 
but those remaining still covered 27,620 possible candidate genes, only 10% less 
than the list prior to filtering.    
3.3.2 Stage 2 Filter: Selecting variants predicted to 
deleteriously affect protein function  
To prioritise only those variants likely to have a deleterious effect on the protein, I 
graded consequence predictions generated by SnpEff, dbNSFP and Alamut HT on a 
scale of 1-7 (Table 3.3), the lowest score reflecting those variants predicted to have 
the most deleterious consequence.  Non-synonymous coding variants were graded 
with a score of 2 if any one of the seven programmes used by dbNSFP predicted it to 
be deleterious.  Alamut-HT software uses 5 splice prediction programmes 
(MaxEntScan, NNSPLICE, Human Splicing Finder, SpliceSiteFinder and 
GeneSplicer) to generate a value corresponding to the strength of predicted effect of 
the variant on either the nearest natural splice site or splicing in the local vicinity.  
Those variants predicted either to create a splice site or alter an existing splice site 
(parameters set: effect on nearest splice site >0.5 or <-0.5 or local effect=’new’ or 
‘strongly activated’) were given a score of 2.5.  Only variants with a consequence 
score of 2.5 or less were taken forward for further filtering excluding a further 24% 
of variants (92% in total) reducing the number of candidate genes in the cohort to 
nearly 15,000 (50% of the initial candidate gene list) with an average of 576 variants 
per family (range = 321-1,313).   
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Table 3.3. Classification and scoring of variants according to predicted protein 
consequence 
 Abbreviations used in annotation by various non-synonymous prediction programmes: SIFT and 
FATHMM_score; D=damaging, T=tolerated. Polyphen2; D=probably damaging, P=possibly 
damaging, B=benign, LRT prediction; D=deleterious, N=neutral, U=unknown, Mutation taster; 








































D or P 
D or P 
D 
A or D 
High, medium 
D 
(or not annotated) 
 
2.5 
  INTRON 
  SYNONYMOUS_CODING 
















N or U 




























3.3.3 Variants in known MPD and 1° MCPH genes 
Following the above two filtering steps, all variants in genes in which mutations are 
known to cause MPD and 1° MCPH (list in Appendix V) were manually reviewed in 
IGV and Alamut software (see Section 3.3.7).  Additionally, if a deleterious 
heterozygous mutation (consequence score =1) was identified in an affected 
individual in one of these genes then the whole gene was resequenced by capillary 
sequencing to ensure that a second variant had not been missed by WES.  This 
allowed patients with mutations in known disease genes to be readily identified early 
in the filtering process and excluded from further analysis.  In total, 169 variants in 
80 families were present in known MPD and 1° MCPH genes and in nine patients 
causality was attributed to these genes (Section 3.5). 
3.3.4 Analysis by mode of inheritance  
Previously identified mutations in MPD and 1° MCPH genes have been inherited in 
an autosomal recessive manner and so this was the default model for analysis.  
However, for multiplex datasets (more than one family member sequenced) 
autosomal dominant and X-linked recessive inheritance patterns were also examined 
(SQL scripts in Appendix IV). 
3.3.4.1 Autosomal recessive (AR) 
To identify all potential variants which had been inherited in an autosomal recessive 
manner, all homozygous and heterozygous variants in affected cases were selected.  
Heterozygous variants were then grouped per individual and gene to identify those 
genes where more than one variant was present per individual.  All heterozygous 
variants occurring within these genes were combined with all homozygous variants 
identified.  This removed a further 6.4% of variants (98.8% in total) reducing the 
number of candidate genes to 7.2% of the initial number (2189 candidate genes).  In 
families where unaffected parents were sequenced (trios and quads), further filtering 
was performed to extract only those variants which were biallelic in the affected 
child.  Therefore homozygous variants were selected only if the variant was 
identified in both parents in a heterozygous state and only those heterozygous 
variants were selected where at least two variants per gene were identified, one in 
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each parent, consistent with autosomal recessive inheritance.  Where an affected 
sibling was also sequenced (pairs and quads), only those variants in common 
between the two siblings were selected prior to the selection of recessive variants.  
This enabled variant number, and thus candidate gene number to be reduced much 
further with biallelic variants only occurring in 183 genes (0.6%).    
3.3.4.2 Autosomal dominant (de novo) 
As none of the parents were reported to be affected analysis was performed under the 
assumption that any pathogenic dominant variants had occurred de novo in the 
affected child.  All heterozygous variants which did not occur in either the 1KG or 
EVS database (minor allele frequency=0.0000 or null) were selected.  Variants 
occurring in dbSNP (i.e. annotated with an ‘rs’ number) were not removed as 
pathogenic dominant mutations are present in this database (Bhagwat, 2010).  In all 
trios, only those variants not occurring in either parent were selected.   Where an 
affected sibling was present (pairs and quads), a de novo event in both siblings was 
unlikely in the presence of unaffected parents and analysis was therefore not 
performed.  Thus the possibility of gonadal mosaicism or incomplete penetrance in 
these families remains.   
In total, de novo variants were identified in 612 genes of which only 91 contained a 
variant with a consequence score of 1.  In singletons, heterozygous variants with a 
consequence score of 1 occurring in two or less families were initially prioritised for 
review due to the large number of variants in this group (>15,000 variants reduced to 
789 variants in 734 genes).    
3.3.4.3 X-linked recessive (XR) 
All hemizygous variants in affected males (36 families) on the X chromosome were 
selected.  In trios, only those variants also occurring in the mother in the 
heterozygous state but not present in the father were selected.  In families designated 
‘trio(m)’ and ‘quad’, analysis was not performed as affected offspring were female.  
Also only one sibling pair consisted of two affected males and so was analysed in 
this manner.  This analysis identified 129 candidate genes in total.  
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3.3.5 Reduction in variant number and candidate genes 
through the filtering pipeline 
Despite a large initial number of variants (mean 114,141 variants per family) the 
filtering pipeline efficiently reduced this number by 99.9% (Table 3.4).  Removing 
common variants (stage 1 filter) had a large impact on variant number removing 68% 
but had little impact on the number of candidate genes with over 90% remaining 
(Figure 3.2).  Selecting deleterious variants (stage 2 filter) appeared more effective in 
reducing the number of both variants and candidate genes (7.6% and 49.6% of total 
remaining respectively) although remaining numbers were still too large to review in 
each family individually (mean 576 variants per family, 15,382 candidate genes in 
total remaining) (Table 3.4). 
Selecting only variants that have potentially been inherited in an autosomal recessive 
manner regardless of whether additional family members were sequenced 
dramatically reduced variant number to 1.2% and candidate gene number to 7.2% 
although this still equated to over 2,000 individual genes (Table 3.4).  However 
filtering was greatly enhanced where parental DNA samples had also been sequenced 
(trios and quads) enabling biallelic variants to be identified reducing the candidate 
gene list to a manageable 183 genes.  Examining the number of variants per family 
demonstrates the power of additionally sequencing parental samples.  In trios and 
quads selecting only biallelic variants resulting in a five fold reduction in number of 
variants and candidate genes (mean of seven candidate genes per family in the trio 
group compared to 52 per family in the singleton group) (Table 3.5).  Selecting 
variants in common between affected siblings (pairs) was also similarly effective in 
reducing variant number and therefore provides an effective but less costly strategy 
than sequencing both parents where multiple affecteds are present.  Notably, in two 
trio sets, no variants remained following analysis for biallelic inheritance.  This may 
reflect variation in exon capture and consequently coverage between samples 
although other possibilities include laboratory errors with DNA samples or non-
paternity.     
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Selecting potential dominant variants (all rare, deleterious heterozygous variants) did 
not reduce variant number as much as selecting all potential recessive variants (over 
11,000 candidate genes remaining) (Table 3.4, Figure 3.2).  However, filtering was 
greatly enhanced when parental samples were used to identify only de novo variants.  
Variant number in trios was reduced to almost 10% of that in singletons (Table 3.5) 
with only 2% of candidate genes remaining in total (Table 3.4, Figure 3.2).  Even in 
the family where only the mother and unaffected sibling were sequenced (trio(m)), 
95% of possible dominant variants could be excluded in the de novo analysis 
although it was not possible to identify biallelic variants using this family structure.  
However, this does demonstrate the power of sequencing additional family members, 
even if DNA from both parents is unavailable.  In contrast, little impact was made on 
variant number in the analysis of X-linked recessive variants where sequencing data 
was available from the mother compared to those without.  This suggests that in 
disorders of clear X-linked inheritance sequencing parental DNA may be of little 
additional benefit. 
Table 3.4. Reduction in variants and candidate gene number through filtering 
pipeline 
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Figure 3.2.  Venn diagram demonstrating reduction in candidate gene number 
through filtering pipeline 
Removing all commonly occurring variants (stage 1 filter) had little impact on the number of 
candidate genes whereas further filtering for deleterious variants had a more pronounced impact on 
gene number.  Autosomal recessive analysis reduced gene number further than selecting all potential 
dominant variants however using parental samples to select either biallelic and de novo variants 
dramatically reduced candidate genes to a manageable number.  
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Table 3.5. Variant and candidate gene number per family following analysis by different inheritance models 
Once diagnosis identified in known MPD gene, families removed from further analysis.  *as parents not sequenced, number indicates variants remaining after filtering 
for those shared between siblings.  Light grey boxes indicate where analysis was not performed.  X-linked recessive analysis was performed in 36 families with 
affected males including 10 trios and 1 sib pair.  
 Mean variant N° per family (range) 
Number of families after known MPD genes identified Singleton(51) Trio(28) Trio(m)(1) Quad(1) Sib pair(5) 
AR analysis All potential AR variants 86 (15-225) 64 (26-200) 21 272 180 (117-240) 
Biallelic variants N/A 13 (0-56) N/A 16 38 (12-64)* 
AD analysis All Het variants 295 (131-629) 233 (113-436) 135   
De novo variants N/A 28 (8-144) 7   
X-linked 
recessive analysis 
Hom variants in males on Chr  5 (1-9) 5 (1-7)   19 
Variants only inherited from mother  N/A 4(1-7)   6 
 Mean candidate gene N° per family (range) 
Number of families after known MPD genes identified Singleton(51) Trio(28) Trio(m)(1) Quad(1) Sib pair(5) 
AR analysis 52 (13-113) 7 (0-29) 12 6 22 (6-38) 
AD analysis 293 (133-609) 25 (7-139) 7   
X-linked recessive analysis 5 (1-9) 4 (1-7)   6 
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3.3.6 Review of variants in other known disease genes 
affecting growth 
OMIM morbid annotation was used to highlight variants occurring in genes already 
known to be associated with a developmental disorder.  Many of these genes also 
impact on growth but may not have previously been associated with such an extreme 
failure in growth as seen in MPD patients.  As well as diagnostic benefit to the 
patient, early identification allowed these cases to be excluded from further analysis 
of novel gene candidates and help prioritise genes for closer review.   
 
3.3.7 Strategies to prioritise remaining candidate genes   
Following the removal of families in whom a likely diagnosis had been identified, 
variants in candidate genes unlikely to be disease causing were filtered out.  This 
included genes whose function was highly unlikely to be related to growth such as 
HLA genes, mucin genes, olfactory receptor genes and hypothetical genes (those 
which have not been experimentally validated and of unknown function).  Also genes 
enriched for ‘rare’ variants, as previously identified by the NHLBI GO Exome 
Sequencing Project, were excluded (Tennessen et al., 2012).  This includes genes 
often poorly mapped, for example pseudogenes, duplicated genes and genes from 
large families sharing similar sequences, and those under weak selective constraint.  
Remaining genes with variants occurring in more than one family and genes with a 
highly deleterious variant (consequence score of 1) were then prioritised for further 
examination.   
The sequencing reads corresponding to each variant were examined by visualising 
alignment files using the Integrative Genomics Viewer (IGV) (Robinson et al., 2011) 
to assess the quality of reads, alignment and read depth at that site.  A variant was 
deemed likely to be real if reads were accurately aligned, a sufficient read depth was 
present (>3 reads for homozygous variants and >10 reads for heterozygous variants) 
and at least 50% of reads had a mapping quality of >0.  The protein consequence was 
then reviewed using Alamut software.  Assuming de novo variants in MPD would be 
haploinsufficient, each candidate gene from the de novo analysis was also reviewed 
in the Database of Genomic Variants (DGV) (MacDonald et al., 2014) and 
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disregarded if a microdeletion incorporating that gene had been observed in the 
control population.  After closer inspection, if the variant(s) within that gene still 
appeared potentially deleterious it was then validated by capillary sequencing.  If 
DNA was available from any family members these were also re-sequenced to 
investigate whether the variants segregate correctly within the family.   
 
Finally, a literature search was performed for each candidate gene.  Genes were 
excluded if function had been well characterised and unlikely to have an impact on 
growth, for example PRSS1 which encodes a pancreatic enzyme required for protein 
digestion.  Also genes previously established to cause a disease totally unrelated to 
growth such as isolated non-syndromic deafness or cataracts were not investigated 
further.  Existing animal models for that gene were then researched in the following 
databases: Mouse Genome Informatics (http://www.informatics.jax.org/, accessed 
06.2013)  (Blake et al., 2014), Zebrafish Model Organism Database (ZFIN) 
(http://zfin.org/, accessed 06.2013) (Bradford et al., 2011) and FlyBase 
(http://flybase.org/, accessed 06.2013)  (St Pierre et al., 2014).  Genes where animal 
knockout studies had been performed and demonstrated no observable impact on 
growth were given lower priority.  Gene expression patterns were also reviewed by 
examining microarray expression data using UCSC human gene sorter as genes 
previously identified in MPD are all widely if not ubiquitously expressed 
(https://genome.ucsc.edu/cgi-bin/hgNear, accessed 06.2013) (Kent et al., 2005).  
Therefore genes with very limited and specific expression patterns, for example 










3.4 Variation in variant number between samples 
Following variant calling I noted that there was a large range in the number of 
variants called per sample with some samples having over 25% more variants than 
others (mean number of variants per sample = 111,381, range 97,868 to 132,821 
prior to stage 1).  The cause of such a large disparity between samples was therefore 
investigated by comparing samples prepared and sequenced at different locations and 
then by comparing those of different ethnic origin.  Variant number between samples 
prepared and sequenced at either the Wellcome Trust Sanger Institute (WTSI), 
Oxford Gene technology (OGT) or Edinburgh-Denmark locations showed some 
variation in variant number prior to filtering with a significant difference occurring 
between the OGT and Edinburgh-Denmark samples and the OGT and WTSI samples 
(p<0.01, Figure 3.3).  Those sequenced at WTSI had the highest number of variants 
(mean=120,508) whilst those at OGT had the lowest number (mean=107,134).  A 
significant difference in variant number was still present between these two sample 
groups following both the stage 1 (p<0.005) and stage 2 filters (p<0.01) (Figure 3.3). 
 
Samples were then grouped by European, Asian, African or Middle Eastern origin.  
Country of origin was unknown in 14 samples, 10 of which were in the WTSI group, 
and so were also excluded.  Seven samples were from more than one ethnic 
background and so also not included.  Prior to filtering, African samples had a 
significantly higher number of variants compared to both European and Asian groups 
(p=0.01) (Figure 3.4).  Following filtering, variation in variant number became more 
evident between samples of different ethnicity with samples of African origin having 
the highest number of apparently rare deleterious variants followed by Middle 
Eastern and then Asian families.  The number of variants in African, Middle-Eastern 
and Asian groups were all significantly increased compared to the European group 
(p=0.0001) but not compared to each other following both stage 1 and 2 filtering.  
This likely reflects the under representation of these ethnic groups in the control 
datasets used to filter out common variants as well as the increased variation known 
to be present in Africans (Tennessen et al., 2012).  Notably, the Edinburgh-Denmark 
and WTSI groups did not include any samples of African origin which may have 




Figure 3.3. Comparison of variant number in samples prepared and sequenced in different locations 
Range in variant numbers for each sample prepared and sequenced at the three different locations A) prior to filtering (mean variant number indicated by horizontal 
bar: Edinburgh/Denmark=115,736 +/-3196 s.d., WTSI=120,508 +/-3816 s.d., OGT=107,134 +/-5862 s.d.), B) post stage 1 filter (mean variant number: 
Edinburgh/Denmark=2,276 +/-666 s.d., WTSI=2,557 +/-806 s.d., OGT=2119 +/-964 s.d.) and (C) post stage 2 filter (mean variant number: Edinburgh/Denmark=524 
+/-136 s.d., WTSI=588 +/-157 s.d., OGT=511 +/-193 s.d.).  Each group was compared to all others using a Kruskal-Wallis test followed by a Dunn’s multiple 
comparison test.  A significant difference was consistently seen between the OGT samples compared to the WTSI samples.  Comparisons in which a significant 
difference was present are indicated by overlying horizontal bars.  ** = p<0.01, *** = p<0.005, ****p<0.0001.  No significant difference was seen on other 





Figure 3.4. Comparison of variant number between samples of different ethnicity 
A) Prior to filtering a significant increase in variant number was seen in African samples compared to European and Asian groups (mean variant number: European 
=109,582 +/-7484 s.d., Asian=109,435 +/-7210 s.d., Middle East=113,064 +/-8252 s.d., African=121,334 +/-2992 s.d.).  Following B) the stage 1 filter (mean variant 
number: European=1,747 +/-678 s.d., Asian=2,693 +/-480 s.d., Middle East= 2,655 +/-457 s.d., African= 4,711 +/-1083 s.d.) and C) the stage 2 filter (mean variant 
number: European =428 +/-135 s.d., Asian=643 +/-88s.d., Middle East=596 +/-112s.d., African=1008+/-185s.d.) samples of African origin continued to show the 
highest number of variants.  Samples of African, Middle-Eastern and Asian origin all showed a significantly higher number of variants compared to European samples.  
Each group was compared to all others using a Kruskal-Wallis test followed by a Dunn’s multiple comparison test.  No significant difference was seen on other group 
comparisons.  **p<0.01, ****= p<0.0001.
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3.5 Variants identified in known disease genes 
3.5.1 Variants identified in known MPD and 1° MCPH genes  
In total 169 variants in 80 families were identified.  The quality and consequence of 
individual variants were assessed using IGV and Alamut (Section 3.3.6).  This 
identified nine families with recessive deleterious variants within these genes.  In 
five families, these variants were previously known, confirming the sensitivity of the 
pipeline to identify causative variants.  These included mutations in ASPM (MIM 
608716), CDK5RAP2 (MIM 604804), ATR (MIM 210600), PCNT (MIM 210720) 
and PLK4 (Martin et al., 2014).  In the other four families, novel variants were 
identified in PCNT (MOPDII), ORC1 (Meier Gorlin syndrome) and CENPJ (Seckel 
syndrome) (Table 3.6).  All occurred in the homozygous state except for one case 
with compound heterozygous mutations in PCNT.  Variants were validated by 
capillary sequencing and found to segregate appropriately with the phenotype in the 
family.    
 
The variants identified in PCNT were nonsense mutations and therefore transcrips 
are predicted to undergo nonsense mediated decay similar to those previously 
described in MOPDII patients (Rauch et al., 2008).  Both patients showed 
proportionate and severe growth failure similar to other MOPDII patients (Bober et 
al., 2012) (Table 3.6).  Patient 1 was also noted to have widespread confetti like 
hypopigmented patches with joint contractures and epilepsy whilst patient 2 was 
reported as having moderate developmental delay.  These features are not 
characteristic of MOPDII and had precluded prior consideration of this diagnosis.  
However, on review of clinical phenotypes both patients were noted to also have 
typical facial features in keeping with this diagnosis.  These cases therefore expand 
the clinical spectrum of MOPDII and demonstrate the power of WES in identifying 
diagnoses in atypical cases.  
 
In another patient, a homozygous non-synonymous coding variant was identified in 
ORC1 affecting a highly conserved residue within the BAH domain and predicted to 
be highly deleterious (Figure 3.5).  Mutations in ORC1 cause Meier-Gorlin syndrome 
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characterised by microtia, hypoplastic or absent patella and short stature (Bicknell et 
al., 2011b), although this triad of features is not universally present in every patient 
with MGS (de Munnik et al., 2012).  This patient was noted to have severe growth 
failure (Table 3.6) in keeping with mutations in ORC1 although microtia was not 
present and no abnormalities were reported concerning the patella.  The patient did, 
however, have some facial features consistent with the diagnosis including 
microstomia.  A mutation altering the same amino acid (c.314G>A, p.Arg105Gln) 
has previously been identified in several MGS patients (de Munnik et al., 2012) and 
occurs at a site conserved in vertebrates (Figure 3.5).  Therefore the likelihood of this 
variant also being pathogenic is high and in conjunction with the clinical phenotype 
of this patient, was attributed as causal.   
Table 3.6. Mutations identified in known MPD genes 
 
Gene  cDNA change Protein change Parents OFC 
/s.d. 
Height 













2 c.9319delAG p.Ser3107Phefs*39 Het Het -11.2 -10.6 
ORC1: 
MGS 




4 c.3302-15A>G  Het Het -11.1 -4 











Figure 3.5. Conservation of amino acid altered by the c.313C>T variant 
identified in ORC1 
A) Schematic of ORC1 protein demonstrating identifiable domains including the BAH (bromo-
adjacent homology) domain, AAA+ ATPase domain (AAA) and a winged helix DNA-binding domain 
(WH).  B) Alignment of sequences encoding the BAH domain in ORC1 in different species using 
ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) demonstrates the affected amino acid is 
conserved in vertebrates (sequence reference in Appendix II).  A similar mutation, affecting the same 
amino acid, c.314G>A (p.Arg105Gln) has been previously reported in several MGS patients (de 
Munnik et al., 2012). 
 
Mutations in CENPJ have only previously been reported in one family with MPD 
(Al-Dosari et al., 2010).  A homozygous mutation was identified in this reported 
family affecting the splice acceptor site of exon 11 (c.3302-1G>C) resulting in a 
reduction in the wild type transcript in patients and the production of three alternate 
transcripts.  These transcripts were found to lack exon 12, exons 11 and 12 and exons 
11 to 13 respectively.  In this study, a homozygous intronic mutation, 15 bases 
upstream of the same exon-intron boundary (c.3302-15A>C), was identified in one 
patient and was predicted to create an alternative splice acceptor site at the position 
of the variant (Figure 3.6A).   This would be predicted to result in an out-of-frame 
transcript with the inclusion of 14 additional bases prior to exon 11.  RT-PCR studies 
in patient lymphoblastoid cells did not identify this transcript possibly because it has 
undergone nonsense mediated decay.  However, a reduction in full length transcript 
was apparent along with the production of three alternate out-of-frame transcripts.  
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Sequencing PCR products extracted from the four separate bands determined that 
they corresponded to the full length transcript and three smaller transcripts which 
were identical to those identified in the previously reported patient (Figure 3.6B).  
The patient in this study had severe microcephaly (-11 s.d.) with short stature (-4 
s.d.), moderate developmental delay and a small right kidney with grade II vesico-
ureteric reflux.  All growth parameters were reported to be below -7 s.d. in all five 
affected family members described in Al-Dosari et al, 2010 and displayed similar 
facial features to the patient identified here including high, prominent nasal bridge, 
hooked nose and receding chin.     
In two families, deleterious heterozygous variants were identified in ASPM 
(c.1138C>T, p.Gln380*) and PCNT (c.2494_2497dupGACG, p.Ala833Glyfs*45) 
respectively (consequence score=1).  Both variants were called with high confidence 
following WES however capillary sequencing did not validate either variant and re-
sequencing of the full gene did not reveal any other likely pathogenic variants.  












Figure 3.6.  A homozygous CENPJ mutation, c.3302-15A>G, disrupting splicing 
A) Alamut graphical display showing that four of the five splice site prediction programmes employed 
predict the presence of a splice acceptor site (green boxes) at the intron-exon boundary of the 
reference sequence (blue shading).  The same programmes also predict the presence of an alternative 
splice acceptor site at the position of the intronic single nucleotide change, c.3302-15A>G identified 
in the patient (additional green boxes in white shading).  B)  RT-PCR studies showed a reduction in 
full length transcript in patient lymphoblastoid cells compared to control cells and the presence of 
three bands representing alternative transcripts.  Sequencing of DNA extracted from these bands 
confirmed that exons 12 to 13 have been removed similar to that caused by the mutation c.3302-1G>C 
identified in Al-Dosari et al., 2010.  No difference in the housekeeping gene, GAPDH, transcript 
levels was observed between patient and control cells.  PCR following RT reaction without reverse 





3.5.2 Variants identified in other known disease genes 
affecting growth 
Review of known disease genes using the OMIM morbid annotation (Section 
2.5.2.2) identified deleterious variants in 20 families, 17 of which had not been 
previously identified (Table 3.7).  Variants in SMARCAL1 (Schimke immuno-
osseous dysplasia, MIM 242900), CREBBP (Rubinstein Taybi syndrome, MIM 
180849) and NSUN2 (Dubowitz syndrome, MIM 223370) had been previously 
identified therefore provided validation of the designed pipeline.  In combination 
with known MPD and 1° MCPH genes, 100% of known variants were detected.  
Ligase IV syndrome (MIM 606593) is a disorder characterised by microcephaly, 
immunodeficiency and cancer predisposition that has not been previously associated 
with growth failure to the degree seen in MPD and so it was surprising to identify 
mutations in LIG4 in three families (Table 3.7).  The contribution of LIG4 mutations 
to MPD was therefore further investigated (Chapter 4).   
A nonsense mutation was also identified in the gene RBM10 (RNA binding motif 
protein 10) on chromosome X.  RBM10 mutations cause TARP syndrome (Talipes 
equinovarus, Atrial septal defect, Robin sequence and Persistent left superior vena 
cava, MIM 311900) (Johnston et al., 2010).  Few patients with this disorder are 
reported in the literature with very limited information on growth.  Affected males 
are typically unwell from birth and die in early life often from unexplained causes 
(Kurpinski et al., 2003).  The patient identified here had features consistent with this 
diagnosis including early lethality and severe micrognathia, an aspect of Robin 
sequence (Table 3.7).  The severe growth failure documented in this patient suggests 
this may be a previously unrecognised aspect of this syndrome.  
Mutations were also identified in the disease genes SRCAP (Floating Harbor 
syndrome, MIM 611421), BLM (Bloom syndrome, MIM 210900), ERCC6 
(Cockayne syndrome, MIM 216400), VPS13B (Cohen syndrome, MIM 216550) and 
TUBGCP6 (microcephaly with chorioretinopathy, MIM 251270) (Table 3.7).  All 
were predicted to either truncate the protein or disrupt an essential splice site 
(consequence score =1) thus highly likely to be deleterious to protein function.  
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Growth failure, comparable to that observed in these patients, has been previously 
reported in other patients with similar mutations (Nance et al., 1992, Keller et al., 
1999, Hennies et al., 2004, Puffenberger et al., 2012, Nikkel et al., 2013).  
Additionally, the patients identified here were also reported to have other clinical 
features consistent with the associated syndrome and thus the mutations were likely 
to be responsible for the phenotype observed in these patients.  Likely causative 
mutations were also identified in ESCO2 (Roberts syndrome, MIM268300) and 
MRE11A (Ataxia-telangiectasia-like/Nijmegen-like breakage syndrome, 
MIM604391) in two further families (Table 3.7).  In both cases intronic mutations 
were identified which were predicted to strongly impact on splicing.  Similarly, the 
phenotype reported in the patients correlated well to those previously described 
(Schule et al., 2005, Matsumoto et al., 2011) however further RNA studies would be 
necessary to confirm the effect on splicing.   
A 22 base pair deletion (c.817-2_837delAGGCCAACGAGGCACGCCCATA) 
disrupting the splice acceptor site of the last exon was also identified in PNKP 
(polynucleotide kinase 3'-phosphatase) in association with a nonsense variant on the 
alternate allele.  Mutations in PNKP have previously been described in association 
with severe microcephaly, developmental delay and seizures which were both 
present in the two affected siblings (Shen et al., 2010).  One sibling also had severely 
reduced stature although height was within normal range in the other sibling 
suggesting short stature may be a variable feature of mutations in this gene.  
Additional RNA studies would also be valuable to confirm the effect on splicing. 
Finally, a de novo heterozygous nonsense mutation was identified in a female patient 
in MED12 which resides on the X chromosome.  Non-synonymous coding mutations 
in males in MED12 have been described in association with three different 
syndromes; Lujan Fryns syndrome (MIM309520), Opitz-Kaveggia syndrome 
(MIM305450) and Ohdo syndrome, the Maat–Kievit–Brunner type (OSMKB, 
MIM249620) (Risheg et al., 2007, Schwartz et al., 2007, Vulto-van Silfhout et al., 
2013).  This female patient presented with features of growth failure with mild 
developmental delay and moderate deafness which are not features typical of MED12 
related disorders (Graham et al., 2013).  However, she did have facial features 
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similar to those described in males with Lujan Fryns syndrome including maxillary 
hypoplasia, receding chin, thin upper lip, prominent forehead and low-set retroverted 
ears (Van Buggenhout et al., 2006).  Affected females with heterozygous MED12 
mutations have only been previously described in one family harbouring a frameshift 
mutation which impacts on splicing resulting in an alternate transcript with a 75bp 
in-frame deletion which does not undergo nonsense mediated decay (Lesca et al., 
2013).  Both female carriers and affected males were reported to have significant 
cognitive impairment but without any growth abnormalities.   The facial features and 
intellectual disability present in this patient could therefore be attributed to the 
MED12 mutation however this does not explain the failure in growth.  It is possible 
this patient also harbours a second disease causing mutation in another gene which is 
responsible for the MPD phenotype.  However, it is interesting to note that Lujan 
Fryns syndrome is also associated with tall stature and macrocephaly (Van 
Buggenhout et al., 2006) indicating that aberrant MED12 function can impact on 
growth.  It is therefore conceivable that gain of function mutations in MED12 may 
result in Lujan Fryns syndrome whereas severe loss of function mutations results in 
growth restriction.  Notably, heterozygous mutations resulting in premature 
truncation of MED12 have not been reported in control populations (EVS).  
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Table 3.7.  Probable pathogenic variants identified in atypical disease genes 
Gene & Disorder 







 cDNA Protein 




















SRCAP: Floating Harbor 
Syndrome 
8 7330C>T Arg2444* 
De novo 
-4.0 -4.0 Duplex kidney 
9 7330C>T Arg2444* -5.1 -5.1 Stenosis of descending colon 







AR -10.5 -8.2 Severe micrognathia 
BLM: Bloom Syndrome 
 
12 1985delAA Lys662Ilefs*5 
AR 
-8.3 -4.8 Crowded teeth 
13 479_480delTT Phe160* -5.3 -3.9 Hypopigmented & café au lait lesions 
ERCC6: Cockayne Syndrome 14 4063-1G>C  
AR 
-5.4 -4.5  
15 2170-2A>G  -6 -7  
MED12: Lujan-Fryns 
syndrome 
16 6448C>T Gln2150* De novo -3.4 -4.1 
Dysmorphic features, bilateral hearing 
loss 
RBM10: TARP syndrome 
17 820C>T Gln274* XR -6.0 -5.3 
Severe micrognathia, unexplained death 
at 9months 
ESCO2: Robert Syndrome 18 862-12A>G  AR -8.1 -7.5 Bilateral mesomelia, absent thumbs, club 
hands and feet. 






AR -4.9 -2.3 Severe developmental delay, neutropenia 
PNKP: Microcephaly & 
seizures 
20 







Epilepsy, severe developmental delay 
TUBGCP6: Microcephaly & 
Chorioretinopathy 
21 4334insT His1445Glnfs*24 AR -11.1 -3.3 
Retinal dystrophy, severe developmental 
delay 
Deleterious variants were identified in genes causing recognisable disorders associated with growth restriction following WES within our cohort.  
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3.6 Novel candidate disease genes identified in MPD 
 
61 families remained after 29 families in whom pathogenic variants were identified 
in known disease genes and five families in whom copy number variation 
abnormalities were identified through ExomeCNV analysis (Chapter 6) were 
removed from further analysis.  However, for these 61 families, almost 2,000 
candidate genes still remained for closer review (Table 3.8).  Therefore further 
filtering steps were implemented to attempt to reduce the candidate gene list to a 
tractable size.  Removing poorly mapped genes had little impact on this number, as 
did excluding those genes which had a high likelihood of being functionally 
unrelated to growth.  However, prioritising genes with variants in more than one 
family and those variants likely to have the greatest functional impact on the protein 
(consequence score=1) was successful in generating a manageable number of 
candidate genes for further review.        
 
Table 3.8. Strategies used to prioritise candidate genes for further investigation 
Percentage of starting gene number at each stage of filtering shown in brackets. 
Following manual inspection of individual variants and corresponding genes as 
described in Section 3.3.7, six genes were identified as strong candidates for further 
investigation (Table 3.9), all of which contained autosomal recessive variants.  Most 
genes were excluded as likely false positives following review of variants with IGV 
due to low read depth or poorly mapped reads.  Review of splice predictions 
(variants annotated with a consequence score of 2.5) also showed that many of these 
 Autosomal Recessive 
(including biallelic) 
Autosomal Dominant 
(including de novo) 
Gene number following exclusion of families 
with diagnosis 
1594 458 


















Number of genes with at least one variant with a 







variants were unlikely to impact on splicing as predicted changes were either very 
small or reduced the strength of a predicted splice site deep within an intron.  Many 
candidate genes following autosomal dominant and de novo analyses were also 
excluded following review of overlying structural variation in control datasets 
(DGV) which indicated that these genes were unlikely to be disease causing as a 
result of haploinsufficiency.     
 
Table 3.9. Novel candidate disease genes identified in MPD following filtering of 
WES
Gene: full name Function 
Variant details 




repair in Chinese hamster 
cells 4 
Non-homologous end 
joining in DNA double 
strand break repair. 22 c.127T>C  p.Trp43Arg 
NCAPD3:  
Non-SMC condensin II 
complex, subunit D3 
Chromosome 
condensation and 







Non-SMC condensin I 
complex, subunit D2 
Chromosome 
condensation and 
segregation in mitosis 
24 c.4120+2T>C [splice] 
FAT1:  
FAT atypical cadherin 1 
Modulates planar cell 
polarity, Hippo pathway 



































Of the six genes identified, there was strong functional evidence for five having a 
connection to growth.  XRCC4 binds to LIG4 as part of the non-homologous end 
joining machinery (NHEJ) which repairs DNA double-strand breaks (Drouet et al., 
2005).  Mutations in LIG4, causing Ligase IV syndrome, were also identified in 
MPD patients in this cohort indicating mutations in XRCC4 may also have a similar 
impact on growth.  Further investigation of mutations in LIG4 and XRCC4 in MPD 
patients is performed in Chapter 4.   
NCAPD2 and NCAPD3 both encode subunits of the condensin complexes which play 
an important role in the compaction of DNA into chromosomes and chromosome 
segregation during mitosis (Hagstrom et al., 2002, Ono et al., 2004).  As perturbed 
mitosis has previously been associated with MPD and impaired cell cycle impacts on 
cell proliferation (Section 1.3.1.3), these genes represented strong candidates in 
growth failure and further investigation of condensin genes in MPD patients is 
performed in Chapter 5.     
FAT1 and USP2 were also both selected for further investigation based on their 
function.  One patient was identified as homozygous for a complex indel variant in 
the first exon of USP2, a nonsense mutation which was predicted to result in a 
premature termination codon in the transcript (Table 3.8).  USP2 encodes an 
ubiquitin-specific protease which has been shown to stabilize cyclin D1, a cell cycle 
regulator which drives G1-S phase transition, in human cancer cells (Shan et al., 
2009).  USP2 has also been shown to stabilize the ubiquitin ligase MDM2 which 
targets the tumour suppressor p53 for degradation promoting cell proliferation (Kim 
et al., 2012).  FAT1 encodes a cadherin protein which may activate the hippo 
pathway (Bennett et al., 2006) important in growth regulation (Section 1.2.2).  Non-
synonymous variants with a consequence score of 2 were identified in three families 
in this gene.  Both genes were therefore included in the custom designed Ion 
AmpliSeq™ panel and sequenced in the remainder of the MPD cohort.  No further 
patients were identified with mutations in USP2 and hence this gene was not 
prioritised for further investigation in this thesis.  In contrast, 31 patients were 
identified with at least one rare deleterious non-synonymous variant (consequence 
score of 2) in FAT1 out of 199 patients sequenced.  High numbers of similar variants 
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are also present in the EVS control dataset at low frequencies suggesting this gene 
may be enriched for rare variation in the general population and thus less likely to be 
disease causing.   
To investigate this further, statistical comparison of the frequency of rare alleles 
between the two cohorts was performed.  Initially EVS variants were annotated with 
consequence scores using SNPEff and dbNSFP as described in section 3.3.2.  A 
cumulative frequency was obtained for all minor allele variants with a consequence 
score of 2 in each cohort (MPD cohort maf = 0.1, EVS cohort maf = 0.02).  Chi 
square test with Yates comparison indicated that FAT1 is significantly enriched for 
rare deleterious non-synonymous coding variants in the MPD cohort compared to 
EVS (p<0.0001).  However, these populations differ in ethnicity with EVS 
containing European-American and African-American populations whereas the the 
MPD cohort additionally contains many families from the Middle-Easte and sub-
Indian continent.  SNV calling and validation pipelines are also likely to differ in 
stringency between the two cohorts and performing the analysis on a cumulative 
frequency does not take into account that some variants may be part of the same 
allele.  Although not performed in this thesis, further statistical analysis using the site 
frequency spectrum of variation in a matched control population (MacArthur et al., 
2014) as well as validation of all deleterious missense variants in the MPD cohort in 
FAT1 could be more informative.   
Mutations in DONSON were identified in two families.  Affected cases harboured a 
strongly deleterious mutation on one allele in combination with an intronic variant 
which was predicted to have a very mild impact on splicing.  Both cases had severe 
microcephaly but more mildly reduced stature.  Sequencing of patients with a similar 
short stature-microcephaly phenotype was performed by Louise Bicknell (HGU 
MRC, Edinburgh) which has identified several more patients with similar mutations.  
Furthermore, many of the additional patients identified also harbour the c.786-
33A>G variant which has been found to reside within a rare haplotype shared by all 
patients with this variant (Louise Bicknell).  DONSON may therefore represent a 
novel disease causing gene in patients with a phenotype that overlaps with MPD.  
Very little is known regarding the function of DONSON however the drosophila 
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homologue, humpty dumpty, has been shown to play a role in DNA replication 
(Bandura et al., 2005).  Further investigation of this gene is ongoing by Louise 






















It is usual for more than 50,000 sequence variants to be identified per exome 
depending on the capture method and sequencing platform used (Gilissen et al., 
2012).  Therefore filtering strategies are required to help identify potentially 
pathogenic variants from such large numbers.  However, this needs to be tailored to 
the disease under investigation, in particular the prevalence of the disease and the 
anticipated mode of inheritance.  Filtering variants also requires a fine balance 
between reducing the variant list to a manageable scale whilst still retaining those 
variants which are potentially damaging.  Previous studies which have been most 
successful in implementing WES to identify pathogenic variants investigated a 
clinically homogeneous group of patients who all harboured mutations in the same 
disease gene (Ng et al., 2010a, Ng et al., 2010b).  In many, DNA from affected 
siblings and/or parents was also sequenced and the mode of inheritance correctly 
anticipated.  In this setting the number of candidate variants could be reduced to 
single figures allowing the disease gene to be readily identified.  Earlier studies also 
have the advantage of uncovering those disease genes which represent a common 
cause of a particular disorder (Ng et al., 2010a, Hood et al., 2012, Schmidts et al., 
2013) whereas rare disease genes, or conditions with large locus heterogeneity such 
as MPD, pose more difficulty due to the low number of cases that will be present in 
the cohort under investigation.   
In this large, diverse cohort where there is established locus heterogeneity many 
cases are likely to be unique in their underlying disease gene.  Similarly family 
samples are not always available.  Following standard filtering methods the final 
variant list for an isolated case following WES may still be as large as 500 (Gilissen 
et al., 2012) and therefore prioritising variants further requires other strategies.  This 
would also be similar to the situation in clinical diagnostics where often isolated 
cases are encountered rather than multi-affected families often prioritised in research 
studies.  Large scale sequencing projects of multiple family members are also costly 
and so unlikely to be feasible in government funded healthcare.   
This Chapter describes the development of a comprehensive filtering strategy for the 
analysis of WES in a Mendelian disorder with substantial locus heterogeneity.  
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Despite a high number of initial variants per sample (>100,000), filtering 
successfully reduced the number of variants to 0.01% whilst retaining established 
pathogenic mutations in the dataset as well as achieving a molecular diagnosis in a 
further 22% of those families sequenced.  Strategies employed by previous studies 
included removing variants outside coding regions and synonymous variants which 
are deemed less likely to have a functional impact on the protein (Zhang et al., 2012, 
Schmidts et al., 2013).  However, non-coding, intronic and synonymous variants can 
be disease causing by impacting on either splicing, gene expression or protein 
function (Richards et al., 2012, Hunt et al., 2014).  Here we additionally analysed 
splice site effects of intronic and synonymous variants identifying mutations in four 
families which would have otherwise been missed.  Furthermore, analysis using 
multiple models of inheritance and specifically examining known disease genes 
identified pathogenic mutations in 30% of families.  However, despite extensive 
analysis disease variants have not yet been identified in 59% of cases.  This may 
reflect the limitations of array-based capture methods and NGS technology although 
other factors including experimental design and stringency of variant filtering are 
also important considerations.   
3.7.1 Experimental design 
Although the cost of NGS technology is falling, undertaking WES in large numbers 
of samples is costly and consideration of experimental design, especially deciding 
who to sequence, is a key issue in using available research funding to maximise gene 
discovery.  In this MPD cohort sequencing the parents and patient as a trio in non-
consanguineous families enabled a large reduction in variant number by filtering 
according to a particular mode of inheritance (Table 3.5).  This resulted in the 
identification of a probable diagnosis in 25% of these families.  Conversely, in 
consanguineous families, only the affected offspring were sequenced as autosomal 
recessive inheritance and homozygosity-by-descent were anticipated in these cases.  
Similarly a diagnosis was obtained in 25% of cases in both trio and singleton groups 
suggesting this strategy was a favourable use of resources in a disorder where 
recessive inheritance was most likely.  Furthermore, identifying regions of 
homozygosity in consanguineous cases could help narrow down candidate disease 
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genes (Becker et al., 2011) and tools are now available to perform this using NGS 
generated data (Seelow et al., 2009).  WES of the proband could also be combined 
with genetic linkage analysis to further limit the region of interest although this 
requires DNA to be available from other family members and is most powerful in 
multiplex families (Yamaguchi et al., 2011).   
This study also demonstrates the importance of considering different modes of 
inheritance in analysis, particularly if no candidate genes are found under the 
favoured model.  Here, examining variants using a range of inheritance models 
uncovered unexpected diagnoses, for example TARP syndrome (X-linked recessive) 
and Floating Harbor syndrome (de novo), expanding the phenotype of these 
disorders.  However, this approach is limited to trios and therefore unless 
consanguinity is likely, sequencing trios over singletons will improve the chances of 
identifying a diagnosis.   
It is also important to consider that causative variants may lie outwith the exome 
either in a non-coding region which can affect splicing or gene regulation or within a 
non-protein coding gene which is not included in the exome capture design.  For 
example, mutations in RNU4ATAC cause MOPDI (Edery et al., 2011, He et al., 
2011), a non-coding gene which is not covered in most exome capture kits.  Whole 
genome sequencing (WGS) may therefore be a preferential alternative to maximise 
the chances of discovering disease causing mutations.  The benefits of WGS, 
including improved uniformity in coverage and absence of capture based bias, need 
to be weighed against problems of increased cost ($1000 per genome), sequencing 
fewer samples and increased data handling capacity.  Furthermore, vastly increased 
variant numbers in non-coding sequence will be identified and predicting the 
functional consequence of variants outwith the exome will be very challenging 
although resources such as the ENCODE (ENCyclopedia Of DNA Elements) project 
(Consortium, 2004) and the development of prediction algorithms for genome wide 
variants (Kircher et al., 2014) can now assist with interpretation.  An alternative 
approach by which to identify abnormalities in gene expression and splicing as well 
as coding variation is to sequence the transcriptome using NGS technology (Cirulli et 
al., 2010).  Not only does this method negate the need for costly exome-enrichment 
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but also entails significantly less sequencing compared to the whole genome.  
However, highly expressed genes will be over-represented and also nonsense 
mediated decay may deplete transcripts containing nonsense and splice mutations.  
As yet, causative variants have yet to be identified in Mendelian disorders through a 
solely RNA-based approach. 
3.7.2 Library preparation  
In this study, there was a high degree of variation in the number of sequencing reads 
produced for each sample (Table 3.2) which in part is explained by the depth of 
sequencing which affects target coverage and consequently the numbers of variants 
identified (Hoischen et al., 2010, Meynert et al., 2013).  Although discrepancies in 
variant number occur with different commercially available capture kits 
(Chilamakuri et al., 2014), other factors also account for this variation including 
library quantification and DNA quality.   
3.7.2.1 Sample to sample variability 
The quality of input DNA (encompassing parameters such as degradation and purity) 
affects the efficiency of library capture with higher levels of dropout occurring in 
samples of poorer quality (Hasmats et al., 2014).  In addition, pooling of sample 
libraries prior to NGS sequencing of several barcoded samples in one lane will 
determine the consistency of sequencing depth between samples with unequal 
pooling altering the representation of each sample in the sequencing run (Quail et al., 
2008).  Furthermore, quantification of libraries prepared in Edinburgh was performed 
using the Agilent 2100 Bioanalyzer, the accuracy of which is influenced by DNA 
concentration (Panaro et al., 2000).  For example, the quantification of libraries with 
lower concentrations may be underestimated leading to an overrepresentation of such 
samples following pooling. 
3.7.2.2 Batch variability 
Significant variation in sequencing metrics was also seen between batches prepared 
and sequenced at different locations despite using the same capture method and 
sequencing platform (Table 3.2).  This study was performed over a 16 month period 
with WTSI samples being prepared and sequenced over a year before the Edinburgh-
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Denmark and OGT samples.  Improvements in experimental protocols and software 
will have occurred during this period and likely contributed to the variability 
between different batches.  Different centres also use different DNA quantification 
methods which often do not produce consistent results (Buehler et al., 2010).  Under- 
or over-representation of quantification can impact on cluster density and 
consequently the total number of sequencing reads generated per run (Quail et al., 
2008).  Even with highly accurate quantification and equal pooling it is still then 
difficult to achieve complete and reproducible uniformity when manually loading a 
small volume of sample onto the flowcell.  The degree to which the library 
preparation process is automated may also vary between the different centres and 
may impact on the efficacy of library capture. 
3.7.3 False positive variants 
One common difficulty encountered with NGS technologies is how to identify real 
variation from false positive variants.  The three main sources of false positive 
variants include errors in sequencing, incorrect alignment of reads to the reference 
genome (mapping errors) and incorrect variant calling in regions of low coverage.  
Since the advent of NGS technology, great efforts have been taken to improve 
alignment and variant calling software.  Despite this, false positive variants still 
present a significant issue with poor concordance between different alignment 
programmes and variant callers (Liu et al., 2013b, Shang et al., 2014).  Strategies 
previously employed include filtering variants based on quality scores (Zhang et al., 
2012) however reads containing a potentially damaging insertion or deletion are 
more likely to be poorly mapped and consequently less reliably called (Chou et al., 
2010).  Such variants are therefore more likely to be excluded when using stringent 
quality controls and therefore no quality filters were used in this pipeline.  
3.7.3.1 Sequencing errors 
Sequencing errors in NGS technology can result from inaccuracies in base calling 
which particularly occur in homopolymer runs and repetitive regions (Boland et al., 
2013).  The degree and type of error varies depending on the method of exome 
capture, template preparation and sequencing technology used, for example, semi-
conductor sequencing has greater inaccuracy in homopolymer runs compared to 
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other methods (Harris et al., 2008, Liu et al., 2012).  False positive variants resulting 
from such errors are therefore likely to occur at similar sites within different samples, 
particularly if the same methodologies were used.  As a large degree of genetic 
heterogeneity was anticipated in this cohort, it was assumed repeatedly occurring 
variants were more likely to represent sequencing errors than common pathogenic 
variants and were excluded.  However, in previous studies where one or a very 
limited number of genes were likely to cause the phenotype, removing variants in 
common between patients would have likely excluded pathogenic mutations (Smith 
et al., 2014).  An alternative and perhaps preferable approach is to use large 
publically available control datasets (matched in methodology) to identify commonly 
occurring errors although this will not remove false positive variants which are 
specific to a batch of samples prepared and sequenced together.   
3.7.3.2 Mapping errors   
Approximately 4% of the genome will map poorly to the reference (DePristo et al., 
2011) which provides an additional source of false positive calls.  Genes more liable 
to incorrect alignment include pseudogenes, those from large gene families with very 
closely related sequences or duplicated genes (Tennessen et al., 2012).  Equally 
genes with multiple repeat regions will also be difficult to align accurately and may 
appear enriched for novel variants (Treangen et al., 2012).  Here, BWA plus Stampy 
was used for read alignment in combination with GATK for variant calling.  This 
approach gives higher sensitivity in variant detection compared to other programmes 
but at the expense of specificity (Altmann et al., 2012).  Using this combination of 
software, Altmann et al found the total number of variants following whole exome 
capture and Illumina sequencing to be in the region of 250,000 which reduced eight 
fold when limiting variants to target regions (exons or 50 bases into flanking 
introns).  The high numbers of starting variants reported here compared to other 
studies (Gilissen et al., 2012) may reflect the inclusion of more off-target variants 
prior to filtering as only those outwith a gene locus (annotated by SnpEff as 
‘intergenic’) were removed.  This, of course, is weighed against the possibility that 
potentially causative variants in other regions (deep intronic, 5´UTR and 3´UTR) 
inadvertently uncovered by off-target capture will be missed.  However, as 
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previously mentioned in Section 3.7.1, interpreting the functional consequences of 
variants which lie outwith coding exons requires additional annotation.  
3.7.3.3 Regions of low coverage 
Regions covered by low read depth will contain more errors in variant calling and 
potentially pathogenic variants are more likely to be missed (Hoischen et al., 2010, 
Meynert et al., 2013).  Low read depth can result from low capture efficiency which 
is a particular problem in regions of large repeats or extremes of GC content 
(Sathirapongsasuti et al., 2011).  Such regions are also more liable to errors during 
sequencing (Hodges et al., 2007, van Dijk et al., 2014).  Attempting to validate all 
candidate variants in such areas is time consuming and inefficient as many are likely 
to be false positives.  Filtering variants based on read depth can be a useful first line 
approach to help reduce noise however homozygous variants can still be confidently 
detected at low read depths (<5X) (Meynert et al., 2013) and thus true-positive 
variants will also be excluded.  If such regions include genes of high interest to the 
study it may be more worthwhile performing a focused capture using alternative 
methods with improved performance in such regions combined with increased 
sequencing to achieve a greater read depth.  For example, (Oyola et al., 2012) 
showed that improved coverage could be achieved in AT rich regions by adjusting 
PCR conditions.  As well as capture by hybridisation methods using customised bait 
panels (e.g. SureSelect™ and HaloPlex™, Agilent), alternative methods which can 
be tailored to target specific genes of interest for high throughput sequencing include 
molecular inversion probes (Boyle et al., 2014) and multiplex PCR primer panels 
(AmpliSeq™) (Millat et al., 2014).   
3.7.4 Identifying rare and deleterious variants  
Pathogenic variants may also be missed when excluding variants previously 
identified in control populations such as those recorded in dbSNP (Sherry et al., 
2001), the 1000 Genomes Project (1KG) (Clarke et al., 2012) or the NHLBI GO 
Exome Sequencing Project (ESP, Seattle, WA) (http://evs.gs.washington.edu/EVS/).  
The large numbers of individuals now sequenced in these projects has resulted in the 
ascertainment of rare heterozygous variants in such databases which may be disease 
causing in the homozygous state (Knowles et al., 2013).  Utilising control population 
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datasets is common practice when filtering for rare variants however an appropriate 
minor allele frequency (maf) threshold needs to be set which takes into account the 
incidence of the disorder in the general population (Bamshad et al., 2011).   
Following the advent of NGS, large sequencing projects has revealed the extent of 
genetic variation between different ethnic groups (Genomes Project et al., 2012).  
Such variation was evident in this study with an enrichment of apparently rare 
variants occurring in non-European samples.  Therefore matching cases with controls 
of the same ethnicity would be ideal to reduce the candidate gene list further in such 
families.  However, many of the families in the MPD cohort are from the Middle-
East or sub-Indian continent, groups for which limited sequencing data is in 
publically available datasets (EVS, 1KG).  Minor allele frequencies for some 
populations are available in both 1KG and EVS datasets and this additional data 
could be utilised by setting the threshold on the basis of the population with the 
highest occurring maf.  An additional consideration is that disease prevalence may 
differ between population groups, particularly with a higher incidence of many 
recessive conditions occurring in consanguineous populations (Al-Owain et al., 
2012).  Therefore a higher minor allele frequency threshold is necessary when 
filtering variants in a subpopulation with a relatively high incidence of the disorder.  
Extensive annotation with a range of consequence prediction programmes assisted in 
the identification of potentially deleterious variants.  Many prediction programmes 
are based on sequence conservation and related functional domains which is limited 
in less well-characterised genes (Wu et al., 2013).  For example a likely causative 
variant in Miller syndrome was initially excluded as it was not predicted to be 
deleterious in any programmes employed (Ng et al., 2010b).  Notably, synonymous 
variants and predicted benign non-synonymous variants (consequence score=3) were 
filtered out in this pipeline.  Therefore causative variants may have been 
inadvertently removed during the filtering process and further refinement and 
optimisation of parameters on a study-by-study basis may be necessary.  However, 
currently in the MPD cohort, the large number of synonymous and predicted benign 
non-synonymous variants precludes a realistic approach to their analysis.  
131 
 
3.7.5 Interpreting ‘noisy’ genes  
During the examination of exome data in this study it was clear that certain genes 
were more enriched for rare deleterious variants compared to others.  These may 
represent either false-positive, as described in the previous Section, or true-positive 
variants.  Interpreting the numerous variants in these genes can be difficult but 
understanding why certain genes are noisy can help prioritise those more likely to 
have phenotypic consequences.  For example, some genes, such as those encoding 
histones, also have a higher degree of non-disease causing genetic variation than 
those under greater selective constraint (Tennessen et al., 2012).  Such related genes 
have a high degree of functional redundancy and therefore numerous deleterious 
variants may be present but have no phenotypic consequence (Zhang, 2012).  
Similarly large genes, for example TTN (Titin), are often more tolerant of genetic 
variation although disease causing mutations can still be present in such genes 
(Chauveau et al., 2014).  Statistical comparison of the frequency of deleterious 
variants between case and control populations can help identify genes in which 
deleterious variants are enriched in the patient cohort and therefore more likely to be 
disease causing (MacArthur et al., 2014).  This was performed in this study 
identifying FAT1 as a strong candidate disease causing gene in MPD (Section 3.6). 
3.7.5 Why WES does not always provide the answer 
Given all the above limitations of whole exome capture and sequencing, the 
probability of detecting a causative mutation in a gene has been estimated at 86% 
(Ng et al., 2009).  This was based on a study in which only four similarly affected 
patients were sequenced to identify dominant disease causing mutations in a known 
gene.  Therefore the probability of identifying pathogenic variants in disorders where 
the disease gene and mode of inheritance are more uncertain is likely to be even 
lower.  There are several reasons why WES may fail to identify a disease causing 
mutation.  Firstly, target capture efficiency is not uniform across the genome and 
variants are less likely to be identified in regions of low coverage.  In 35 samples in 
this study at least 15% of the exome was covered by less than 15 reads.  To obtain a 
sensitivity of  95% in the detection of a heterozygous SNV a read depth of at least 
13X is required compared to just 3X in the detection of homozygous SNVs (Meynert 
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et al., 2013).  Sensitivity to detect such variants will therefore be reduced in genes 
which have been inadequately covered especially when identifying compound 
heterozygous mutations.  This is particularly relevant when analysing parent-child 
segregation of variants, for example, during autosomal recessive and X-linked 
analysis where such analysis assumes all samples have equal coverage and that all 
variants have been called and genotyped correctly in each family member.  Given the 
variability in sequencing metrics observed in this study, this is unlikely to always be 
the case.  It is also worth noting that non-paternity or laboratory based errors can 
occur with samples giving misleading results when filtering using parental data.  
Performing a SNP array on samples prior to WES can be a useful way to confirm the 
fidelity of sample handling during preparation especially if this has been out-sourced.  
This has previously been successfully utilised to identify a sample handling error in 
the MPD exome cohort (L Bicknell, personal communication).  
Secondly, reads containing large insertions, deletions or complex indels are less 
likely to align to the reference sequence.  Such variants have a higher probability of 
impacting on protein function by causing a frameshift in the coding sequencing and 
hence are usually prioritised for review.  However, indel detection from NGS has 
much lower sensitivity and specificity compared to SNVs, with higher false positive 
rates (Grimm et al., 2013) and it is therefore harder to discriminate between error and 
true variation.  One causal deletion, initially missed during variant calling, was 
identified in neurofibromatosis type 1 syndrome by examining unmapped reads and 
performing a de novo assembly (Chou et al., 2010).   This requires extended 
bioinformatic skill and in this instance the authors had the advantage of prior 
knowledge of the variant.   
Finally, alternative possibilities for the causality of MPD not explored in this 
Chapter, but also potentially identifiable using WES, include digenic disease, 
inherited variants with incomplete penetrance, uniparental disomy (UPD), errors in 
imprinting, copy number variation (CNV) and mosaicism.  Alternative filtering 
strategies could be employed to identify possible causative variants in more than one 
gene within the same pathway (Yoshimura et al., 2014) and contiguous variants 
within a chromosomal region which do not appear to conform to Mendelian 
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inheritance can indicate regions of UPD (King et al., 2014).  Increasing read depth or 
changing parameters used for variant calling may assist in identifying mosaic 
variants (Pritchard et al., 2013) and several programmes now exist to identify CNVs 
in WES (Tan et al., 2014).  The use of one of such programme in CNV detection in 
WES is further explored in Chapter 6.   
In summary, WES provides a method by which to screen a large numbers of genes 
for pathogenic mutations which has not been previously feasible by other methods.  
However, interpreting the large number of variants even with efficient filtering 
strategies remains challenging.  Knowledge of limitations can improve the likelihood 
of success by tailoring experimental design and filtering strategies to the disorder in 
question.  Although, significant progress has been made in the efficiency of target 
capture, sequencing technologies, accuracy of alignment and variant calling this 
method is still error prone and in many cases pathogenic variants are unable to be 
identified.  In Chapter 7 alternative approaches for investigating the remaining 
patients in whom a molecular diagnosis has not yet been identified following WES 













Chapter 4: Mutations in components of the non-
homologous end joining machinery cause MPD 
 
4.1 Introduction 
In Chapter 3, mutations were identified in three families in LIG4 and in one family in 
XRCC4 following exome sequencing.  Both genes encode proteins with a critical role 
in non-homologous end joining (NHEJ), the predominant repair mechanism of DNA 
double-strand breaks within the cell.  
4.1.1 Non-homologous end joining (NHEJ) 
In NHEJ (Figure 4.1), the damaged termini of DNA at the site of a DSB promote 
rapid binding of the KU70-KU80 heterodimer to each free end independent of its 
sequence (Mimori et al., 1986, Walker et al., 2001).  This recruits and activates the 
endonuclease DNA-dependent protein kinase catalytic subunit (DNA-PKcs) 
(Gottlieb et al., 1993) along with the exonuclease Artemis which also acquires 
endonucleolytic activity on binding to DNA-PKcs (Ma et al., 2002).  The combined 
activity of Artemis and DNA-PKcs ensures damaged DNA overhangs can be cleaved 
at a variety of positions (Yannone et al., 2008) allowing the removal of damaged or 
non-ligatable groups.  Infilling of nucleotides is performed by Polymerases mu 
and/or lambda, as required, through their binding to KU complexes (Ma et al., 2004).  
Polymerase mu does not require a template to synthesise DNA which particularly 
lends itself to processing breaks with no sequence homology (Ramadan et al., 2004).  
The final ligation step is performed by the XRCC4-XLF-LIG4 complex (Ahnesorg et 
al., 2006), recruited by DNA-PKcs (Drouet et al., 2005).  The X-ray repair cross-
complementing protein 4 (XRCC4) and Cernunnos (XLF) have similar structures 
and it has been proposed they alternate to form a filament that wraps around the 
DNA ends, bridging the break (Hammel et al., 2011, Ropars et al., 2011, Wu et al., 
2011, Andres et al., 2012).  This may act to stabilise the free ends allowing Ligase 
IV (LIG4) to complete ligation (Roy et al., 2012, Mahaney et al., 2013).   
One important aspect about NHEJ machinery is its flexibility.  The KU-DNA end 
complex is able to recruit the different multifunctional components in any order (Ma 
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et al., 2004) and these different components can also involve a variety of other end 
processing factors as required.  This increases the range of end-processing abilities 
allowing the repair of various DNA end configurations which may occur from 
different types of damage but also results in variable outcomes from the processing 
of identical DSBs (joining heterogeneity) (Ma et al., 2004).  Polynucleotide Kinase 
PNKP (PNKP) is phosphorylated by DNA-PKcs and can interact with XRCC4 
(Zolner et al., 2011).  It can function to remove terminal blocking groups which 
prevent DNA ligation (Weinfeld et al., 2011).  Aprataxin (APTX) (Clements et al., 
2004) and Aprataxin and PNK like factor (APLF) (Iles et al., 2007, Kanno et al., 
2007, Macrae et al., 2008) have both also been shown to interact with XRCC4.  
APLF is both an endo- and exo-nuclease whereas APTX possesses DNA 
deadenylation activity able to convert 5ʹAMP groups resulting from unsuccessful 
ligation reactions.   NHEJ components are therefore likely to perform iterative 
rounds of DNA processing until the free ends are compatible for ligation (Ma et al., 
2004).  Tyrosyl-DNA phosphodiesterase 1 (TDP1) (Inamdar et al., 2002) and 
Apurinic/apyrimidinic endonuclease (APE1) (Suh et al., 1997) are also able to 
process free DNA ends in DSBs however currently no in vivo evidence exists 




Figure 4.1. Overview of DNA double-strand break repair by NHEJ 
The KU complex initially coats the damaged DNA ends recruiting the end processing factors DNA-
PKcs and Artemis as well as polymerases for nucleotide infilling.  Other enzymes such as PNKP may 
also be activated by DNA-PKcs to facilitate end processing.  Final end joining is performed by the 
LIG4-XRCC4-XLF complex although iterative rounds of end processing involving the recruitment of 
further enzymes by XRCC4 may be required until the DNA ends are compatible for ligation by LIG4.   
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4.1.2 Mutations in NHEJ components cause radiosensitive 
severe combined immunodeficiency (RS-SCID) 
In humans, mutations have been identified in DCLRE1C encoding Artemis (Moshous 
et al., 2001), PRKDC encoding the catalytic subunit of DNA-PKcs (DNA dependent 
protein kinase) (van der Burg et al., 2009), NHEJ1 encoding Cernunnos-XLF (Buck 
et al., 2006a) and LIG4 encoding Ligase IV (Table 4.1).  All are associated with 
increased cellular radiosensitivity and severe combined immunodeficiency due to 
defective V(D)J recombination leading to early arrest of both B and T cell 
maturation.  Patients with mutations in DCLRE1C exhibit RS-SCID without any 
additional phenotypes whereas mutations in PRKDC (Woodbine et al., 2013), NHEJ1 
(Buck et al., 2006a, Dutrannoy et al., 2010) and LIG4 (Table 4.1) have been 
associated with other developmental abnormalities.  Most notably these include 
microcephaly and short stature although growth failure to the degree seen in MPD 
has not been previously described.  
Unlike mutations in other NHEJ genes, immune compromise has not always been 
evident in cases with LIG4 mutations (Table 4.1).  The first case to be reported was a 
‘developmentally normal’ 14 year old boy (with presumably normal growth) who 
exhibited severe radiosensitivity during treatment for leukaemia without prior 
immunodeficiency (Riballo et al., 1999, Riballo et al., 2001).  As well as in patients 
with RS-SCID (Buck et al., 2006b, Enders et al., 2006, van der Burg et al., 2006), 
LIG4 mutations have been identified in individuals with milder degrees of 
immunodeficiency, microcephaly, developmental delay and pancytopenia (O'Driscoll 
et al., 2001, O'Driscoll et al., 2004).  Ligase IV syndrome has therefore often been 
considered as a rare differential to Nijmegen breakage syndrome (caused by 
mutations in Nibrin, NBN) characterised by microcephaly, mild immune dysfunction 
and malignancy predisposition as well as a cause of RS-SCID.   
Following the identification of three MPD cases with LIG4 mutations in Chapter 3, 
sequencing of LIG4 was undertaken in the remainder of the cohort.  Given the rarity 
of ligase IV syndrome, it was somewhat surprising that this identified a further seven 
families with truncating mutations in LIG4 all initially presenting with severe growth 
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failure.  In this Chapter, more extensive characterisation of the Ligase IV phenotype 
is performed as well as the description of a genotype-phenotype correlation.  As 
XRCC4 is a direct binding partner of LIG4 and another important component of 
NHEJ, resequencing of XRCC4 was also performed in the remainder of the MPD 
cohort identifying a further five families, all with nonsense mutations in XRCC4.  
This substantiates XRCC4 as a new disease causing gene in MPD and allows a 
common phenotype to be described which overlaps LIG4 patients.  These findings 
place mutations in LIG4/XRCC4 as the second most common cause of MPD in this 
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associated lymphoproliferative 
syndrome and died shortly after 
F No Microcephaly - Severe 
BMT at 2mths but died shortly 




Growth parameters given as standard deviations where measurements were reported otherwise description stated as reported in article. Dash indicates where no 
information was provided.  Abbreviations: RS-SCID=radiosensitive severe combined immunodeficiency, BMT=bone marrow failure, EBV=Epstein-Barr virus  
van der 




Europe F - No Normal RS-SCID 
SCID diagnosed at 2yrs.  Died 









Height at 10th 
centile 
Normal RS-SCID 
SCID diagnosed at 2yrs.  EBV 








RS-SCID Underwent successful BMT 








Croup & bronchitis, 
poor social 
circumstances 
Anal squamous cell carcinoma at 
34yrs, died after severe reaction 
to local radiotherapy for 
malignancy.  Preceding cytopenia. 
Yamada et 
al., (2001), 










Episode of thrombocytopenia 
at3yrs, 
Pre-axial polydactyly, EBV 
associated large B cell lymphoma.  
Died during chemotherapy 
treatment. 
Grunebau









Protracted universal scaly 
erythroderma, 
hepatosplenomegaly, generalised 
lymphadenopathy and diarrhoea.  
Underwent successful BMT 













Progressive bone marrow failure 
from 8 yrs.  Underwent successful 
BMT. 
F No 






Progressive bone marrow failure 




4.2.1 Resequencing of LIG4 in MPD patients 
In Chapter 3, analysis of WES data using an autosomal recessive model of 
inheritance identified three cases with two heterozygous truncating mutations in 
LIG4 (consequence score=1) (Figure 4.2A).  All mutations were then validated in the 
affected by capillary sequencing (Figure 4.2B).  The coding exon of LIG4 was then 
sequenced in 138 patients with MPD in whom exome sequencing had not been 
previously performed.  This identified a further five cases, all with two heterozygous 
truncating mutations in LIG4 (in one family sequencing was performed 
collaboratively in The Netherlands, (Ijspeert et al., 2013)).  Two additional cases 
were then identified through WES by a collaborating group in Cologne, Germany, 
both of which also had a clinical diagnosis of MPD.  Parental DNA was available in 
eight families, and all were found to be heterozygous carriers following capillary 
sequencing, confirming the mutations to be biallelic in the offspring (Table 4.2).  All 
parents were reported to be healthy.  In one family, there was also a similarly 
affected sibling (F1.2) and sequencing confirmed the same LIG4 mutations were 
present in both affected offspring.   
 
In total, 11 patients from 10 families were identified with biallelic truncating 
mutations in LIG4 (Murray et al., 2014).  One further patient with MPD was found to 
carry the heterozygous truncating mutation, c.128delT, p.L43*, but a second likely 
deleterious variant was not observed in the remaining coding sequence.  Cellular 
testing for sensitivity to ionising radiation, however, has been recommended as a 
second pathogenic non-coding variant may be present.  LIG4 was also sequenced in 
43 patients with primary microcephaly and in 56 with microcephaly and milder short 
stature (OFC<4sd and height -2 to -4sd from population mean) but no further 
mutations were found.  In total, eight different truncating mutations were identified, 
six of which have not been previously reported.  One mutation, c.2440C>T 
(p.Arg814*), was identified recurrently in nine families.  This mutation was also 
present in control datasets at a low frequency in the heterozygous state (dbSNP: 
rs104894419, EVS: maf=0.00015, 1000genomes: maf=0.0005).  Comparing the 
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frequency of the c.2440C>T allele reported in EVS with the frequency identified in 
this cohort (0.015) showed a significant enrichment of c.2440C>T in MPD patients 
(two-tailed p=0.0001 using Chi squared test with Yates correction).      
 
 
Figure 4.2.  Mutations identified in three patients in LIG4 following WES 
A) Sequencing reads following WES aligned to the reverse compliment of the LIG4 reference 
sequence using the Integrative Genomics Viewer (IGV) demonstrating compound heterozygous 
truncating mutations identified in  F1.1; c.1271_1275delAAAGA (horizontal line identified in 160 out 
of 335 reads) and c.2440C>T (green/brown identified in 76 out of 132 reads).  B) Chromatograms 
following capillary sequencing in each child and parents/siblings (where DNA available) confirmed 
mutations segregated appropriately with the phenotype in i) F1.1 ii) F2 and iii) F3.  
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Reproduced from Murray et al, 2014.  F1.1 and F1.2 represent individual affected siblings.  All mutations are predicted to cause premature truncation of the protein.  
*Sequencing and identification of mutations occurred in The Netherlands (Ijspeert et al., 2013).  See Appendix II for details of reference sequence.  N/A=not available. 
Patient Nucleotide change Protein change Country of Origin Mother Father 




































































The Netherlands p.(Ser205Leufs*29) p.(Lys635Argfs*10) N/A 
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4.2.2 Haplotype analysis in families sharing the recurrent 
p.R814* mutation  
To determine whether c.2440C>T (p.Arg814*) represented a founder mutation in 
these families, polymorphic SNPs in a 2 Mb region surrounding LIG4 were 
genotyped in the nine families (Figure 4.3).  This identified a common haplotype of 
at least 2 Mb in two families (F4 and F8) and three families (F1, F2 and F6) shared 
6-12 SNPs of the same haplotype immediately adjacent to the gene (Murray et al., 
2014).   This established that c.2440C>T represents a founder mutation in at least 
two of the families and potentially five families in total.  However in the remaining 
three families no common haplotype was seen indicating a mutation at this 
nucleotide has occurred on multiple occasions.  This provides clear evidence that 
c.2440C>T is the causative mutation in these families rather than another co-
segregating variant.  Notably this nucleotide is part of a CpG motif which, when 
methylated, is prone to spontaneously deaminate (Scarano et al., 1967).  CpG motifs 
are therefore frequent sites of C>T mutations.   
4.2.2 Characterisation of phenotype associated with 
truncating LIG4 mutations  
4.2.2.1 Growth impairment 
Intrauterine growth retardation was observed in all cases (mean birth weight -3.0 s.d., 
birth OFC -3.6 s.d. and length -3.8s.d.) (Figure 4.4, Table 4.3).  Growth then 
continued to be delayed postnatally with a severe reduction in weight, OFC and 
height.  Again this was present in all cases (mean weight -6.8 s.d., OFC -10.1 s.d. 
and height -5.1 s.d.).  Disproportionate microcephaly was also universally observed 
with OFC substantially more reduced than height (p=0.0001).  Growth parameters of 
previously described cases (where available) are shown in Table 4.1 and Figure 4.4 
(grey) (mean birth weight -1.3 s.d., birth OFC -1.5 s.d., birth length -1.5 s.d., 
postnatal weight -2.4 s.d., OFC -5.6 s.d. and height -2.4 s.d.).  Notably, none of these 
cases had growth parameters which fell into the defined range for MPD (see Section 
1.1.2).  The growth failure observed in the patients identified in this study was found 
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to be significantly greater than those cases previously reported (Figure 4.4) (Murray 
et al., 2014). 






Figure 4.3.  Haplotype analysis in 5 families sharing the recurrent c.2440C>T 
(p.R814*) mutation  
Reproduced from Murray et al, 2014.  A common 2Mb haplotype is present in two families, F4 & F8.  
F1, F2 and F6 also shared a smaller region of identical SNPs adjacent to LIG4, suggesting that the 
c.2440C>T mutation may have the same ancestral origin in these families.  Dash indicates where the 






4.2.2.2 Facial characteristics, malformations and intellectual 
development 
Clinical photographs were available for review in nine cases (Figure 4.5).  All were 
noted to share similar facial characteristics particularly in early childhood.  Common 
features included fine sparse hair, epicanthic folds, wide depressed nasal bridge, 
broad nasal tip and prominent chin.  No dental problems were reported.  
Malformations were observed in some cases but were only present at a low 
frequency (Table 4.3).  The most commonly reported malformation was congenital 
hip dysplasia occurring in three individuals.  One case was also reported to have 
severe vomiting episodes occurring from birth and this had resulted in significant 
feeding difficulties throughout childhood.  The cause for this has not been 
established.  Most of the cases had not yet reached pubertal age but of the two oldest 
patients (F1.1 and F1.2) primary ovarian failure was observed in both.   
In three cases development was reported to be normal whereas six showed evidence 
of mild developmental delay and one exhibited moderate delay.  Where delay was 
present, expressive language skills were predominantly affected.  All school-aged 
children were in mainstream school although some patients required additional 
support.  Development could not be assessed in one case (F10) who died at 6 months 



















Figure 4.4. Growth impairment in patients with LIG4 truncating mutations   
Adapted from Murray et al, 2014.  Measurements plotted as Z-scores (standard deviation of 
measurement from population mean for age and sex) for previously reported cases (grey) alongside 
the patients reported here (black) for each growth parameter.   A) Measurements at birth of MPD 
cases (mean weight -3.0 +/-0.93 s.d. (n=11), OFC -3.6 +/-1.37 s.d. (n=8) and length -3.8 +/-1.88 s.d. 
(n=3)) compared to previously reported cases (mean weight -1.3 +/-0.8 s.d. (n=6), OFC -1.5 +/-1 s.d. 
(n=4) and length -1.5 +/-0.7 s.d. (n=4)).  B) Most recent postnatal measurements of MPD cases 
(weight -6.8 +/-1.96 s.d., OFC -10.1 +/-0.95 s.d. and height -5.1 +/-1.62 s.d.) compared to previously 
reported cases (weight -2.4 +/-2.3 s.d. (n=5), OFC -5.6 +/-2.8 s.d. (n=6) and height -2.4 +/-1.5 s.d. 
(n=5)).  Mean and standard deviation of patient group indicated by horizontal and vertical bars 
respectively.  * p<0.05; ** p<0.01; *** p<0.001 (unpaired t-test).  
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Table 4.3.  Anthropometric data and clinical findings of patients with truncating LIG4 mutations 



























Malformations & additional features 










Mild Small cerebral aneurysm, primary ovarian failure 










Atrial-ventricular septal defect, atrophic kidney, rib hypoplasia, fusion of 
carpal bones, copper beaten skull, platybasia, abnormal C1 vertebrae and 
primary ovarian failure 










Mild Anal atresia with rectovaginal fistula, esotropia 










Mild Unilateral congenital hip dysplasia, cutis marmorata 



















None Unilateral congenital hip dysplasia 











Congenital hip dysplasia, 2/3 toe syndactyly, excessive vomiting 
(gastrostomy in situ) 































Hypopigmentation, hypermobile knees, single palmar crease, 2/3 toe 
syndactyly, sandal gap 











Pre-axial polydactyly 2/5 toe syndactyly, dysplastic kidney and dysgenesis 





Figure 4.5.  Facial features of nine LIG4 cases with microcephalic primordial dwarfism   
Reproduced from Murray et al, 2014.  Age of patient at time of photos; F1.1 at 20 years, F1.2 at 14 years, F2 at (a) 3 years and (b) 6 years 10months, F3 at (a) 3 months and 




4.2.2.3 Haematological abnormalities  
At time of recruitment to the study, three patients were reported to have experienced 
episodes of pancytopenia with no apparent trigger.  This was subsequently reported 
in a further six patients, the first episode occurring after recruitment to the study 
(Table 4.4).  The earliest reported episode occurred at two years of age (F3 and F4) 
and the latest at 15 years (F1.1) (Murray et al., 2014).   
Platelets were always the most significantly affected cell type (calculated as percent 
of normal; 11.8%, p=0.0001) followed by leukocytes (33.7%, p=0.0001) with only a 
mild reduction in haemoglobin levels (79.3%, p=0.002) (Figure 4.6A, Table 4.4). 
Seven patients followed a progressive course of bone marrow failure with an 
increase in transfusion frequency with age (Figure 4.6B).  One patient (F1.1) 
experienced pancytopenia over a six month period requiring regular platelet 
transfusions but this spontaneously improved and whilst she is no longer transfusion 
dependent indices still remain subnormal on recent investigation (Table 4.4).  Only 
one patient has had no documented evidence of cytopenia at the age of three years 
(F5).  Finally, in patient F10 cytopenia occurred in association with acute sepsis 
towards the end of life at five months of age (Ijspeert et al., 2013).  No evidence of 
malignancy of any type was reported in any of the 11 cases with the oldest patient 
being 21 years at time of writing.  Bone marrow aspiration was performed in four 
individuals and demonstrated a hypocellular marrow but no morphological 
abnormalities were seen.   
 
4.2.2.3 Immune dysfunction  
On recruitment to the study, immunodeficiency had not been clinically suspected in 
10 of the 11 cases.  However, on retrospective questioning, several children (F1.2, 
F3, F6 and F9) have had recurrent common childhood illnesses (respiratory, skin and 
gastrointestinal) and one patient (F1.1) had a severe influenza illness requiring 
hospitalisation despite vaccination (Murray et al., 2014).  Severe immunodeficiency 
had only become clinically apparent in one patient (F10) at an early age with 
recurrent and opportunistic infections from birth.  The patient unfortunately died at 
six months of age due to an acute gastric bleed in association with a clinical sepsis 
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syndrome.  Immune function was noted to be profoundly impaired on investigation 
in this patient (Ijspeert et al., 2013) (Table 4.5).   
Subsequent to diagnosis with Ligase IV deficiency, detailed immunological 
investigations have been performed in many of the remaining patients.  Eight of the 
nine patients tested demonstrated hypogammaglobulinemia, particularly low IgG, 
and in the eight patients for which T/B cell subset data is available, B cell counts 
were found to be severely depleted with a variable reduction in T cells (Table 4.5).  
Vaccination response was also found to be generally impaired where assessed.  This 
has impacted on the clinical management of these patients and all are now under the 
care of a specialist paediatric immunologist.  Currently bone marrow transplantation 
is underway in patient F3, and is also being considered in several others (F1.2, F6 





Figure 4.6.  Haematological parameters in LIG4 patients during episodes of 
cytopenia  
Reproduced from Murray et al, 2014.  A) Documented blood counts from nine patients during the 
most recent cytopenic episode.  Values are shown as percentage of average normal count: 
Haemoglobin 79.3%+/-13 s.d. (p=0.002), leucocytes 33.7%+/-19 s.d. (p=0.0001) and platelets 
11.8%+/-8 s.d. (p=0.0001).   Platelets were the most significantly affected cell type.  B) Serial blood 
counts in one patient (F8) over time demonstrating increasing transfusion dependency with age.  




Table 4.4.  Clinical course of bone marrow failure in LIG4 patients and details 
of haematological investigations 




























15y 20y 8.2 1.5 53 40 30 




3y 3y 12.6 1.8 55 24 43 
F3 4m None 2y 2y 11.1 2 30 40 18 
F4 2y None 2y 6y 8.2 2.34 N/A N/A 32 
F5 1y None 
None 
at 3y 
N/A N/A N/A N/A N/A N/A 
F6 Neonate None 3y 10m 3y 10m 8.5 4.9 55 32 42 
F7 3y8m None 3y9m 4y4m 11.9 4.9 54.3 26 3 
F8 4y None 6y 6y2m 8.2 3 N/A N/A 33 
F9 2y6m None 6y 6y 11.7 5.6 60.8 27.2 78.1 
F10 4m None 5m 6m 4.4 35 90 7 58 
Adapted from Murray et al, 2014.  Absolute full blood count values are the most recent recorded in 
which cytopenia is demonstrated.  Normal range of absolute counts varies with age, sex and 
laboratory methods but approximate reference ranges are as follows: Hb 10.8-13.9g/dl, Total WCC 
5.5-12.9 x103/µl, Neut 30-60%, Lymph 20-50%, Plts 130-400x103/µl.  Levels considered below 
normal range (according to local laboratory) are highlighted in bold.  Abbreviations: Hb = 
Haemoglobin, WCC = White Cell Count, Plts = Platelet count, Neut = Neutrophil count, Lymph = 




Table 4.5.  Clinical course of bone marrow failure in LIG4 patients and details of haematological investigations 












T and B Lymphocyte subset  
Cells/µl Antibody response to Vaccination 
IgG IgA IgM CD3 CD8 CD4 CD19 
F1.1 17y Mild 15y 4.31 1.06 0.14 680  380 240 0 N/A 
F1.2 14y Mild 14y 5.59 1.29 0.76 660 370 190 10 N/A 
F2 3y None Awaiting investigations 
F3 4m Mild 2y 3.7 0.58 0.74 710  170 500 very low Poor response to pneumococcal vaccine 
F4 2y None 6y Low N/A N/A N/A N/A low very low Poor response to pneumococcal vaccine 
F5 1y None 2y 3.66 0.8 0.62 467 204 164 6 N/A 
F6 Neonate Mild 4y 5.76 4.23 0.27 983 292 583 11 
Tetanus and Diphtheria normal, HiB and 
pneumococci low 
F7 3y8m None Awaiting investigations 
F8 4y None 6y 4.8 2.4 <0.3 N/A N/A 
F9 2y6m Mild 5y6m 9.7 3.1 1.0 normal normal normal very low N/A 
F10 4m Severe 4m 0.76 0.22 0.85 5730  2410 3380 60 N/A 
Adapted from Murray et al, 2014.  Increase in infections:  ‘Mild’ defined as an increased frequency of common pathogens (upper & lower respiratory, skin and 
gastrointestinal) or increased severity of a single illness above that deemed normal for childhood by their clinician.  Normal range of absolute counts varies with age, sex and 
laboratory methods but approximate reference ranges are as follows: IgG 5.65-17.65g/dl, IgA 0.85-3.85g/dl, IgM 0.55-3.75g/dl, Total T lymphocytes (CD3+) 870-2080/µl, T 
helper subset (CD4+) 530-1290/µl, T cytotoxic subset (CD8+) 220-960/µl, B lymphocytes (CD19+) 100-400/µl.  Levels considered below normal range (according to local 
laboratory) are highlighted in bold.  In F1.1 and F1.2, naïve CD4 and CD8 cells were reported to be very low.  In F5, total lymphocyte count was also reported to be reduced.  
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4.2.5 Sensitivity to ionising radiation in patient cells  
Assessment of radiosensitivity of lymphoblastoid cells was performed in three 
patients (F2, F5 and F7) by S. Haghayegh (UCLA Department of Pathology & 
Laboratory Medicine, Los Angeles, USA) using a colony survival assay previously 
established for the testing of patients with ATM mutations and ataxic telangiectasia 
(Sun et al., 2002).  Increased sensitivity to DNA damage was observed in patient 
cells, with reduced survival of cells (3 to 5% cell survival) following exposure to 1 
Gray of ionising radiation (lab reference range for wild-type cells:  50.1% +/-13.5, 
n=24).  Notably, this was greater than the increase in sensitivity seen in ataxic 
telangiectasia patient cells (13.1% +/-7.2, n=104) and that observed in previous 
studies of LIG4 patients, <30% cell survival at 1 Gray (O'Driscoll et al., 2001).   
Increased cellular sensitivity to ionising radiation was also present in patient F10, 
<5% cell survival (Ijspeert et al., 2013). 
 
4.2.6 Delineation of a phenotype-genotype correlation in 
LIG4 patients 
The difference in growth phenotype between the cases identified in this study and 
those previously reported led me to examine if any genotype-phenotype correlation 
was evident.  As the LIG4 gene contains two exons (Figure 4.7A), with only exon 2 
encoding the 911aa protein, transcripts should not be targeted for nonsense mediate 
decay and thus truncating mutations would not be anticipated to be null.  The protein 
is comprised of an enzymatic domain containing highly conserved sequence motifs 
(Shuman et al., 1995, Marchetti et al., 2006), and a C-terminal XRCC4 binding 
domain comprised of two BRCT domains with a linker region that contains the 
minimal XRCC4 binding motif (Sibanda et al., 2001) (Figure 4.7B).  Mutations were 
defined as late-truncating if occurring after the XRCC4 binding motif, mid-
truncating if located between the start of the enzymatic domain and the end of the 
XRCC4 binding motif and early truncating if occurring before the start of the 
enzymatic domain.  The recurrent c.2440C>T, p.Arg814* mutation, represents the 
most distal truncating mutation reported and only affects the last BRCT domain of 
the XRCC4 binding domain (Figure 4.7C).  Only one patient homozygous for this 
156 
 
mutation has been reported in the literature to date.  They exhibited microcephaly 
with normal stature (Ben-Omran et al., 2005) and developed leukaemia at four years 
of age.  No prior immune dysfunction or cytopenic episodes had been noted in this 
patient.  The majority of cases identified in this study (F1.1-F9) also carry the 
c.2440C>T mutation but combined with a mid-truncating mutation on the alternate 
allele.  These patients displayed a more severe growth phenotype with chronic or 
progressive cytopenia and evidence of immune dysfunction on investigation.  The 
most severely affected case in this study presented with SCID early in life and severe 
growth failure (F10).  They carried a ‘mid-truncating’ mutation which completely 
removed the XRCC4 binding site in combination with an ‘early’ truncating mutation 
that removed the entire enzymatic domain.  Severity of the phenotype therefore 
appears to correspond to the degree of protein truncation with severe growth 
retardation only occurring when the critical XRCC4 binding region (between the two 
BRCT domains) has been disrupted in at least one allele.  Immune compromise and 
bone marrow failure were also observed in these patients but severe 
immunodeficiency (SCID) was only evident in the patient where the XRCC4 binding 
region had been totally lost from both alleles.  As XRCC4 binding confers stability to 
LIG4 (Bryans et al., 1999), variation in the strength of this interaction may in part 


















Figure 4.7.  Degree of protein truncation correlates with severity of growth 
failure and immune deficiency  
Reproduced from Murray et al, 2014.  A) Schematic of the LIG4 gene.  B) LIG4 protein domain 
structure: enzymatic domain (purple) with highly conserved sequence motifs (pink), XRCC4 binding 
domain (grey) with critical binding motif (black).  C, D) Position of truncating mutations correlating 
with phenotype.  C) Biallelic mutations representative for each group are depicted: (i) Late Truncating 
mutations are associated with the mildest phenotype (ii) Late & mid truncating were observed in 
patients with severe growth delay, cytopenia and subclinical immunodeficiency (iii) Mid and early 
truncating mutations were associated with the most severe immune phenotype as well as severe 





4.2.7 Resequencing of XRCC4 in MPD patients 
In Chapter 3, a non-synonymous coding variant (consequence score=2) was 
identified in the homozygous state in a singleton case, c.127T>C (p.Trp43Arg) in 
XRCC4 following WES (Figure 4.8A).  The mutation was validated by capillary 
sequencing and both parents were found to be heterozygous carriers (Figure 4.8B).  
The predicted amino acid change occurred at a residue conserved in vertebrates 
(Figure 4.8C) and was predicted to have a functional impact on the protein by all 
prediction programmes used in analysis.  The same mutation was subsequently 
reported in another case with MPD from the same country (Shaheen et al., 2014). 
XRCC4 was then re-sequenced in 199 patients with MPD, primary microcephaly or 
microcephaly and short stature using a custom designed Ion AmpliSeq panel to 
amplify desired coding regions and sequencing using either the Ion Proton™ or Ion 
Torrent™ platforms.  This sequencing technology (semi-conductor method) has a 
markedly lower sensitivity for identifying indels compared to SNVs (see Section 
1.4.1) therefore if a single deleterious heterozygous variant was identified, all coding 
regions were re-sequenced by capillary sequencing to ensure a second pathogenic 
variant was not present.  This approach identified an additional five cases with 
recessive mutations in XRCC4 (Table 4.6).  In three families, where parental DNA 
was available, the mutations were confirmed to be biallelic in the affected offspring.  
Three patients of European origin all carried the same deletion on one allele, 
c.25delC, potentially representing a founder mutation in these families.  Two of these 
patients also carried the same nonsense mutation on the alternate allele, c.823C>T.    










Figure 4.8.  Non-synonymous mutation identified in XRCC4 following WES  
A) Sequencing reads following WES aligned to XRCC4 reference sequence using IGV identifies a 
homozygous variant, c.127T>C (blue) present in all reads (60 X) in the affected child.  B)  Capillary 
sequencing chromatograms confirming the mutation in the child and identified both parents as 
heterozygous carriers.  C) Alignment of sequences from different species demonstrating the 
nucleotide change affects an amino acid which is conserved in vertebrates.  Alignment performed 






































M France N/A 




p.(His9Thrfs*8) M UK p.(His9Thrfs*8) c.[-1-10G>T] 
See Appendix II for details of reference sequence.   
 
4.2.8 Predicted Impact of XRCC4 mutations on protein 
function 
Nonsense mutations were predominantly identified in XRCC4 and were distributed 
throughout the gene (Figure 4.9).  As XRCC4 is composed of eight exons and all 
mutations were upstream of the last exon (encodes amino acids 297-366), it is 
anticipated that transcripts would undergo nonsense mediated decay.  As 
examination of other predicted transcripts did not identify an alternative transcript 
which would be unaffected by these nonsense mutations, it is likely that no 
functional protein would be produced by any of these alleles.  One variant identified 
resulted in a single nucleotide change immediately adjacent to the first base of exon 
two, c.-10-1G>T.  This was predicted to completely abolish the splice acceptor site of 
intron 1 (Figure 4.10), although the precise effect on splicing is yet to be determined 
by RNA studies.   
XRCC4 is composed of an N-terminal head domain which forms a globular structure 
followed by a coiled-coil domain forming an α-helical stalk and terminates in an 
unstructured C terminal region (Junop et al., 2000).  The linker region between the 
two BRCT domains of LIG4 has been shown to bind directly to XRCC4 through an 
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area in the coiled-coil stalk region (Sibanda et al., 2001).  It has been proposed that 
XRCC4 plays a structural role in NHEJ and may act with XLF to stabilise the DNA 
break prior to ligation (Roy et al., 2012).  Two XRCC4 proteins interact through the 
head domains to form homodimers in a similar fashion to XLF (Hammel et al., 2011, 
Ropars et al., 2011, Wu et al., 2011, Andres et al., 2012).  XRCC4 and XLF 
homodimers then alternate through interactions of the head domains to form long 
protein filaments which may bridge the DNA gap promoting ligation.  The non-
synonymous coding variant identified in F11, c.127T>c (p.Trp43Arg), lies within the 
head domain of the encoded protein and may exert a deleterious effect on protein 





Figure 4.9.  Mutations in XRCC4 gene and location in the encoded protein   
A) XRCC4 is composed of eight exons.  B)  The 366aa protein is encoded by exons 2-8.  The non-
synonymous mutation, p.Trp43Arg (red), lies in the head domain of the protein which binds to XLF.  
LIG4 binds to XRCC4 via a region in the coiled-coil domain (light pink).  The remaining coding 
mutations were predicted to produce truncated transcripts which would undergo nonsense mediated 






Figure 4.10.  Predicted effect of a splice site variant identified in XRCC4  
A) Schematic of exons 1-3 of XRCC4 with position of splice variant indicated within the 5’ UTR of 
the gene (white box).  B) The 5’UTR of XRCC4 spans the first two exons (white box).  The c.-10-
1G>A variant occurs immediately adjacent to the start of exon 2 and is predicted to completely 




4.2.8 Characterising the phenotype associated with XRCC4 
mutations 
4.2.8.1 Growth Impairment 
Growth parameters were available in five of the six XRCC4 patients (Table 4.7).  
IUGR was observed in four patients (mean birth weight -2.9 s.d., birth OFC -3.2 s.d. 
and length -3.9 s.d.).  On comparison with LIG4 cases there was no significant 
difference between growth parameters at birth (p>0.6) (Figure 4.11).  Postnatal 
microcephaly was seen in all five cases with XRCC4 mutations and this was 
disproportionate to the reduction in height (OFC -8.12 s.d., height -4.8 s.d.) similar to 
the LIG4 patients.  This is in contrast to patients with PCNT mutations (MOPD II) in 
which OFC is more proportionately reduced in comparison to height (mean postnatal 
OFC -10.3 s.d. and height -8.5 s.d.) (Bober et al., 2012).  Postnatal head 
circumference was slightly less reduced compared to LIG4 patients (p=0.04) but no 
significant difference in stature (p=0.3) or weight (mean weight -5.0 s.d., p=0.2) was 
seen between the two groups (Figure 4.11).   
4.2.8.2 Facial characteristics, malformations and intellectual 
development 
Patients show various degrees of developmental delay from none at all to severe 
delay (Table 4.7).  No malformations are as yet reported.  One patient is described as 
having feeding difficulties and has a gastrostomy in situ.  The cause of this is unclear 
although it is noted that there is also severe developmental delay in this case.  Facial 
photographs were available in patient F16 only (Figure 4.12).  Similar features to the 
LIG4 patients were evident with fine sparse hair, epicanthic folds, small chin and 



















































































None N/A N/A Nil reported 







































Unknown N/A N/A Eczema 
Anthropometric data stated as Z scores (standard deviation from population mean for age and sex), actual measurements in brackets.  F13 reported as having microcephaly 






Figure 4.11.  Growth impairment in cases with XRCC4 mutations compared to 
LIG4 patients with MPD  
Measurements plotted as Z-scores (standard deviation of measurement from population mean for age 
and sex) for LIG4 cases identified in this study (black) alongside those with mutations in XRCC4 
(grey) for each growth parameter.   A) Measurements at birth of XRCC4 patients (mean weight -2.9 
+/-1.35 s.d. (n=5), OFC -3.2 +/-1.69 s.d. (n=5) and length -3.9 +/-2.05 s.d. (n=4)) compared to LIG4 
patients. B) Most recent postnatal measurements of XRCC4 patients (mean weight -5.0 +/-2.27 s.d. 
(n=4), OFC -8.12 +/-2.56 s.d. (n=4) and height -4.8 +/-1.72 s.d. (n=5)) compared to LIG4 patients.  
Mean and standard deviation of patient group indicated by horizontal and vertical bars respectively.   







Figure 4.12.  Clinical photographs of patient with mutations in XRCC4 
Patient F16 at A) five months and B) two years of age shows similar features to the LIG4 patients 
shown in Figure 4.5. 
4.2.8.3 Haematological and immune dysfunction 
No cytopenic episodes or clinical evidence of immunodeficiency had been reported 
in any of the XRCC4 cases.  Following identification of mutations, immune and 
haematological investigations were recommended to all clinicians.  Results from two 
patients are currently available (Table 4.7).  In F11 there was leucopenia 
(WBC=3.03x103/µl, approximate normal range 5.5-12.9) with a reduction in both T 
and B cell numbers.  Total immunoglobulin levels have not yet been performed.  In 
F15 total immunoglobulin levels were normal, total lymphocyte count was slightly 
reduced (1658/mm3, normal range 2100-3076) with some mild abnormalities in T 
and B cell counts. 
4.2.8.4 Malignancy 
Malignancy was not reported in any of the probands however one mother (confirmed 
heterozygous carrier of a nonsense mutation) is suffering from metastatic breast 
cancer at the age of 34 years.  There was no other family history of malignancy 
known.  All other parents were reported to be healthy except for the father of a 




4.3.1 Mutations in LIG4 and XRCC4 are a common cause of 
MPD  
Mutations were identified in two components of the NHEJ machinery, LIG4 and 
XRCC4, in 16 families with MPD.  This accounts for 4% of cases in our cohort and is 
the second most common cause of MPD behind PCNT mutations (approximately 
20% of the cohort).  Although severe microcephaly has been reported in patients 
with mutations in NHEJ genes, including LIG4, a global failure in growth to the 
degree observed in this group of patients has not been previously described (Table 
4.1, Section 4.1.2).  Importantly, the majority of patients identified with LIG4 
mutations in this study presented with severe growth failure whereas other features 
indicative of Ligase IV syndrome, such as immunodeficiency, pancytopenia or 
malignancy, were not readily apparent delaying the diagnosis in this patient group.  
During this study mutations were also identified in XRCC4 in six independent cases.  
Since this discovery, mutations in XRCC4 have only been reported in one additional 
patient who also presented with severe growth failure (OFC -8.3, height -7.1 at 4 
years) (Shaheen et al., 2014).  Identification of this number of cases allows more 
detailed characterisation of this novel disorder.   
4.3.2 Clinical implications: diagnosis and management 
This is the first time a comprehensive and consistent clinical phenotype has been 
described in a group of LIG4 patients and in contrast to many previous reports 
immunodeficiency was not suspected clinically prior to molecular diagnosis (Buck et 
al., 2006b, Enders et al., 2006, van der Burg et al., 2006, Grunebaum et al., 2008).  
However, further investigation has revealed significant humoral and cellular 
immunodeficiency is present in the majority of patients.  This highlights the need for 
early recognition and subsequent immunological investigation even in asymptomatic 
patients.  Bone marrow failure, primarily presenting with episodic thrombocytopenia, 
appears to be a strongly discriminative diagnostic feature of Ligase IV syndrome, 
occurring in 72% of all reported cases to date.  However, cytopenia may not be 
evident at initial presentation, particularly in very young children.  Increasing 
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awareness in clinicians that Ligase IV syndrome commonly presents with severe 
growth failure without any other suggestive features will hopefully lead to improved 
diagnosis.   
Early identification of LIG4 patients is important as there are significant implications 
for clinical management.  In view of increased cellular radiosensitivity in patient 
cells (O'Driscoll et al., 2001, Murray et al., 2014), it would be important to minimise 
exposure to ionising radiation where possible such as through radiographic imaging.  
Even though malignancy was not reported in any of the patients identified in this 
study, this has been a feature of previous reports (Plowman et al., 1990, Ben-Omran 
et al., 2005, Buck et al., 2006b, Enders et al., 2006, Toita et al., 2007, Yue et al., 
2013) with a 25% incidence of malignancy in all cases reported in the literature to 
date.  Therefore all LIG4 patients should be considered at increased risk.  
Furthermore, bone marrow transplantation is being considered in several patients in 
this cohort.  This has previously been associated with poor outcomes in LIG4 
patients and it is now apparent that modifications to conditioning regimes are 
required to improve survival due to increased sensitivity to certain 
immunosuppressants (O'Driscoll et al., 2008).   
Given the functional overlap between LIG4 and XRCC4 it is unsurprising that 
phenotypic overlap between the two patient groups was observed.  Most notably, a 
comparable degree of growth failure was present in both XRCC4 and LIG4 patients 
as well as similarities in facial features.  However, as yet, no evidence of bone 
marrow failure has been reported in any of the seven XRCC4 patients identified to 
date with the oldest being 10 years of age (Shaheen et al., 2014) (range of onset in 
LIG4 patients was 2-15 years).  Additionally, in the two patients tested in this study, 
relatively mild abnormalities were seen in T and B cell levels compared to LIG4 
patients in which B cells were severely depleted in all patients investigated.  This is 
surprising given that significant immune dysfunction is common to all disorders of 
NHEJ repair (Moshous et al., 2001, Buck et al., 2006a, Buck et al., 2006b, van der 
Burg et al., 2009) and V(D)J recombination is impaired in Xrcc4 deficient mice 
(Guirouilh-Barbat et al., 2007).  Despite minimal evidence of either immune or 
haematological compromise in XRCC4 patients identified to date it would therefore 
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still be prudent to monitor these parameters until further data from additional patients 
is available.  XRCC4 patient cells also exhibit increased cellular sensitivity to 
ionising radiation (Grant Stewart, personal communication, July 2014) which reflects 
defective DSB repair (Sun et al., 2002).  Additionally, radiosensitivity is observed in 
XRCC4 null mouse embryonic stem cells (Gao et al., 1998b) along with marked 
genomic instability in XRCC4 deficient mouse embryonic fibroblasts (Gao et al., 
2000).  Thus, similar to LIG4 patients, XRCC4 patients should also be considered at 
increased risk of malignancy although longer follow up is required to establish the 
degree of risk.  Of note, in the 16 families identified in this study malignancy was 
reported in one parent, a heterozygous carrier of a nonsense mutation in XRCC4.  
Modification of cancer risk in heterozygous carriers of LIG4 SNPs has been 
suggested (Roddam et al., 2002) however, longer follow up and the identification of 
more cases are required to ascertain whether this case is related to the XRCC4 
mutation or coincidental given the high rate of breast cancer in the general 
population (Ly et al., 2013).  
4.3.3 Genotype-phenotype correlations suggest LIG4-XRCC4 
binding is critical to growth 
As such a consistent phenotype was observed in the majority of LIG4 patients in this 
cohort, it was hypothesised that this may be related to the type of mutation identified.  
All the patients identified in this cohort have biallelic truncating mutations in LIG4 in 
combination with MPD whereas previously reported cases have predominantly non-
synonymous coding mutations and generally less severe growth impairment (Table 
4.1).  Indeed, a genotype-phenotype correlation was observed in which the degree of 
protein truncation was related to the severity of the growth phenotype, in particular, 
the extent to which the XRCC4 binding domain was disrupted.   
Furthermore, all LIG4 patients identified to date (in which growth parameters are 
available) who harbour at least one truncating mutation have significant growth 
impairment ranging from severe microcephaly (OFC < -5 s.d.) with normal stature to 
MPD (O'Driscoll et al., 2001, Ben-Omran et al., 2005, Buck et al., 2006b, Gruhn et 
al., 2007, Toita et al., 2007, Yue et al., 2013, Murray et al., 2014).  Interestingly, 
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patients harbouring biallelic non-synonymous coding or in-frame deletions in the 
enzymatic domain were the least growth impaired but exhibited severe immune or 
haematological dysfunction (Plowman et al., 1990, Riballo et al., 1999, O'Driscoll et 
al., 2001, van der Burg et al., 2006, Unal et al., 2009).  In these cases the XRCC4 
binding domain was preserved in both alleles.  In addition, MPD is evident in all 
patients identified with biallelic XRCC4 mutations.  This suggests the LIG4-XRCC4 
interaction is the critical determinant in the severity of the growth phenotype.    
XRCC4 binding is required for LIG4 stability (Bryans et al., 1999), localisation to 
the nucleus (Girard et al., 2004) and chromatin binding (Liu et al., 2013a).  
Additionally, the LIG4-XRCC4 complex has been shown to prevent the degradation 
of terminal nucleotides, a function which appears independent of ligation (Smith et 
al., 2003).  The recurrently occurring c.2440C>T (p. Arg814*) mutation results in 
impaired LIG4 cellular activity, with reduced LIG4 protein levels (O'Driscoll et al., 
2001) and also impairs ligase activity (Girard et al., 2004).  Notably, the c.2440C>T 
mutation impairs enzymatic function less than earlier truncating mutations (Girard et 
al., 2004).  Arg814 lies at the start of the second BRCT domain of the XRCC4 
binding site (Critchlow et al., 1997).  Loss of this BRCT domain impairs XRCC4 
binding (Girard et al., 2004), though the major determinant of XRCC4 binding, the 
‘intervening linker sequence’, is retained (Grawunder et al., 1998).  Earlier (close to 
the N-terminus) protein truncation leads to a more complete loss of function, with 
truncated protein resulting from the c.2094C>G (p.Arg580*) mutation not interacting 
with XRCC4 or localising to the nucleus (Girard et al., 2004).   
Surprisingly, nine of the ten families identified with LIG4 mutations harboured the 
g.2440C>T (p.Arg814*) mutation which is found only in European populations with 
an allele frequency of 0.0005 and 0.001, in EVS and 1KG databases respectively.  
Therefore the frequency of g.2440C>T homozygotes would be expected to be 1 in 
1,000,000 to 1 in 4,000,000.  Such patients may only be mildly affected with non-
syndromic microcephaly and normal development (Ben-Omran et al., 2005).  This 
may therefore represent an under-diagnosed group of LIG4 patients with increased 
malignancy risk.  For those cases that reach the genetics clinic, the routine adoption 
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of high-throughput sequencing in molecular diagnostics is likely to improve 
ascertainment; however, appropriate setting of allele frequency filters will be crucial.   
4.3.3 Role of NHEJ in growth and neurogenesis  
The identification of LIG4 and XRCC4 mutations as a relatively common cause of 
profound impairment in growth highlights the critical importance of NHEJ in early 
development.  Despite mutations in NHEJ genes not previously being associated 
with such severe global growth failure in humans, animal models have shown 
otherwise.  Ku80 and Ku70 mutant mice are viable and exhibit a 40-60% reduction 
in size (Nussenzweig et al., 1996, Gu et al., 1997).  Null Lig4 mice are early 
embryonic lethal (Barnes et al., 1998, Frank et al., 1998) but two viable 
hypomorphic mouse models show an approximately 40% reduction in size (Nijnik et 
al., 2007, Rucci et al., 2010).  Additionally, Xrcc4 null mice show late embryonic 
lethality with an approximately 30% reduction in size at E15.5 (Gao et al., 1998b).  
Furthermore, mouse embryonic fibroblasts from null Xrcc4 and Lig4 embryos 
exhibited slower growth, failure to repair DSBs and growth arrest following 
exposure to ionising radiation (Gao et al., 1998b).  Interestingly, DNA-PKcs and 
Artemis deficient mice display RS-SCID without any apparent growth defects 
similar to that observed in humans (Gao et al., 1998a, Rooney et al., 2002) indicating 
LIG4 and XRCC4 are more critical to development compared to other NHEJ 
components.  Artemis and DNA-PKcs are required for the opening of RAG-
generated hairpins arising in V(D)J recombination (Ma et al., 2002) and, in contrast 
to LIG4 and XRCC4, are therefore perhaps less critical in the repair of DSBs 
occurring from other sources which do not have the same processing requirements 
(Adachi et al., 2004). 
Notably, five of the six patients with XRCC4 mutations identified in this study 
harboured biallelic nonsense mutations and therefore are anticipated to be null in 
contrast to LIG4 truncating mutations which are predicted to be hypomorphic.  It is 
unclear why XRCC4 null mutations are embryonic lethal in mice but apparently 
viable in humans.  Possible explanations include the presence of a human-specific 
alternate transcript which partly rescues function similar to that observed in MPD 
patients with mutations in PLK4 (Martin et al., 2014).  However, this seems unlikely 
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given that nonsense mutations were distributed throughout the gene.  Alternatively, a 
greater degree of redundancy in the multiple components which can be utilised in 
NHEJ may exist in humans compared to mice.  For example, LIG1 and LIG3 are 
both able to perform NHEJ in the absence of LIG4 in DT40 chicken cells, albeit, less 
efficiently (Paul et al., 2013).  Compensatory mechanisms unique to humans might 
therefore occur in the presence of XRCC4 deficiency.   
One interesting observation in all LIG4 and XRCC4 patients described to date is the 
presence of severe and disproportionate microcephaly in comparison to height.  A 
similar pattern is also observed in patients with mutations in genes encoding the 
MRN complex indicating that neuronal cells are especially sensitive to defective 
DSB repair (Weemaes, 2000, Waltes et al., 2009, Matsumoto et al., 2011).   
Neuronal stem cells lie in the ventricular and sub-ventricular zones (VZ/SVZ) of the 
developing brain and undergo rapid symmetrical cell division in early development.  
Slightly later in embryogenesis there is a switch to asymmetric cell division 
generating post-mitotic neurons populating the intermediate zone (IZ) and distal 
cortical plate (CP) (Pontious et al., 2008).  High levels of endogenous DNA breakage 
are seen in the VZ/SVZ layers during embryogenesis as well as a marked increase in 
sensitivity to DNA damage with activation of apoptosis at much lower doses of IR 
compared to the adult brain (Gatz et al., 2011).  Additionally, neuronal stem cells are 
not fully sensitive to G2/M checkpoint arrest (Gatz et al., 2011), perhaps to ensure 
rapid cell division occurs unperturbed by DNA damage in such cells.  Any 
unrepaired DSBs will therefore persist in daughter cells including post-mitotic cells 
within the IZ following asymmetric division.  Proliferating cells are able to utilise 
homologous recombination in DSB repair due to the availability of a sister chromatid 
whereas non-proliferating post-mitotic neurons are reliant on NHEJ for repair (Orii et 
al., 2006).   In both Xrcc4- and Lig4-null murine embryos, lethality results from 
severe p53-dependent neuronal cell death occurring predominantly in the IZ (Gao et 
al., 1998b, Orii et al., 2006).  Gatz et al., (2011) therefore postulated that p53-
dependent apoptosis is triggered with increased frequency by the presence of 
persisting DSBs within IZ cells.  Failure to repair such damage in LIG4/XRCC4 
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deficiency would therefore lead to substantial neuronal cell death and consequently 
fewer cells and a smaller brain.    
Stem cell depletion along with reduced capacity for renewal has also been shown in 
the haematopoietic system in Lig4 hypomorphic mice (Nijnik et al., 2007).  The 
depletion of other stem cell pools through defective DSB repair may therefore 
explain the global failure in growth in LIG4 and XRCC4 patients (Woodbine et al., 
2014).  Bone marrow failure is not a feature of other DSB repair disorders such as 
Bloom syndrome (Kaneko et al., 2004) or Nijmegen breakage syndrome (Weemaes, 
2000) suggesting LIG4 specifically, whether through its role in NHEJ or while 
undertaking a different function, is critical to the development and maintenance of 
haematopoietic stem cell pools.  Additionally, the increased IZ apoptosis observed in 
Lig4- and Xrcc4-deficient mice was found to be ATM-dependent (Sekiguchi et al., 
2001) however, patients with ATM mutations only exhibit a subtle postnatal 
microcephaly (Nissenkorn et al., 2011).  Finally, this does not account for why some 
LIG4 patients with different mutations have no reported growth defect despite the 
fact that LIG4 enzymatic capacity and thus NHEJ is greatly reduced.  These 
observations suggest the possibility that the role of LIG4-XRCC4 may extend 
beyond NHEJ in stem cells.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
4.3.4 Conclusions 
This Chapter describes the identification of mutations in LIG4 and XRCC4 as a 
common cause of MPD along with further characterisation of associated features 
which include immunodeficiency, bone marrow failure and malignancy 
predisposition.  This will hopefully improve diagnosis in this patient group as well as 
impact on the clinical management of those affected.  Identification of these 
mutations, along with the observation of a genotype-phenotype correlation, indicates 
that the LIG4-XRCC4 interaction specifically is critical in ensuring normal growth.  
Increased p53-mediated cell death in stem cell pools during embryogenesis may 
partly explain the hypocellularity in LIG4/XRCC4 deficient patients but does not 
account for phenotypic variability observed in LIG4 and ATM deficient patients 
suggesting that the LIG4-XRCC4 complex may have an additional, as yet 
unidentified, role in development.  In the next Chapter the pathogenicity of mutations 
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in two further novel candidate disease genes identified following WES (NCAPD2 























CHAPTER 5:  Mutations in the Non-SMC subunits of 
Condensin I & II complexes in MPD 
 
5.1 Introduction 
In mitosis, replicated genetic material within each cell is required to be equally 
transmitted to two daughter cells.  To ensure genomic integrity is maintained during 
segregation, DNA is compacted into chromosomes in a process referred to as 
chromosome condensation (Koshland et al., 1996).  Critical to the mechanism and 
maintenance of DNA compaction is the highly conserved protein complex, 
condensin (Hagstrom et al., 2002).  In vertebrates there are two types of condensin 
complexes, I and II, each composed of five subunits (Ono et al., 2003).  In Chapter 3 
the identification of six candidate novel disease genes in MPD patients through WES 
was described.  Two of which, NCAPD2 and NCAPD3, encode subunits of the 
condensin I and condensin II complexes respectively.       
Given their important role in mitosis, it is conceivable that abnormal condensin 
function impacts on the rate of cell division and consequently body mass.  Genes 
encoding subunits of the condensin complexes are therefore plausible candidates that 
could affect growth.  In this Chapter, further studies are performed to investigate 
whether the variants identified in these genes in MPD patients are deleterious to 
protein function as well as ascertain whether the disruption of these proteins is 
responsible for the observed growth phenotype.      
5.1.1 Structure of condensin complexes 
Both the condensin I and II complexes, share the same overall structural arrangement 
with two SMC subunits, SMC2 and SMC4 (members of the structural maintenance 
of chromosomes ATPase family), but differ in their three associated non-SMC 
subunits (Figure 5.1) (Ono et al., 2003).  The SMC subunits are composed of a distal 
central hinge domain flanked by two long coiled coils which fold back on each other 
and interact forming an antiparallel coil (Saitoh et al., 1994).  Consequently, the two 
outer ends of the coils are proximally located and form ATPase head domains.  The 
SMC2 and SMC4 subunits together create a V-shaped heterodimer through 
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interactions at their hinge domains (Hirano et al., 2001).  Bridging the gap between 
the two ATPase domains at the ends of the SMC subunits is a kleisin protein, 
encoded by NCAPH in the condensin I complex and NCAPH2 in condensin II 
(Schleiffer et al., 2003).   The two remaining proteins, composed of multiple HEAT 
repeats, complete the complex through interactions with the kleisin subunit and, 
more weakly, each other (Onn et al., 2007).  These two proteins are encoded by 
NCAPD2 and NCAPG in condensin I and NCAPD3 and NCAPG2 in condensin II 
(Figure 5.1).  
 
Figure 5.1.  Structure of the two condensin complexes 
Both complexes are composed of the same two SMC subunits which dimerize at the hinge domain 
(SMC2 and SMC4).  The two coiled coil domains extending from each hinge domain form 
antiparallel coils ending in an ATPase head domain.  The two complexes then differ in the three non-
SMC subunits: A kleisin protein (NCAPH in condensin I and NCAPH2 in condensin II) which 
bridges the ATPase head domains of the two SMC subunits and two HEAT repeat proteins which 
associate with the complex predominantly through interactions with the kleisin subunit (NCAPG, 
NCAPD2 in condensin I and NCAPG2, NCAPD3 in condensin II) (figure adapted from (Piazza et al., 
2013). *Indicates subunits in which mutations were identified in MPD patients through WES. 
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5.1.2 Function of condensin complexes 
The two complexes associate with chromosomes independently of each other and at 
distinct chromosomal regions with different dynamics suggesting they each have 
discreet and independent functions (Ono et al., 2003).   
Condensin II localises to the nucleus during interphase and is bound to chromosomes 
from early prophase until the end of mitosis (Yeong et al., 2003).  There is evidence 
supporting a role of condensin II in the early axial shortening of chromosomes in 
prophase.  Depletion of condensin II in several organisms delays the onset of 
chromosome condensation until just prior to nuclear envelope breakdown and results 
in the appearance of elongated, ‘curly’ chromosomes (Ono et al., 2003, Green et al., 
2012).   
In contrast, condensin I is excluded from the nucleus only gaining access to 
chromosomes after breakdown of the nuclear envelope in prometaphase and then 
remains bound to chromosomes until late anaphase (Ono et al., 2004).  Condensin I 
appears to then be required for the lateral compaction of chromosomes (Ono et al., 
2003, Green et al., 2012) as well as ensuring chromosome stability (Gerlich et al., 
2006) and aiding the separation of chromosome arms through the removal of cohesin 
(Hirota et al., 2004).  Depletion of condensin I results in a delay in progression 
through prometaphase and metaphase as well as the appearance of wider, shorter 
chromosomes (Ono et al., 2003, Hirota et al., 2004, Green et al., 2012). 
Despite extensive work on the condensin complexes, still relatively little is known 
regarding the mechanisms controlling condensin function.  Now an active area of 
investigation, several factors have been implicated in the recruitment of condensins 
to chromosomes as well as the regulation of their activity.  This also differs between 
the two condensin complexes in keeping with their different functions during 
mitosis.  For example, A-kinase anchor protein 8 (AKAP8) has been implicated in 
condensin I binding to chromosomes but not condensin II (Eide et al., 2002) whereas 
retinoblastoma 1 (RB1) assists in the chromatin association of condensin II but not 
condensin I (Longworth et al., 2008).  The regulation of condensins also varies 
between the two complexes and appears to involve a dynamic and intricate system of 
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phosphorylation throughout mitosis.  Regulatory proteins so far identified include 
cyclin-dependent kinase 1 (CDK1) (Kimura et al., 1998), polo-like kinase 1 (PLK1) 
(Abe et al., 2011), aurora B kinase (AURKB) (Lipp et al., 2007, Takemoto et al., 
2007), casein kinase 2 (CK2) (Takemoto et al., 2006) and protein phosphatase 2 
(PP2A) (Takemoto et al., 2009).  Intriguingly, as well as a critical role in 
chromosome condensation and segregation, further evidence now also suggests a role 
for condensins in the DNA damage response (Blank et al., 2006, Heale et al., 2006, 
Tanaka et al., 2012a) suggesting condensins may have a wider range of functions 
than previously thought.   















5.2 Mutations identified in the non-SMC subunits of 
condensin complexes 
5.2.1 NCAPD2 
In Chapter 3, a splice site variant was identified in NCAPD2, c.4120+2T>C 
(consequence score=1) in a single case following WES (Figure 5.2A) which was 
subsequently confirmed to be homozygous by capillary sequencing (Figure 5.2B).  
DNA was also available from three additional unaffected family members; the 
mother, father and sibling.  All were found to be heterozygous carriers confirming 
that the variant segregated correctly with the phenotype in these family members.  
The variant is located two nucleotides into intron 31 and is predicted to abolish the 
splice donor site of exon 31 in four out of five prediction programmes used by 
Alamut software (Figure 5.2C).  It was also not present in any of the control datasets 
examined (EVS, 1KG or dbSNP).  The predicted inclusion of intron 31 following 
disruption of this splice site would result in the introduction of a premature 
termination codon prior to the last exon (exon 32).   
5.2.2 NCAPD3 
Biallelic variants were also identified in NCAPD3 following WES in a trio set as 
described in Chapter 3 (Figure 5.3A).  Capillary sequencing confirmed the affected 
child to be heterozygous for the variants, c.382+14A>G (consequence score=2.5) 
and c.1783delG (p.Val595Serfs*34) (consequence score =1).  Resequencing also 
confirmed the intronic variant was inherited from the mother and the nonsense 
mutation from the father (Figure 5.3B).  The intronic variant was predicted to create 
an alternative splice site 13 nucleotides into intron 3 by four out of five prediction 
programmes used by the Alamut software (Figure 5.3C).  The nonsense mutation is 
predicted to introduce a premature termination codon prior to the last exon and thus 
it would be anticipated that no functional protein would be produced by this allele 





Figure 5.2.  Splice site variant identified in NCAPD2.   
A)  Sequencing reads following WES aligned to NCAPD2 reference sequence using the Integrative 
Genomics Viewer (IGV) identified the variant c.4120+2T>C (blue) in 50 out of 52 reads in the 
affected child.  B)  Chromatograms following capillary sequencing of all family members where DNA 
available confirmed the affected child to be homozygous for the variant and this segregated correctly 
with the observed phenotype in the parents.  C)  The variant was predicted to completely abolish the 




Figure 5.3.  Compound heterozygous variants identified in NCAPD3.   
A) Sequencing reads following WES aligned to the reverse compliment of the  NCAPD3 reference 
sequence using IGV identifies (i) a single nucleotide deletion, c.1783delG (arrow), in 14 out of 24 
reads and (ii) an intronic variant, c.382+14A>G (red/blue) in 5 out of 10 reads.  B) Chromatograms 
following capillary sequencing of the child and parents confirmed the affected child to be compound 
heterozygous for both variants.  C) The intronic variant, c.382+14A>G, was predicted to create an 
alternative splice site in intron 3, 13 nucleotides upstream of the exon 3 splice donor site (graphic 




To identify whether other MPD patients had mutations in genes affecting the same 
complex, all eight genes encoding the condensin subunits and two genes encoding 
the key condensin regulators AURKB and PLK1 were sequenced in the remainder of 
the cohort (199 samples, all affected cases from unique families).  This included 222 
exons amplified using the custom designed Ampliseq primer set described in Section 
2.4.6.2 followed by sequencing using the Ion Proton™ (192 samples) and Ion 
Torrent™ (6 samples) platforms.  This included patients with primary microcephaly 
and microcephaly with short stature (height -2 s.d. to -4 s.d.).  Identified variants in 
samples sequenced using the Ion Proton™ sequencer were annotated as previously 
described using SnpEff, dbNSFP and Alamut-HT (Section 2.5.2.1).  Initially 463 
variants were identified in total across the 10 genes.  These were filtered in an SQL 
database using the same pipeline as described in Section 3.3 (Table 5.1).  All 
remaining candidate variants (30 in total) were reviewed in IGV and, if likely true 
positives (see Section 3.3.7), resequenced along with any additional family members 
to check whether the variant segregates correctly with the phenotype.  No potentially 
pathogenic recessive variants were identified in the 6 samples sequenced using the 
Ion Torrent™ sequencer which were analysed independently using NextGENe 
software (described in Section 2.5.3). 
Any exons with poor coverage (read depth less than 10) were resequenced by 
capillary sequencing.  In 39 cases (including four sequenced on the Ion Torrent™ 
sequencer), a single heterozygous, but potentially deleterious variant was identified 
in at least one gene.  As the sequencing technology (semi-conductor method) used in 
this experiment has a markedly lower sensitivity for identifying indels compared to 
SNVs (see Section 1.4.1), repeated resequencing of the whole gene was performed 
by capillary sequencing to ensure a second, possibly pathogenic variant was not 
present.  This, however, did not identify any further candidate variants.  The 
possibility of causative de novo variants was also considered, however none were 
identified following capillary sequencing of the affected in combination with 
parental samples.  
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Table 5.1.  Filtering of identified variants following targeted resequencing of 
condensin genes using Ion Proton™ sequencer. 
Filtering Step Variant Number 
Initial number of unique variants prior to filtering 463 
Select Rare Variants: 1KG, EVS (maf<0.005 or no frequency 
data) 
159 
Exclude variants occurring in more than 6 families 143 
Variants with a consequence score<3 129 
Variants following autosomal recessive analysis 30 
Number of variants validated with correct segregation 
confirmed in parents 
1 
 
This analysis identified only one potentially deleterious variant which confirmed on 
resequencing and segregated correctly in the family.  The non-synonymous coding 
variant c.728C>T (p.Pro243Leu) was identified in NCAPH, another subunit of the 
condensin I complex (Figure 5.4A), in a patient with primary microcephaly.  The 
patient was confirmed to be homozygous by capillary sequencing and both parents 
were confirmed to be heterozygous carriers (Figure 5.4B).  This variant was 
predicted to be deleterious by all prediction programmes used (Table 3.3) and alters 
an amino acid which is highly conserved across all species including 
Schizosaccharomyces pombe (Figure 5.5A). 
Splicing programmes in Alamut software predicted that the variant would have 
minimal effect on neighbouring splice sites (Figure 5.5B).  An impact on splicing is 
therefore unlikely to underlie the pathogenicity of this variant.  Although this variant 
was not identified in any control datasets examined (1KG, EVS or dbSNP), another 
variant change has been reported in Europeans affecting the preceding nucleotide and 
altering the same amino acid, c.727C>T (p.Pro243Ser).  It is present at a minor allele 
frequency of 0.0005 in the European population sequenced in EVS and was not 
observed in the homozygous state.  Similarly it is predicted to be deleterious to 
protein function and so it is possible this may also be a disease causing variant when 






Figure 5.4.  Non-synonymous coding variant identified in NCAPH.   
A) Sequencing reads following Ampliseq multiplex PCR and next generation sequencing (Ion Proton) 
aligned to the NCAPH reference sequence using the Integrative Genomics Viewer (IGV).  This 
identified a variant, c.728C>T (red) in 123 of 129 reads, in one affected case.  B)  Chromatograms 
following capillary sequencing of the affected patient and unaffected parents confirmed both parents 

















Figure 5.5.  Conservation of amino acid affected by NCAPH variant and 
predicted impact on splicing 
A)  Alignment of NCAPH sequences in different species illustrating the affected amino acid is highly 
conserved across both eukaryotes and prokaryotes.  The rare variant, c.727C>T, reported in the EVS 
database also affects the same amino acid.  Alignments performed using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/, reference for sequences used given in Appendix II), B) 
Splice programmes in Alamut software predicted the variant to have a minimal impact on 
neighbouring splice sites.  Percentage values indicate confidence of prediction with 100% being 
highly confident.  Only altered values are shown.             
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5.3 Clinical description of patients with mutations in 
condensin genes 
A summary of the clinical features of each patient along with corresponding 
mutation details is provided in Table 5.2. 
5.3.1 NCAPD2 
The patient is of Indian origin and was referred to the study at nine months of age for 
further investigation of severe microcephaly.  He was born at 37weeks gestation to 
non-consanguineous parents after an uneventful pregnancy.  No antenatal scans were 
performed but IUGR was evident at birth, weight -4.88 s.d. (1kg at 37weeks 
gestation).  No medical support or intervention was required in the neonatal period.  
Hypospadias was noted on early examination along with reticular hyperpigmented 
patches on the right knee.  Growth continued to be impaired postnatally.  At 
9months:  OFC -12.76 s.d. (31cm), Height -3.8 s.d. (62cm), weight -5.87 s.d. (4.7kg).  
At 3years:  OFC -11.9 s.d. (34.8cm), Height -5.8 s.d. (74cm), weight -7.25 s.d. (7kg).  
Development has been significantly delayed with social smile only occurring at 
7months (normally present from six weeks) and at nine months only cooing sounds 
were apparent (babbling with a variety of sounds are usually present at this age).  
Abnormal movements were also noted at the nine month exam with gross 
hyperactivity and jerky movements of limbs being described.  At three years he was 
able to walk although no speech was apparent at this stage.  He was also noted to 
display little interaction with his parents and exhibited stereotypic repetitive 
movements similar to behaviours often described in autism.  Facial features include 
large prominent eyes with upslanting palpebral fissures, prominence of the mid-
forehead, a wide, flat nasal tip and small chin (Figure 5.6A).    
5.3.2 NCAPD3 
The patient was born to Caucasian, non-consanguineous parents at 37 weeks 
gestation.  Birth weight was at the lower end of normal, weight -1.85 s.d. (2.15kg), 
whilst length was more substantially reduced, -4 s.d. (40.6cm) (birth OFC not 
available).  At 6 years and 5 months considerable failure in growth was apparent; 
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OFC -5.4 s.d. (45cm), height -5.7 s.d. (90cm) and weight -9.47 s.d. (9.07kg).  On 
examination he had a discrepancy in leg length and an asymmetry in chest wall 
shape.  Facial features include mild hypertelorism, long philtrum, wide nasal tip and 
small, low set, posteriorly rotated ears (Figure 5.6).  Further skeletal assessment 
showed bone age to be delayed, long gracile bones, coning of epiphysis in the hands 
and metaphyseal striations of uncertain significance.  Development was reported to 
be entirely normal.  Hyperpigmented patches were noted on the lower face and back 
along with slight webbing of the neck.  Both of these features, along with short 
stature, are common to neuro-cardio-facial-cutaneous (NCFC) syndromes, a group of 
autosomal dominant disorders associated with mutations in the Ras-induced MAPK 
pathway (see Section 1.2.1.1) (Bentires-Alj et al., 2006).  Sequencing of genes 
associated with one of these conditions, Noonan syndrome, was undertaken by the 
local diagnostic laboratory who identified the patient to be homozygous for a non-
synonymous coding variant in SOS1 (c.1964C>T, p.Pro655Leu) (Roberts et al., 
2007).  The variant was found to be relatively common in the European population 
with a minor allele frequency of 0.01 in EVS.  This exceeds what would be expected 
for a disease causing variant in MPD given the low incidence of this disorder in the 
general population.  The variant was predicted to be benign by all but one prediction 
programme used in Alamut and a leucine residue also occurs at the corresponding 
site in Drosophila indicating this change is tolerated in other species.  Only 
dominant, gain of function mutations have so far been described in SOS1 in 
association with Noonan syndrome (Roberts et al., 2007).  Notably, both parents 
were found to be healthy heterozygous carriers of the SOS1 variant.  The patient also 
did not exhibit any other features consistent with this diagnosis, such as cardiac 
defects, pectus excavatum/carinatum or coagulation defects (Tartaglia et al., 2007).  
Short stature is also predominantly postnatal in onset and severe microcephaly is not 
a feature previously reported in this disorder (van der Burgt, 2007).  Therefore this 
variant was unlikely to be responsible for the phenotype observed and further 
investigation with WES was subsequently performed.   
At the age of 8 he was found to have a malignant brain tumour which was highly 
aggressive and poorly responsive to treatment.  This unfortunately resulted in his 
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death at 11 years of age.  The malignancy was classified as an anaplastic 
medulloblastoma.   
5.3.4 NCAPH 
This patient originates from Portugal and was described as small at birth (growth 
parameters at birth are unavailable).  At 42 years he was microcephalic (OFC= 
51.1cm, -3.4 s.d.) but stature was within normal range (height= 168.5cm, -1.4 s.d.).  
A moderate degree of mental retardation was reported but no other associated 
medical issues.  The patient had an elongated face with a long narrow nose and 
philtrum (Figure 5.6).   
Table 5.2.  Molecular and clinical details of three patients with mutations in the 
non-SMC condensin subunits.    
 Condensin II subunit Condensin I subunits 
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Figure 5.6. Clinical photographs of patients with mutations in the non-SMC 
condensin subunits  
A) Patient at 9 months of age, homozygous for a splice site mutation in NCAPD2.  B)  Patient at 6 
years of age, compound heterozygous for mutations in NCAPD3.  C)  Patient at 42 years of age, 




5.4 Functional impact of NCAPD3 mutations on protein  
The mutations identified were predicted to significantly impair but not totally 
abrogate protein function.  To establish whether the variants identified disrupted 
condensin function, cell lines were requested from referring clinicians.  Only cells 
from the patient with compound heterozygous mutations in NCAPD3 
(c.[382+14A>G]+[1783_1784delG]) were available during this thesis.  These were 
therefore compared to fibroblasts from two independent healthy controls referred to 
as control 1 and control 2.  Early passage (≤6) fibroblasts were used with control and 
patient cells matched to within two passages for each experiment.   
5.4.1. Impact of intronic mutation on splicing 
The intronic mutation identified in NCAPD3 was predicted to create an alternative 
splice donor site in intron 3 (Figure 5.3).  To investigate whether this variant 
disrupted normal splicing, RT-PCR studies were performed.  Primers were used to 
amplify the coding region between exon 2 and 4 (Figure 5.7, red), exon 2 and 6 
(Figure 5.7, green) and exon 2 and 10 (Figure 5.7, orange) and demonstrated a 
marked reduction in the level of full length transcript present in patient cells 
compared to control 1 cells.  Notably there was also a marked increase in an alternate 
smaller transcript which was detected with all three primer pairs.  The difference in 
band size between the full length and alternate transcripts corresponded to the size of 
exon 3 (163 bp).  To confirm this, the DNA present in each band was extracted and 
sequenced which confirmed the large PCR fragment corresponded to the full length 
reference transcript and the smaller fragment corresponded to a transcript in which 
exon 3 had been omitted.  A third, even smaller transcript was also identified in both 
patient and control cell lines following amplification between exon 2 and 6 and 
between exon 2 and 10.  Extraction and sequencing of the DNA in this band revealed 
the presence of a transcript which lacks exon 3 and 4.  This transcript appeared 
similarly expressed in both patient and control cells as judged by the intensity of the 
band on the gel following electrophoresis (Figure 5.7B).  Absence of exon 3 results 
in a frameshift of the coding sequence whereas no shift in frame occurs when exon 3 
and 4 are omitted. 
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These findings are different from the predicted impact on splicing shown in Figure 
5.3 which suggests an alternative transcript incorporating an additional 13 bp of 
intron 3 may occur.  However, this fragment was not detected following extraction 
and sequencing of the large PCR fragment obtained from the patient cells which 
corresponded to the full length transcript.  The difference between predicted and 
observed transcripts in patient cells may be explained by the presence of a co-
segregating variant which was not identified on WES.  Alternatively, this may reflect 
the limitations of splice prediction programmes in encapsulating the full complexity 
























Figure 5.7.  Impact of intronic mutation in NCAPD3 on splicing 
Ai) NCAPD3 is composed of 35 exons, the first 10 exons (E1-10) of which are depicted to show the 
position of the intronic mutation identified and the position of three primer pairs used in the 
amplification of cDNA (orange , red and green).  The second nonsense mutation (c.1783_1784delG) 
identified in this patient resides in exon 15.  Aii) The intronic mutation is predicted to create an 
alternative splice site which would be expected to result in a transcript with an additional 13 bases of 
intron 3.  B) RT-PCR of RNA extracted from patient fibroblasts (Pt) and control 1 fibroblasts (WT) 
showed alternate splicing of NCAPD3 was present in patient cells but there was no change in splicing 
of a control transcript (ELP4).  Notably, a band corresponding to the predicted transcript shown in Aii 
was not present in patient cells.  C) Sequencing of gel-extracted DNA from the different bands 
amplified by primers at exon 2 and 10 in both patient and control established that the largest band 
which appeared reduced in patient cells, corresponded to the full length transcript while the second, 
shorter PCR fragment, which appeared increased in the patient cells, corresponded to a transcript in 
which exon 3 had been skipped.  The smallest band identified following amplification with primers 
between exon 2 to 6 (green) and 2 to 10 (orange) was composed of a transcript in which exon 3 and 4 
had been removed.  Levels of this transcript were similar between patients and controls.  
Abbreviations:  RT=reverse transcription, -RT=reverse transcription performed in the absence of 
reverse transcriptase enzyme. 
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5.4.2 Impact of mutations on protein levels 
To determine if NCAPD3 protein levels were reduced in patient cells, 
immunoblotting was performed on whole cell extracts from patient-derived 
fibroblasts.  NCAPD3 protein levels were markedly reduced in patient cells 
compared to control 1 and 2 (Figure 5.8).  Depletion of NCAPD3 with RNAi in a 
control fibroblast line showed reduction in a protein band of similar molecular 
weight confirming specificity of the NCAPD3 antibody.  No change in NCAPD3 
levels was seen following transfection with RNAi targeting luciferase in the same 
control cell line. 
Protein immunoblotting was also performed to determine whether cellular levels of 
other condensin subunits were affected by the reduction in NCAPD3.  No change in 
protein levels were observed in the other two non-SMC condensin II subunits, 
NCAPH2 and NCAPG2, or in the condensin I subunit, NCAPH in patient cells 
compared to control cells.  RNAi depletion of NCAPD3 in control 1 cells also had no 









Figure 5.8.  Impact of NCAPD3 mutations on protein levels of condensin 
subunits 
Immunoblotting showed reduced NCAPD3 protein levels in patient fibroblasts compared to two 
control fibroblast cell lines.  Actin used as loading control.  No consistent difference was seen in the 
protein levels of other condensin I and II subunits.  NCAPD3 protein levels were also reduced in 
control cells transfected with RNAi targeted to NCAPD3.  Again, other condensin subunits were 
unaffected in these cells.  Transfection with RNAi targeted to luciferase had no impact on NCAPD3 
or other condensin subunits.      
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5.5 Abnormalities in NCAPD3 patient fibroblasts during 
mitosis 
5.5.1 Abnormal chromosome morphology  
Previous studies have shown that disruption of NCAPD3 expression results in 
abnormally shaped chromosomes in mitosis (Green et al., 2012).  To determine 
whether the patient cells carrying NCAPD3 mutations display a similar phenotype, 
metaphase spreads were prepared from the patient-derived cultured fibroblasts.  
Strikingly, condensed chromosomes in the patient cells also appeared ‘thin and 
curly’ compared to both control fibroblast lines (Figure 5.9 A-C).  100% of 
metaphase cells examined in the patient (n = 20) exhibited the same chromosome 
morphology.  Metaphase spreads were also examined following RNAi knockdown of 
NCAPD3 in one of the fibroblast control lines, control 1.  Condensed chromosomes 
displayed a similar, although less severe phenotype to the NCAPD3 patient cells 
(Figure 5.9 D), possibly because NCAPD3 protein levels were not depleted to the 
same extent as in patient cells (Figure 5.8).  Transfection with RNAi targeting 
luciferase in the same cell line (Figure 5.9 E) had no impact on morphology.   
5.5.2 Chromosome segregation defects 
Previous studies have also shown that NCAPD3 and the condensin II complex are 
required for faithful chromosome segregation (Green et al., 2012).  To determine 
whether patient cells show a similar phenotype, fibroblasts were fixed on coverslips 
and both DNA and microtubules were visualised with immunofluorescent markers.  
Chromosome segregation abnormalities were observed in patient cells including 
anaphase bridges and lagging chromosomes (Figure 5.10A).   
Chromosome segregation defects were found to be significantly increased in the 
patient fibroblasts (14%) compared to both controls (control 1=3%, control 2=2%, t-
test; p<0.006) (Figure 5.10B).  The most frequently observed abnormality in patient 
cells was lagging chromosomes (8.5% +/-4.1 s.d.) followed by anaphase bridges 




Figure 5.9.  Metaphase spreads in NCAPD3 patient fibroblasts 
Chromosomes appear normally condensed in two independent control cell lines, control 1 (A) and 
control 2 (B).  In contrast, chromosomes in the NCAPD3 patient cell line are abnormally shaped 
appearing thin and curly (C).  A similar but less extreme phenotype was observed in control cells 
transfected with RNAi targeted to NCAPD3 (D) whereas transfection with RNAi targeted to 





Figure 5.10.  Chromosome segregation defects in NCAPD3 patient fibroblasts 
A) Images of patient-derived fibroblasts in anaphase.  DNA stained with DAPI (white) and 
microtubules stained with α-tubulin antibody (green).  i) Normal chromosome segregation. ii and iii) 
Anaphase bridges are shown in which chromatin can be visualised spanning the distance between 
segregating chromosomes.  This suggests a failure in separation of homologous chromosomes.  (iv) a 
lagging chromosome is present suggesting a failure in the spindle assembly checkpoint (SAC) has 
occurred.  B) 80-100 anaphase cells were scored in each cell line in three independent experiments.  
There was a significant increase (unpaired t-test) in the total number of cells with chromosome 
segregation defects in the patient (mean=14% +/-2.5 s.d.) compared to two independent controls 
(control 1; mean=3% +/-1 s.d., control 2; mean=2.5% +/-2.8 s.d.).  Scale bar =5.4µm. 
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5.5.3 Prevalence of aneuploidy  
As NCAPD3 patient cells showed an increase in chromosome segregation defects 
this may result in an increase in the proportion of cells with an abnormal DNA 
content.  To determine if low NCAPD3 levels results in an increase in the proportion 
of aneuploid (DNA content>4N) or tetraploid cells (DNA content =8N), flow 
cytometric analysis of DNA content following staining with propidium iodide was 
performed in patient cells compared to both control lines (Figure 5.11).  Over three 
independent experiments, no significant difference was seen in the proportion of 
cells with a DNA content of more than 4N between any of the cell lines (patient; 
mean=0.39% +/-0.06 s.d., control 1; mean=0.37% +/-0.27 s.d., control 2; 


















Figure 5.11.  Measurement of DNA content (>4N) in NCAPD3 patient 
fibroblasts by flow cytometry. 
A) Following flow cytometry, cells were gated using scatter plots of FSC (a measure of size) vs SSC 
(a measure of granularity) to exclude debris (i).  Cell aggregates were then excluded from further 
analysis based on area vs height (ii).  Percentage indicates % of cells within gated region.  B) 
Histograms of a representative flow cytometric experiment showing cells in G1 (2N), S phase 
(between 2N and 4N peaks) and G2/M (4N) in two independent control cell lines and NCAPD3 
patient cells.  Very few cells were seen in the area indicating a DNA content > 4N (horizontal bar) in 










5.7.1 Deleterious mutations in condensin complex genes 
identified in MPD patients 
In this Chapter, mutations in NCAPD2 and NCAPH, encoding two of the non-SMC 
subunits of condensin I and mutations in NCAPD3, encoding a non-SMC subunit of 
condensin II, are described in three separate cases presenting with varying degrees of 
growth failure.  This is the first time mutations in genes encoding subunits of the 
condensin complexes have been described in association with human disease.   The 
advent of NGS has led to a large increase in the number of genes implicated as 
disease-causing in MPD following the identification of apparently deleterious 
variants (Alazami et al., 2012, Dauber et al., 2012, Shaheen et al., 2014).  However, 
as each genome harbours approximately 100 loss of function variants (MacArthur et 
al., 2012) assigning causality without supporting evidence can lead to variants being 
incorrectly documented as disease causing (Bell et al., 2011, Norton et al., 2012) 
which is misleading for clinicians and potentially harmful to patients and their 
families (MacArthur et al., 2014).  Therefore, further cellular studies to verify the 
pathogenicity of the variants identified in these novel candidate disease genes were 
performed.   
Experiments in primary fibroblasts derived from the patient with mutations in 
NCAPD3 demonstrated a marked reduction in total NCAPD3 protein levels as a 
consequence of altered splicing of one allele in combination with a null allele 
confirming the mutations have a deleterious impact on the protein.  Total cellular 
levels of the other condensin II subunits appeared unaffected although isolating and 
examining chromatin bound protein would be useful in the future to determine 
whether the localisation or stability of the condensin complex is adversely affected 
by loss of NCAPD3.  Additionally, chromosome morphology was strikingly 
abnormal appearing elongated and ‘curly’ similar to observations following depletion 
of condensin II in various other cell types including human HeLa cells (Ono et al., 
2003, Green et al., 2012).  Although not performed in this study, measuring axial 
length and width of chromosomes would allow quantification of the defect and an 
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indication of severity (Hudson et al., 2003).  Furthermore, an increase in 
chromosome segregation defects were also observed in keeping with findings from 
other studies (Hudson et al., 2003, Green et al., 2012) providing evidence that 
condensin II function is impaired in this patient.  Similar experiments examining the 
effect of the variants discovered in NCAPD2 and NCAPH would also be useful to 
establish the impact of these mutations on protein function but unfortunately patient 
cells were not available in these cases.   
Notably, the phenotypes of the three cases varied although microcephaly was present 
in all patients.  This is perhaps either a reflection of the differing functions of the two 
condensin complexes (Section 5.1.2) or of the severity of different mutations 
identified.  The phenotypes included isolated microcephaly with intellectual 
disability (NCAPH), severe microcephaly with short stature and severe 
developmental delay (NCAPD2) and lastly, MPD with normal development 
(NCAPD3).  Strikingly, the patient with mutations in NCAPD3 developed 
malignancy in childhood.  The unusual and aggressive nature of the malignancy, an 
anaplastic medulloblastoma, in combination with a rare growth disorder, raises the 
possibility the two are causally related.  However, confidently determining 
associated clinical phenotypes is difficult at this point in time with only mutations 
identified in single patients for each gene.  Identifying additional mutations in other 
similarly affected patients will increase confidence that mutations in condensin genes 
cause growth failure and will help to clarify commonly associated phenotypes.  
Longer term follow up will also be required to establish whether cancer 
predisposition is common to condensin related disorders or a chance association in 
this one case.  However, as only three patients were identified from a total of 301 
patients sequenced (1%), mutations in condensin genes likely represent a rare cause 
of growth failure and identifying further patients may be difficult.  This emphasises 
the importance of open access databases and sharing of data between researchers to 
create larger more informative patient cohorts.  Accessing data from large 
sequencing projects such as Deciphering Developmental Disorders (Firth et al., 
2011) may also help identify additional patients.     
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5.7.2 Mechanism of growth failure in condensin dysfunction 
Condensin complexes are critical in the regulation and coordination of chromosome 
condensation as well as ensuring resolution of sister chromatids during mitosis 
(Hirano, 2005).  It has now been demonstrated in several organisms that disruption of 
either condensin I or II results in aberrant mitosis with increase in chromosome 
segregation defects and mitotic delay (Bhalla et al., 2002, Hudson et al., 2003, Hirota 
et al., 2004, Green et al., 2012).  It is therefore conceivable that mutations in 
condensin complex genes can impact on global cellularity by preventing efficient and 
effective cell division.  Further supporting evidence for a role of condensin 
complexes in ensuring normal growth is seen in animal studies with microcephaly 
being reported in ncapg, ncapd2 and ncaph morphant zebrafish (Seipold et al., 
2009).  Additionally, decreased head size and length were reported in smc4 mutant 
zebrafish (Amsterdam et al., 2004) (ZFIN historical data, 2006).  Early embryonic 
lethality is observed in Ncapg2 null mice due to failed expansion of the inner cell 
mass (Smith et al., 2004) and embryonic lethality has also been documented in 
Ncaph and Ncaph2 null mice (http://www.sanger.ac.uk/mouseportal/).  Interestingly, 
a homozygous hypomorphic mutation in Ncaph2 in mice affecting two of three 
predicted transcripts results in impaired T cell development with reduced thymus size 
and circulating numbers of T-lymphocytes (Gosling et al., 2007).  No other 
abnormalities in development or growth however were reported suggesting a lineage 
specific role of the affected transcript or a separation of function effect in which 
chromosome segregation is not impaired.  In humans, aberrant chromosome 
condensation is also seen in microcephalin (MCPH1) deficient cells, mutations in 
which cause autosomal recessive primary microcephaly (Trimborn et al., 2004, 
Trimborn et al., 2006). MCPH1 appears to prevent premature mitotic entry through 
early activation of chromosome condensation providing evidence of a link between 
neurogenesis and the misregulation of chromosome condensation. 
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5.7.3 Possible mechanisms of cancer predisposition in 
patients with condensin mutations 
The occurrence of a severe and unusual malignancy during childhood in one of the 
patients suggests cancer predisposition may be a feature of condensin mutations.  
Cancer predisposition due to abnormal condensin function is plausible given the 
segregation defects observed that may lead to structural rearrangements or abnormal 
DNA content in daughter cells.  However, the mechanism by which condensin 
dysfunction results in chromosome segregation defects has not yet been fully 
elucidated.  In simplistic terms, it is widely considered that failure in chromosome 
compaction leads to entanglement between sister chromatids which persist during 
segregation (Hirano, 2005, Jeppsson et al., 2014).  Additionally, condensin I 
complex assists in the removal of cohesin just prior to anaphase (Hirota et al., 2004) 
and also appears to have a specific function in the resolution of repetitive DNAs in 
Saccharomyces cerevisiae (D'Amours et al., 2004).  Thus segregation defects may be 
a direct consequence of loss of condensin at chromatin but may also in part be due to 
indirect effects on other proteins including type II topoisomerase which assists in the 
detanglement of sister chromatids and whose localisation to chromosomes is 
disrupted by depletion of condensin in other organisms (Coelho et al., 2003, Hudson 
et al., 2003).  Furthermore, condensin depletion impairs kinetochore orientation 
impacting on kinetochore-microtubule attachments but without activating the spindle 
assembly checkpoint (Cimini et al., 2001, Ono et al., 2004).  As well as essential 
roles in chromosome condensation and segregation, accumulating evidence also 
supports a role for condensin in the regulation of gene transcription (Bhalla et al., 
2002, Rawlings et al., 2011).  It is hypothesised that intramolecular linking and 
compaction of DNA by condensins reduces the accessibility of transcriptional 
activators to chromatin (Jeppsson et al., 2014).  Failure in gene silencing during 
mitosis is therefore another factor which could possibly contribute towards the 
development of malignancy.  Finally, condensin complexes have been directly 
implicated in DNA repair during interphase presenting another possible source of 
genome instability in condensin dysfunction (Heale et al., 2006). 
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Despite a marked increase in chromosome segregation defects, no increase was seen 
in aneuploidy or tetraploidy in patient cells compared to controls following flow 
cytometry in this study.  However, flow cytometry may not be the ideal experiment 
to address this question for two reasons.  Firstly, a delay in mitosis may cause patient 
cells to grow much slower in culture compared to control cells and this may make 
small increases in aneuploidy difficult to detect as fewer patient cells will be actively 
dividing at any one point.  Secondly, in this study the DNA content of every cell was 
measured regardless of its stage in the cell cycle.  As the chromosome number 
changes as a cell progresses through the cell cycle, a post mitotic tetraploid cell in 
G1 phase will be indistinguishable in terms of DNA content from a diploid cell 
which has just replicated its DNA in preparation for mitosis.  Alternatively, changes 
in chromosome number as well as structural rearrangements can be detected in 
interphase cells using a range of techniques such as G-banding, spectral karyotyping 
and fluorescence in situ hybridisation (FISH) analysis either using a small panel of 
probes or whole chromosome painting (Ried et al., 1998).  Large numbers of cells 
would need to be reviewed to identify subtle increases in aneuploid cells which 
would be possible with automated analysis (Wang et al., 2012).  This would enable 
more sensitive detection of subtle alterations in chromosome number independent of 
variation in DNA content throughout the cell cycle. 
5.7.3 Conclusions 
In this Chapter, variants identified in genes encoding subunits of the condensin 
complexes were characterised further by examining their effect on RNA, protein and 
mitosis providing supporting evidence for the discovery of mutations in condensin 
genes as a novel but rare cause of growth failure. Aberrant and delayed mitosis 
resulting from impaired condensin function could be responsible for the growth 
phenotype observed in these patients and future experimental plans to investigate this 






CHAPTER 6:  Contribution of changes in chromosomal 
copy number variation (CNV) to the aetiology of MPD 
 
6.1 Introduction 
The preceding three Chapters describe the identification of single nucleotide variants 
(SNVs) or small insertions/deletions (less than 20 base pairs) in disease causing 
genes in MPD patients.  However, more than 50% of families within this cohort still 
remain without a diagnosis despite performing WES in the majority of cases.  One 
possibility is that some patients have larger alterations in chromosome structure 
resulting in the gain or loss of genetic material which are unable to be detected by 
standard variant calling methods.  As each human somatic cell contains two copies of 
its DNA, any variation in DNA content will alter the copy number of the affected 
region.  Variation in copy number could involve a whole chromosome, which most 
commonly results from a failure in the segregation of chromosome pairs during 
meiosis (non-disjunction) (Sankaranarayanan, 1979), or just part of a chromosome.  
The latter can occur following the breakage and re-joining of chromosome segments 
(Currall et al., 2013) in which genetic material is either lost (microdeletion) or gained 
(microduplication) resulting in a reduction or increase in copy number respectively.  
The size of the region affected can vary greatly from 1 kb to several megabases 
covering a large number of genes (Iafrate et al., 2004, Redon et al., 2006).   
CNVs, defined as a DNA segment that is present at a variable copy number in 
comparison with a reference genome, are a common occurrence in the general 
population affecting both coding and noncoding regions (Redon et al., 2006).  On 
average each individual harbours approximately 12 large scale CNVs (greater than 1 
Mb) in their genome (Iafrate et al., 2004).  The majority of these occur in regions in 
which variation in copy number is frequently observed in healthy individuals 
(polymorphic regions) and therefore are unlikely to be of clinical significance.  
However, if the CNV involves one or several genes whose function is dosage 
dependent then this may have a negative impact on cellular processes resulting in 
phenotypic abnormalities.  Loss or gain of a specific genomic region has now been 
identified as a common cause of intellectual disability (Shaw-Smith et al., 2004) and 
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many malformation syndromes have been attributed to contiguous gene deletions 
(Theisen et al., 2010).  Some of the more commonly recognisable syndromes 
resulting from chromosomal microdeletions include Williams syndrome (7q11.23 
deletion) (Martens et al., 2008), DiGeorge syndrome (22q11.2 deletion) (Monteiro et 
al., 2013) and Miller-Dieker syndrome (17p13.3 deletion) (Stratton et al., 1984).  
Abnormal growth has also been reported in association with variation in copy 
number.  For example, deletion of the 5q35 region encompassing the gene NSD1 
(nuclear receptor binding SET domain protein 1) causes Soto syndrome characterised 
by overgrowth and macrocephaly (Kurotaki et al., 2002).  Additionally, duplications 
of NSD1 have been identified in patients with growth restriction (Franco et al., 
2010).  Reciprocal growth phenotypes have also been seen in association with CNVs 
at other loci including 16p11.2 (Jacquemont et al., 2011) and 1q21.1 (Brunetti-Pierri 
et al., 2008).  It is therefore important to explore the possibility of CNVs as a cause 
of MPD.  This may lead to the discovery of novel disease genes by identifying those 
in the affected regions which are critical to the growth phenotype.   
Submicroscopic CNVs can be detected by comparative genomic hybridisation using 
chromosomal microarrays (array-CGH) and currently this is the first line clinical 
diagnostic test for the detection of CNVs in patients with intellectual disability and 
developmental abnormalities (Miller et al., 2010).  Although array-CGH is the 
current diagnostic gold standard method for identifying CNVs, the size of CNVs 
detectable is limited by the probe density of the microarray.  The increasing 
implementation of large scale sequencing projects has led researchers to design 
strategies for detecting CNVs in NGS data (Chiang et al., 2009).  Current NGS 
methods result in the production of multiple short reads (less than 200 base pairs) 
across each defined genomic region within a DNA sample.  A reduction in copy 
number within the sample will result in a lower number of sequencing reads covering 
the affected region (reduced depth of coverage).  Conversely, duplicated regions will 
lead to an over-representation of reads corresponding to a higher read depth.  This 
provides a potential method for the detection of CNVs from NGS data with the 
possibility of high resolution given the short read length.   
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Many programmes have now been designed to identify CNVs from NGS data (Zhao 
et al., 2013) and have been successfully implemented to identify clinically relevant 
CNVs with patient cohorts (de Ligt et al., 2013, Gilissen et al., 2014).  This Chapter 
investigates the utility of WES in identifying CNVs using ExomeCNV 
(Sathirapongsasuti et al., 2011) (Section 2.5.2.3), a programme specifically designed 
for this purpose and potentially able to identify single exon deletions (120 bp).  
ExomeCNV analysis was performed in 105 MPD patients resulting in the 




















6.2 Identification of pathogenic microdeletions from WES 
following ExomeCNV analysis 
Although ExomeCNV was performed in all 102 affected individuals from 95 
families, 18 samples failed analysis (9 singletons and 9 samples with parents) as a 
consistent baseline indicating neutral copy number was not achieved in at least 50% 
of the exome, therefore these samples were too noisy to interpret.  Only 
microdeletions were prioritised for further analysis as these are a more common 
cause of disease compared to microduplications (Vissers et al., 2012) with analysis 
of gain in copy number planned for the future.   
In total, 20,347 microdeletions were called by ExomeCNV ranging from a single 
exon (118 bp) to 248 Mb in size in 84 affected cases (mean 242 per patient).  As it 
was not feasible to validate every region called following ExomeCNV analysis, I 
designed and implemented a filtering process (similar to that described in Section 
3.3) to prioritise possible microdeletions for validation.  Figure 6.1 shows an 
overview of the designed filtering pipeline.   
Array-CGH data was available from two patients prior to WES in which CNVs of 
uncertain significance had already been identified.  Both CNVs were identified on 
ExomeCNV analysis and this was used to define a log2 ratio (log2R) threshold for 
prioritising deleted regions (minimum log2R of known deletion = -0.79).   Therefore 
all regions with a log2R of -0.70 or below were selected for further review.  This 
identified a total of 744 regions in 84 affected patients (mean deletions per patient=9, 
range 1 to 50) (Table 6.1) with size of deletion ranging from 188 bp to nearly 18 Mb.  











Figure 6.1.  Analysis pipeline of ExomeCNV data for the detection of pathogenic 
microdeletions 
Abbreviations; DGV=database of genomic variation, DECIPHER= Database of Chromosomal 








Of the deleted regions identified with a Log2R of less than -0.7, 90% were under 100 
kb in size and only 2.4% were over 1 Mb (Figure 6.2A).  The most frequently 
occurring deletion size was between 1 and 50 kb (68%).  Only 16 single exon 
deletions of less than 500 bp were called in the analysis (2.3%).  There was no 
significant difference in the Log2R for each group (Figure 6.2B) indicating that 
regions with a log2R of less than -0.7 were called with similar confidence 
independent of size.    
 
Figure 6.2.  Comparison of frequency and Log2 ratios of different sized 
deletions  
A) Number of deletions with log2R less than -0.7 within each size range demonstrating the majority 
of deletions called were less than 50 kb in size.  B) Corresponding mean Log2R of deletions in each 
size range.  Vertical lines indicate standard error of the mean.  Each group was compared to all others 
using a Kruskal-Wallis test followed by a Dunn’s multiple comparison test.  No significant difference 
was seen in Log2R between each group.  Only regions in autosomes were included in this analysis.  
As it was anticipated that large genetic heterogeneity is present within the cohort, 
apparent deletions incorporating exactly the same region in multiple cases were 
deemed more likely to represent sites of common polymorphism or result from 
inconsistencies in exon capture between case and control samples leading to a 
consistent source of error in CNV calling.  Therefore, as a first line approach, only 
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deletions called in three or less patients (3.5% of affected cases sequenced) were 
prioritised for review.  This excluded 49.5% of regions (376 remaining, Table 6.1).  
To further prioritise likely causative regions, those occurring in patients in whom a 
molecular diagnosis had been identified, as described in Chapter 3, were also 
removed excluding a further 20% of regions (228 remaining in 49 patients, Table 
6.1).     
Deleted regions were then uploaded into the UCSC genome browser 
(http://genome.ucsc.edu/, accessed 06.2013) and compared to CNVs identified in 
control cohorts in the Database of Genomic Variants (DGV; http://dgv.tcag.ca/; 
accessed 13.06.13) (MacDonald et al., 2014).  Any region overlapping with 
commonly occurring CNVs (polymorphic regions) in DGV were removed resulting 
in 97 possible deletions in 22 affected cases (Table 6.1).  These remaining regions 
were then compared to CNVs in DECIPHER (Database of Chromosomal Imbalance 
and Phenotype in Humans Using Ensembl Resources) (Bragin et al., 2014)  
(https://decipher.sanger.ac.uk/, accessed 06.2013) which contains the results of array-
CGH analysis performed in patients with developmental disorders.  This allowed 
identification of any patients with possible deletions overlapping CNV regions 
previously associated with abnormalities in growth.  These regions were then 
prioritized for validation (three regions in three cases, Table 6.1).   







Log2 ratio below -0.7 744 84 
Regions occurring in more than 3 patients removed 376 83 
Regions occurring in patients with single gene diagnosis 
removed 
228 49 
Microdeletions occurring in polymorphic regions removed 97 22 
Microdeletions identified in known disease regions 3 3 
Microdeletions identified with evidence to support possible 






In trios, remaining regions which were identified in the child but not in either parent 
(de novo deletions) were then examined in closer detail along with all possible 
remaining regions in singleton samples (parents not sequenced).  Using DECIPHER, 
the phenotypes of all patients with CNVs overlapping these regions were reviewed.   
If growth abnormalities were frequently reported, then these regions were also 
prioritised for validation.  This identified two possible causative deletions 
encompassing a similar region of (3q27) in two independent patients.  If no 
overlapping cases were reported in either DGV or  DECIPHER, then all genes within 
the region were reviewed to determine if they provided a possible link to growth 
either through the function of the encoded protein or through animal models as 
previously described (Section 3.3.6).   
Finally, the possibility of autosomal recessive inheritance was explored by reviewing 
genes lying within potentially inherited regions.  Such regions included those in 
common between affected siblings or those also found to be present in the parent of 
an affected child.  Any gene with a potential functional link to growth was then 
reviewed for a second possible pathogenic variant (consequence score < 3) in the 
WES analysis described in Chapter 3.  No candidate disease genes were identified 
from this autosomal recessive analysis. 
In total, five potentially pathogenic microdeletions were identified with a minimum 









6.3 CNVs identified encompassing known disease regions 
6.3.1 Wolf-Hirschhorn syndrome 
Two microdeletions located at the terminus of the short arm of chromosome 4 (4pter) 
were identified in two independent patients of 18.5Mb (4p16.3-p15.31 in patient 1) 
and 3.1Mb (4p16.3 in patient 2) (Figure 6.3A).  Array-CGH performed on DNA 
from the affected patient and parents confirmed the CNVs to be de novo in both 
cases (Figure 6.3B).   
The deletions both overlapped a region associated with Wolf-Hirschhorn syndrome 
(WHS) (Figure 6.4).  WHS is a well characterised developmental disorder in which 
affected patients typically show distinctive facial features with a wide forehead, 
ocular hypertelorism and prominent glabella which is often described as a ‘Greek 
helmet’ appearance (Wilson et al., 1981).   Other features of this syndrome include 
pre- and post-natal growth retardation, developmental delay, congenital hypotonia, 
seizures, malformations (cardiac, brain and genito-urinary) and common variable 
immunodeficiency (Battaglia et al., 2008).  Growth failure is considered one of the 
cardinal features of WHS occurring in at least 75% of patients and growth 
parameters to the degree seen in MPD have been previously described (mean OFC 
and height measurements being -3.5 s.d. and -4 s.d. respectively) (Antonius et al., 
2008).  Following identification of the microdeletion, on clinical review both patients 
were found to have subtle but characteristic facial appearance along with severe 
growth retardation in keeping with a diagnosis of WHS but without significant 











Figure 6.3.  4p terminal deletions identified in two patients following 
ExomeCNV analysis 
A) Log2 ratios at each exon (Log2R) generated following ExomeCNV analysis (yellow line = copy 
neutral, red = amplification, green = deletion).  Grey dots indicate log2R at exons with insufficient 
coverage to provide adequate power to call a CNV at that exon by itself.  A two fold reduction in copy 
number (Log2R = -1, green line) was identified at the terminus of the short arm of chromosome 4 
(4pter) in two independent patients indicating a heterozygous microdeletion of this region.  
Underlying schematic of chromosome 4 indicates region of microdeletion (red).  B) Array-CGH 
confirmed the deletions to be de novo in the affected cases.  Black dots indicate log2R at each probe.  
Red line indicates log2R across each segment (minimum of 5 consecutive probes).  Genomic position 
of deletion as indicated corresponds to the hg19 reference genome.   
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Genomic coordinates are according to hg19 reference genome.   
 
Two critical regions (WHSCR1 and WHSCR2) have been defined in WHS (Altherr 
et al., 1997, Wright et al., 1997, Zollino et al., 2003) with two respective candidate 
genes proposed to be primarily responsible for the cardinal features of this syndrome 
including severe growth failure (Figure 6.4) (Stec et al., 1998, Wright et al., 1999).  
The two genes are Wolf-Hirschhorn syndrome candidate 1 (WHSC1) and negative 
elongation factor complex member A (NELFA).  Both deletions identified in this 
Chapter encompassed both these genes.  WHSC1 encodes a protein ubiquitously 
expressed in early development (Stec et al., 1998) and has been implicated in the 
DNA damage response following replicative stress (Hajdu et al., 2011).  
Haploinsufficient mice also show growth retardation (Nimura et al., 2009).  NELFA 
(also referred to as WHSC2) shows a similar expression pattern to WHSC1 and 
haploinsufficiency results in slow progression from S to M phase, reduced DNA 
replication and altered higher ordered chromatin assembly (Kerzendorfer et al., 
2012).  Thus both genes have potential functions that may impact on the cell cycle 
and consequently affect growth.  Reviewing heterozygous variants with a 
consequence score of 1 in WHSC1 and NELFA in WES data from this cohort of 
MPD patients did not identify any likely pathogenic de novo mutations in these two 










Figure 6.4.  The identified 4p microdeletions overlap a critical region for growth 
in Wolf-Hirschhorn syndrome 
A) Schematic of chromosome 4 indicating 18.1 Mb region deleted in patient 1.  B) USCS genome 
browser graphical display showing the two regions deleted in MPD patients (grey) and the two 
previously defined critical regions (black) responsible for the cardinal features of WHS.  C) This has 
led to the identification of two candidate genes, WHSC1 and NELFA (also referred to as WHSC2) 
thought to play a critical role in the phenotype of WHS including growth failure.  Abbreviations: 





6.3.2 Chr15 deletion encompassing IGF1R identified in two 
affected siblings 
One patient was identified with a 2.99 Mb heterozygous microdeletion in the long 
arm of chromosome 15 (15q26.1 to 15qter) which was validated by array-CGH 
(Figure 6.5).  Deletion of the same region has been previously reported in patients 
with growth retardation, microcephaly and developmental delay (Rudaks et al., 
2011) whereas duplication of the same region is associated with tall stature (Kant et 
al., 2007).  The deletion includes 19 coding genes including IGF1R which encodes 
the insulin-like growth factor 1 receptor.  IGF1R is a receptor tyrosine kinase which 
binds insulin-like growth factor leading to a range of cellular responses that promote 
cell proliferation and differentiation (Liu et al., 1993, Worrall et al., 2013).  
Deleterious heterozygous and compound heterozygous mutations in this gene have 
previously been identified in patients with MPD (Abuzzahab et al., 2003, 
Walenkamp et al., 2013)  and therefore haploinsufficiency of this gene has been 
thought to be primarily responsible for the growth phenotype in this microdeletion 
syndrome.  A literature review of the other genes in the deleted region did not 
identify any other biologically plausible candidates.   
The patient identified here was male and reportedly showed growth restriction at 
birth (birth weight unavailable, birth length -3 s.d.) although birth OFC was normal 
(-0.6 s.d.).  Growth failure was also evident post-natally (height and OFC both -3s.d. 
at 11 years of age) similar to patients previously described with microdeletions of 
this region (Rudaks et al., 2011).  Growth hormone deficiency was suspected 
following endocrine investigation of IGF1 and growth hormone levels and he was 
commenced on replacement therapy.  Over four years of treatment his height 
increased by 1 s.d. (-4 s.d. prior to treatment).  The patient also had a similarly 
affected sister with IUGR reported at birth (birth measurements unavailable) and 
postnatal growth failure (OFC -4 s.d. and height -6 s.d. at approximately four years 







Figure 6.5.  15q microdeletion identified in one case encompassing IGF1R 
following ExomeCNV analysis   
A) Schematic of chromosome 15 with deleted region highlighted in red.  A deletion at the terminus of 
the long arm of chromosome 15 (15qter) was identified in one patient following ExomeCNV analysis 
as indicated by a Log2R of -1 at the end of chr15 (green line).  Other possible deletions indicated in 
green were excluded during filtering.  B) Array-CGH confirmed a 2.99 Mb deletion at chromosome 
15 (q26.3).  Genomic coordinates correspond to the hg19 reference genome.  C) The deleted region 
contained 20 coding genes including IGF1R (red), haploinsufficiency of which has previously been 
associated with severe growth failure.   
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The deletion initially appeared to be de novo in the child as it was not identified in 
either parent (Figure 6.6 A, B).  It was subsequently found to be present in both the 
affected siblings as well as a third sibling who was reportedly unaffected (Figure 6.6 
C,D), suggesting instead the presence of gonadal mosaicism or more likely, a 
balanced structural rearrangement in one of the parents.  Notably, growth parameters 
for the unaffected sibling were unavailable.  Repeat examination of the third 
unaffected sibling with careful growth measurements would be prudent as they may 
have a mild phenotype which has previously been overlooked.  Although uncommon, 
it is also important to be aware that sample mix up can occur and it would therefore 
be appropriate to reconfirm the results in a fresh DNA sample from the unaffected 
sibling and parents.      
It was also considered whether further modifiers are present in the two affected 
siblings additionally impacting on growth.  Capillary sequencing of IGF1R coding 
regions was undertaken in all five family members to ascertain whether a second 
mutation was present on the alternate allele.  However, no likely pathogenic variant 
was identified.  It is still possible that a variant in a noncoding region of the gene or a 
regulatory region may be impacting on gene expression which could be further 
investigated by cellular studies examining IGF1R transcript and protein levels.  
Alternatively, a variant in another disease gene could be compounding the 
haploinsufficiency of IGF1R in the two affected siblings although no other candidate 











Figure 6.6.  Array-CGH analysis of the 15q microdeletion in multiple family 
members 
The 15qter deletion was not apparent in either parent following array-CGH but was present in both the 
affected and unaffected sibling.  Genomic coordinates correspond to the hg19 reference genome.   




6.4 Identification of a novel CNV as a cause of MPD  
6.4.1 3q27 microdeletion  
Two patients were identified with microdeletions encompassing a region on the long 
arm of chromosome 3 (3q27-3q28).  Both deletions were validated by array-CGH 
(Figure 6.7).  Parental DNA was only available in parents of one of the patients and 
this confirmed the deletion to be de novo in their affected child (patient 3).  Both 
cases showed similar growth parameters with prenatal and postnatal growth failure 
although postnatally OFC was disproportionately reduced in comparison to height 
(Pt3 and 4, Table 6.3).  Developmental delay was reported in both cases but 
otherwise there were no malformations or other associated features.  Given this 
microdeletion was present in two of the 85 patients where ExomeCNV analysis was 
able to be performed, it could potentially represent a relatively common cause of 
MPD.  Therefore array-CGH was performed in five further patients with similar 
phenotypes.  This identified another patient with a similar, overlapping deletion at 
3q27 (Pt 5) and array-CGH analysis of parental DNA confirmed this to be de novo in 
the child.        
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Figure 6.7.  3q27 microdeletions identified in three MPD patients    
A)  Log(2) ratios generated following ExomeCNV analysis identifies two patients with a two fold 
reduction in copy number (green line) within the long arm of chromosome 3(q27.1-q27.3) indicating a 
heterozygous microdeletion of this region.  Underlying schematic of chromosome 3 indicates region 
of microdeletion (red).  B) Validation by array-CGH confirmed both deletions.  Genomic position of 
deletion corresponds to the hg19 reference genome.  C) Array-CGH in patients with a similar 
phenotype identified one further case with a deletion overlapping the same region.   
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6.4.2 IGF2BP2 is a novel candidate gene for growth restriction 
at the 3q27 locus 
All three deletions shared a common region 1.7 Mb in size (chr3:183,897,305-
185,587,305, hg19) encompassing 24 genes (Figure 6.8).  Of all the candidate genes 
in this region (Table 6.4), IGF2BP2 had the strongest supporting evidence for a 
functional role in regulating growth along with a low HI score.  A brief summary of 
these genes is shown in Table 6.4 along with corresponding haploinsufficiency (HI) 
scores obtained from the DECIPHER database.  HI scores are predictive, based on a 
classification model trained on the characteristics of genes known to be either 
haploinsufficient or sufficient from previous documentation of structural variation 
and associated disease (Huang et al., 2010).  A low percentage score (<10%) 
indicates the gene is more likely to be haploinsufficient. 
IGF2BP2 encodes one of three IGF2 mRNA binding proteins, otherwise known as 
IMP2, which facilitates nuclear export, stability and translation of IGF2 mRNA.  All 
three IGF2 mRNA binding proteins are ubiquitously expressed during 
embryogenesis (Nielsen et al., 1999, Christiansen et al., 2009).  In humans, down 
regulation of IGF2 through hypomethylation of a differentially methylated region 
results in Russell Silver syndrome, a short stature syndrome in which head size is 
typically normal.  Conversely, up regulation of IGF2 occurs in Beckwith-
Wiedemann syndrome which is characterised by overgrowth (Nativio et al., 2011).  
In addition, IGF2-deficient mice are noted to be small with microcephaly (Liu et al., 
1993).  Therefore haploinsufficiency of IGF2BP2 may impact on growth by 
destabilising IGF2 mRNA resulting in reduced protein levels.  IGF2BP2 is 
phosphorylated by mammalian target of rapamycin (mTOR) (Dai et al., 2011) and its 
expression is regulated by HMGA2 (Brants et al., 2004), a gene known to be strongly 
and reproducibly associated with height (Weedon et al., 2007, Weedon et al., 2008, 
Lango Allen et al., 2010) and head circumference in genome wide association 
studies (Ikram et al., 2012a, Taal et al., 2012b).  Additionally, Hmga2 null mice 
show a severe reduction in body size described as a pygmy phenotype (Zhou et al., 
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1995) and in humans haploinsufficiency of HMGA2 is also associated with growth 
restriction as part of the 12q14 microdeletion (Mari et al., 2009). 
Therefore capillary sequencing of IGF2BP2 was performed in 239 patients with 
MPD, short stature and microcephaly (OFC>-4 s.d., height -2 to -4 s.d.) or primary 
microcephaly (normal height).  However, this did not identify any potentially 
pathogenic mutations in this cohort.  Additionally, no likely pathogenic variants were 
detected in the remaining copy of IGF2BP2 in the three patients with a 3q27 
microdeletion suggesting that growth failure is not the result of biallelic 
abnormalities in IGF2BP2.  Considering at least two of the deletions are de novo it is 
therefore most likely that gene haploinsufficiency is responsible for the observed 




















Figure 6.8.  3q27 microdeletions identified in three MPD patients   
A) Schematic of chromosome 3 with region displayed in B highlighted in red.  B) The three patients 
identified in this study with 3q27.3 microdeletions shared a common region 1.7 Mb in size 
(chr3:183,897,305-185,587,305, hg19).  C) This region encompassed 24 genes including IGF2BP2 
which has a strong functional link to growth and a low haploinsufficiency (HI) score highlighting it as 





Table 6.4.   Genes within 3q27 region deleted in three MPD patients 







specific peptidase 2 
21 
Processes SUMO1, a ubiquitin-like protein 
involved in nuclear transport, 
transcriptional regulation, apoptosis, and 
protein stability 
IGF2BP2 
Insulin-like growth factor 2 
mRNA binding protein 2 
7 Regulates IGF2 translation 
C3orf65 
Chromosome 3 open reading 
frame 65 
40 Unknown 
LIPH  Lipase, member H 88 
Catalyses the production of the lipid 
mediator LPA.  Recessive mutations cause 
hypotrichosis (Woolly hair syndrome). 
TMEM41A Transmembrane protein 41A 60 Unknown 
C3orf70 





kinase kinase kinase 13 
37.6 
Possible role in the JNK signalling 





92.2 Peroxisomal beta-oxidation pathway 
VPS8 
Vacuolar protein sorting 8 
homolog (S. cerevisiae) 
68.9 Endosomal trafficking in yeast 
EPHB3 EPH receptor B3 22.5 Ephrin receptor 
MAGEF1 Melanoma antigen family F, 1 93.7 
Member of MAGE superfamily, function 
unknown 
CHRD Chordin 38.1 
Dorsalizes early vertebrate embryonic 
tissues 
THPO Thrombopoietin 52.1 
Platelet production.  Mutations cause 
thrombocytopenia 1, 
POLR2H 
Polymerase (RNA) II (DNA 
directed) polypeptide H 




51.7 Voltage gated cholride channel 
FAM131A 
Family with sequence 




initiation factor 4 gamma, 1 
4.1 
Initiation of protein synthesis by recruiting 
mRNA to the ribosome 
PSMD2 
Proteasome 26S subunit, non-
ATPase, 2 
2 











dependent protein kinase II 
inhibitor 2 
31.5 Regulates neuronal synaptic plasticity 
ECE2 
endothelin converting enzyme 
2 
56.4 







von Willebrand factor A 




family F (GCN20), member 3 
14.2 




complex 2, mu 1 subunit 
44.9 Acidification of endosomes and lysosomes 
 
6.4.3 Variable growth in other reported patients with 3q27 
deletions argues against IGF2BP2 haploinsufficiency as a 
cause of MPD 
Clinical information concerning other patients with overlapping de novo 
microdeletions to further refine the region responsible for reduced growth were 
obtained from DECIPHER (http://decipher.sanger.ac.uk, accessed 24/03/12) and by 
literature review.  In total, 16 patients with overlapping de novo microdeletions were 
identified, 12 in DECIPHER and an additional four from the literature (Figure 6.9B).  
Growth parameters were available in nine cases which, for DECIPHER patients, 
were obtained directly from the listed clinician if not previously published.  Six 
patients had microdeletions which spanned the entire 1.7 Mb critical region defined 
by the three patients identified in this study (Figure 6.9B, purple and black 
respectively).  Although none of these patients had growth failure which fell into the 
defined range of MPD, microcephaly was reported in all six patients and two had 
additional short stature (height -3 s.d. to -4 s.d.).  Ten patients were reported with 
deletions which only partially overlapped the region and, where growth parameters 
were available, this was associated with a significantly milder reduction in OFC 
(mean OFC -2.6 s.d. +/- 1.5 s.d., p=0.007, n=5) in comparison to those with deletions 
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encompassing the entire 1.7 Mb region (mean OFC -6.3 s.d. +/- 2 s.d., n=7).  No 
significant difference was observed in height between the two groups (mean height 
of patients with 1.7 Mb deletion; -3.32 s.d. +/- 1.7 s.d., n=7, mean height of patients 
with partial deletion; -1.68 s.d. +/-1 s.d., n=5, p=0.08).  This suggest that complete 
deletion of this region is associated with growth failure which ranges from isolated 
microcephaly to MPD and that the three patients identified in this study may lie at 
the extreme end of this spectrum. 
Of the nine patients with deletions encompassing IGF2BP2, six had microcephaly 
(OFC < -3 s.d.) with or without short stature, however two patients showed only a 
very mild reduction in growth parameters (OFC -2 s.d., height 0 to -2 s.d.) and one 
patient was described as disproportionately tall (patient 277546).  Additionally, no 
growth phenotype was reported in three DECIPHER patients with partial IGF2BP2 
deletions despite other phenotype data being recorded and therefore it is probable 
that growth is unremarkable in these cases.  These latter patients argue against 
haploinsufficiency of IGF2BP2, in isolation, as critical for normal growth and 
suggest that other genetic modifiers, possibly in cis with IGF2BP2, are contributing 




Figure 6.9.  Additional patients reported with 3q27 microdeletions and 
associated growth phenotype 
A) Schematic of chromosome 3 indicating region shown in B (red).  B) Reported patients with 
microdeletions overlapping the entire 1.7 Mb region (purple) shared by the three MPD patients 
identified in this study (black) and reported patients with partial deletions of this region (white).  Left 
hand annotation indicates DECIPHER identification number or reference (Mandrile et al., 2013, 
Zarate et al., 2013, Thevenon et al., 2014).  Available growth data of each patient shown on the right.  
Patients with the full 1.7 Mb deletion showed a significant reduction in OFC compared to patients 
with partial deletions (p=0.007, unpaired t-test).  Growth was within normal limits in at least three of 
the twelve additional patients with deletions encompassing IGF2BP2 (C, red box) suggesting 





6.6.1 Microdeletions are a relatively frequent cause of MPD 
In this Chapter, microdeletions were identified in 5% of families in whom WES was 
performed in comparison to single gene mutations which were identified in 33% 
(Chapter 3).  Extending this to all MPD patients in the cohort (including those in 
which a diagnosis was made prior to WES), alteration in gene copy number due to 
microdeletions is responsible for approximately 2.5% of all cases and is therefore as 
common as mutations in NHEJ genes (Chapter 4).  Pathogenic microdeletions are 
frequently associated with microcephaly and/or short stature (Nevado et al., 2014) 
and thus several microdeletion syndromes could potentially be associated with a 
growth phenotype that falls into the range of MPD (Section 1.1.4.5.1).  This analysis 
enabled the detection of microdeletions covering known disease regions which have 
previously been associated with severe growth failure, Wolf-Hirschhorn syndrome 
and the IGF1R locus (Antonius et al., 2008, Walenkamp et al., 2013).  However, this 
analysis also identified a previously uncharacterised microdeletion on chromosome 
3q27 in three independent MPD patients.   
6.6.2 3q27 is a novel microdeletion syndrome associated with 
MPD 
The 3q27 deletion detected in these three cases allowed a novel locus for the growth 
phenotype to be defined which contained a strong candidate disease gene, IGF2BP2.  
However, no cases were identified with point mutations in this gene on resequencing 
over 200 patients with growth deficiency.  Furthermore, other cases out with this 
study have since been reported with microdeletions encompassing IGF2BP2 and 
relatively normal growth (Thevenon et al., 2014).  This suggests that 
haploinsufficiency of another gene in this region may be responsible for the 
phenotype.  Alternatively, the growth phenotype is not exclusively caused by the loss 
of a single gene and rather results from the loss of several contiguous genes and/or 
regulatory regions.  This is supported by the compilation of growth data from other 
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reported cases with overlapping deletions (Figure 6.9) which showed a significantly 
greater reduction in OFC in those with a complete deletion of the 1.7 Mb region 
compared to those with only a partial loss of this region.  Other deleted genes which 
may contribute to the growth failure include the Mitogen-activated protein kinase 
kinase kinase, MAP3K13, which may function in c-Jun N-terminal kinase (JNK) 
signalling, a pathway regulating neuronal apoptosis (Ikeda et al., 2001, Xu et al., 
2001) as well as the SUMO-specific protease, SENP2, which deconjugates 
sumolated proteins including the p53 regulator, MDM2 (Jiang et al., 2011). SENP2 
deficient mice are embryonically lethal with impaired cell cycle progression in 
trophoblastic stem cells and defective placental development (Chiu et al., 2008).  
SENP2 depletion in human fibroblasts has also been shown to induce p-53 dependent 
premature cell senescence (Yates et al., 2008) and thus conceivably impacts on 
global cellularity in development.  Additionally, the functions of seven of the deleted 
genes are largely unknown and so also remain potential growth modulating 
candidates (Table 6.4). 
6.6.3 Difficulties in CNV detection from WES 
In contrast to WGS, capture bias and discontinuity in coverage are inherent to WES 
and need to be taken into account during copy number analysis.  At least14 tools now 
exist for CNV detection from WES (Tan et al., 2014) and all follow a four step 
approach; mapping of reads to the reference, normalization to correct for biases in 
read depth resulting from variable capture efficiencies, estimation of copy number 
variation and segmentation to detect discordancy in copy number between adjacent 
regions (Zhao et al., 2013).  However, comparison of different CNV detection 
programmes highlights the difficulties with WES with poor concordance between 
different tools and large sample to sample variability occurring within each 
programme (Samarakoon et al., 2014, Tan et al., 2014).   
ExomeCNV is one such tool primarily designed to compare a test sample to a single 
paired control matched in terms of capture method and sequencing platform.  
However the results are consequently highly dependent on the depth of coverage in 
the one reference sample as it assumes that the read density across each exon will be 
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the same in both test and control samples in copy neutral regions.  Given the large 
sample to sample variability in sequencing and depth of coverage identified in this 
study (Section 3.2.2) this method is likely to incur a high false positive rate.  Similar 
difficulties were experienced by Samarakoon et al., (2014) who found the number of 
microdeletions called per individual ranged from zero to over 2,000 following 
analysis of 30 different exomes using ExomeCNV.  To limit errors occurring from 
sample variation both case and control should be prepared in the same batch and 
sequenced in the same run.  The importance of this was noted in this study as all 
samples failed analysis where the affected was compared to a single parental sample 
prepared and sequenced at a different location.   
The authors of ExomeCNV did report a greater precision in CNV detection 
following pooling independent samples to create a reference thus reducing the 
variance in read depth between different samples (Sathirapongsasuti et al., 2011).  
Consequently this method was implemented for singleton cases in this study where 
parental sequencing data was not available.  Combining samples to create a reference 
is a method used by many of the other programmes which have been designed 
specifically for the detection of CNVs in large cohorts (Fromer et al., 2012, Krumm 
et al., 2012) with improved consistency between samples compared to ExomeCNV 
(Samarakoon et al., 2014).  Improved accuracy in CNV detection may also be 
achieved by combining the results of multiple programmes (Zhao et al., 2013, 
Samarakoon et al., 2014). 
Another difficulty with CNV detection in WES data is achieving high resolution with 
many tools performing poorly at the single exon level (de Ligt et al., 2013).  In this 
study at least 2/3rds of deletions called in this analysis with a log2R below -0.7 
covered less than 50 Kb and 43% covered less than 10 Kb.  This is similar to 
previous observations in which structural variants of less than 10 Kb were found to 
be the most abundant in control populations (Mills et al., 2011b).  All deletions less 
than 1 Mb were either excluded during the filtering pipeline or considered unlikely to 
be pathogenic on manual review.  In contrast 50% of deletions covering over 1Mb of 
sequence were identified as likely causative deletions and subsequently validated on 
array-CGH indicating reasonable specificity at this level as well as fewer 
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polymorphisms occurring in this size range.  Additionally, single exon deletions of 
less than 500 bp only represented 2.3% of deletions which is much lower than that 
anticipated from WGS studies (Mills et al., 2011b) suggesting a lower sensitivity in 
CNV detection at this level.  As so few of the called deletions were validated it is not 
possible to draw firm conclusions regarding the sensitivity and specificity of 
ExomeCNV for different sized deletions.  However, other studies have noted 
improved sensitivity in detecting smaller CNVs (1-4 exons) with programmes using 
other strategies such as ExomeCopy (Samarakoon et al., 2014) which utilises read 
count normalisation followed by a Hidden Markov Model based approach to identify 
CNVs (Love et al., 2011).   
Other studies reporting on the detection of CNVs from WES have either focused on 
the identification of previously validated CNVs (de Ligt et al., 2013), identified 
CNVs in known disease genes (Bademci et al., 2014, Lieber et al., 2014) or 
estimation of CNV frequency within a patient cohort (Poultney et al., 2013).  As yet, 
the identification of novel causative deletions from WES has not been described and 
thus filtering strategies for handling such a large number of false positive calls have 
not been reported.  In this study a pragmatic approach was taken to filtering out noise 
by excluding commonly occurring regions with identical genomic coordinates.  
However, this would not be an advisable approach in more homogenous disorders as 
the likelihood of removing pathogenic deletions would be much greater.  An 
alternative approach would be to use larger independent datasets captured and 
sequenced using the same method although, as discussed above, different tools are 
likely to be more suitable in such an analysis.   
6.6.4 Alternative approaches to CNV detection 
The discontinuity in coverage arising from selected capture precludes the accurate 
identification of CNV breakpoints.  As these could occur anywhere in the region 
between adjacent exons the distance between the CNV boundary identified from 
WES analysis and the actual breakpoint could range from as little as 125 bp to over 
22 Mb in size (Sathirapongsasuti et al., 2011).  CNV analysis from WGS 
circumvents many of the difficulties arising from WES by providing more even 
coverage and continuity in read distribution and thus is able to achieve higher 
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resolution with lower false positive rates along with accurate breakpoint detection 
(Duan et al., 2013).  However these advantages need to be weighed against the 
increased sequencing costs incurred by WGS.   
Array-CGH represents the gold standard for diagnostic CNV detection and high 
resolution arrays can detect deletions as small as 200 bp (Urban et al., 2006) 
although such genome wide arrays are costly.  Alternative strategies such as MAPH 
(Mulitplex Amplifiable Probe Hybridisation) (Armour et al., 2000), MLPA 
(Mulitplex Ligation-dependent Probe Amplification) (Schouten et al., 2002), qPCR 
(Babashah et al., 2009) and digital droplet PCR (Mazaika et al., 2014) could present 
a more cost-effective option to validate small deletions (<100 Kb) in specific genes.  
These latter methods could also be used to screen a large number of patients for 
intragenic deletions in a small number of candidate genes which have been identified 
through the detection of SNVs/indels or reside within a larger CNV region such as 
IGF2BP2 or WHSC1.   
6.6.5 Conclusions 
Despite the limitations of CNV detection in WES, it was still possible to detect large 
CNVs (greater than 1Mb) in this cohort of MPD patients using ExomeCNV, 
establishing a diagnosis in a further five families.  Given the frequency of large 
CNVs in the MPD cohort, performing diagnostic array-CGH prior to embarking on 
large scale NGS in the future should be considered.  Notably, this analysis does not 
include the analysis of microduplication in the WES dataset and will not detect 
balanced structural rearrangements which could also be disease causing.  With 
decreasing costs, WGS may provide a more cost-effective approach to WES in the 
future by combining mutation discovery in both coding and non-coding regions as 
well as greater sensitivity in CNV detection (Gilissen et al., 2014) with the added 
benefit of detecting breakpoints and chromosomal rearrangements.   
This Chapter demonstrates that WES can be used to successfully identify causal de 
novo CNVs in developmental disorders although this method is highly error prone 
and lacks sensitivity in the detection of small intragenic deletions.  Although a 
potential strategy for novel gene discovery, identification of possible pathogenic 
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deletions was biased in this study by prioritising regions encompassing genes with a 
known functional link to growth.  This was required due to the high level of noise in 
the dataset which rendered validation of all CNVs infeasible despite filtering.  Given 
the relative frequency in which pathogenic CNVs have been identified despite 
suboptimal methodology, improved resolution in CNV detection either by improved 
















Chapter 7:  Summary of thesis findings and future 
plans 
7.1 Improving molecular diagnosis in MPD patients 
7.1.1 Outcome and observations of WES analysis  
Performing WES in combination with a comprehensive filtering pipeline to detect 
both point mutations and copy number variation resulted in the identification of a 
molecular diagnosis in 39 families (41% of those sequenced).  As expected, a large 
degree of genetic heterogeneity was observed with mutations being identified in 25 
different genes (Chapter 3) as well as three distinct microdeletion syndromes 
(Chapter 6).  In comparison a diagnostic yield of only 16% was achieved following 
WES of another large heterogenous cohort with severe intellectual disability (de Ligt 
et al., 2012), although CNV analysis was not undertaken.  The majority of molecular 
diagnoses made in this study were in known disease genes/regions demonstrating a 
large degree of overlap between MPD and other previously characterised 
developmental disorders expanding the phenotypic spectrum of these conditions.  
Additionally in this study, WES has led to the discovery of several novel disease 
causing genes including XRCC4, NCAPD3, NCAPD2, NCAPH, DONSON and 
possibly FAT1 (Section 3.6).  This demonstrates the power of WES in enabling the 
rapid identification of causal variants in a rare, heterogeneous disorder which were 
unlikely to be detected through previous gene finding methods (Section 1.4).    
However, although WES has enabled sequencing of the majority of the exome it is 
by no means fully comprehensive and in 59% of families no candidate disease-
causing variants were identified.  Difficulties in WES experienced in this and other 
studies (Ng et al., 2009, Mamanova et al., 2010) include variation in capture 
efficiency between different samples which impacts on sequencing volume and 
consequently depth of coverage (Section 3.2.2) (Sathirapongsasuti et al., 2011, 
Chilamakuri et al., 2014).  Consistency may be further optimised by ensuring the 
same methodology is used and that matched samples, such as affected and parental 
samples, are prepared and sequenced in the same batch.  However, despite this 
marked variability can still occur which will impact on downstream filtering 
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particularly when identifying de novo or biallelic variants in the analysis of trios and 
quads (Section 3.7.5).  The second issue is dealing with the high number of false 
positives variants that result from sequencing and mapping errors (Section 3.7.3) 
(DePristo et al., 2011).  Although a pragmatic approach was taken in this study to 
filter out commonly occurring variants, this would not be desirable in a more 
homogeneous cohort where multiple patients may share a common pathogenic 
variant.  Removing this step would considerably increase the number of false 
positive variants remaining following filtering.  Additionally, although filtering out 
common polymorphisms and ‘ benign’ variants reduced the total number of variants 
by over 90% (Section 3.3.5), large variability in remaining variant number was still 
present between individual samples.  This reflected the patients’ countries of origin 
(Section 3.4) as limited availability of large scale sequencing data in African, 
Middle-Eastern, sub-Indian continent and Asian populations prevented the use of 
ethnically matched controls in filtering (Section 3.7.4).   
Finally, it is important to be aware of the limitations of NGS technology with the 
identification of indels being particularly problematic (Chilamakuri et al., 2014).  
Notably, there is a significant difference in the performance of different technologies 
with semi-conductor sequencers having substantially reduced performance in indel 
detection in homopolymer runs (Harris et al., 2008, Liu et al., 2012).  This was 
observed in Chapter 4 in which indel mutations in XRCC4 were initially missed in 
three patients following sequencing using the Ion Proton/Torrent™ platforms and 
only subsequently identified on capillary resequencing (Section 4.2.7).  
Consideration of such limitations during experimental design is therefore crucial to 
maximise the mutation finding potential of WES. 
7.1.2 Implications for the future application of WES in clinical 
practice 
This study demonstrates the advantage of WES in uncovering unexpected diagnosis 
and the potential benefits of WES in the clinical diagnostic setting.  Some disease 
genes, for example VPS13B which causes Cohen syndrome (Kolehmainen et al., 
2003), are very large and therefore expensive to sequence by capillary methods.  
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Furthermore the phenotype associated with mutations in this gene can be very 
variable (Seifert et al., 2006) making a clinical diagnosis difficult.  WES provides a 
cost effective way to sequence a large number of plausible disease genes regardless 
of size and detect causal mutations in genes which are not initially clinically 
apparent.   
Despite the huge expansion in gene discovery following the advent of NGS 
technology, WES has yet to become a mainstay investigation in clinical diagnostic 
genetics in the UK and will be challenging to implement, not least because of the 
costly bioinformatics skill, processing power and storage capabilities needed to 
handle the large amount of data generated from NGS technologies.  There are also 
ethical considerations such as the inadvertent uncovering of disease related variants 
which are not part of the condition being investigated, an issue highlighted in the 
Miller syndrome study by Ng et al, 2010a which also identified a mutation in 
DNAH5 in one family establishing a second diagnosis of primary ciliary dyskinesia.  
Although a likely advantageous discovery for this patient, identifying variants which 
confer susceptibility to certain conditions such as malignancy (e.g. BRACA1/2 
mutations) or predicate the onset of disease (e.g. Alzheimer’s or Parkinson’s disease) 
may not always be welcomed by that individual or family (van El et al., 2013).  
Therefore, in the clinical setting, limiting the review of variants to only those 
occurring in known disease genes relevant to the condition being investigated may 
circumvent such issues.  However, the American Society of Medical Genetics also 
recommends that incidental findings which potentially provide significant medical 
benefit for the patient should be reported, for example pathogenic mutations in genes 
known to cause hypertrophic obstructive cardiomyopathy or familial 
hypercholesterolemia (Green et al., 2013). 
Finally, there also lies the inherent challenge of assigning pathogenicity to previously 
unclassified variants especially relevant where prenatal diagnosis or pre-implantation 
genetic diagnosis is being sought by the family.  Although several freely available 
databases detailing variants discovered within each gene exist, for example the 
human gene mutation database (Stenson et al., 2014) or the Leiden open variation 
database (Fokkema et al., 2011), one single comprehensive database would clearly 
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be desirable.  Additionally, to avoid misleading other clinicians it is critical that 
variants entered into such databases are correctly annotated, for example ‘implicated’ 
rather than ‘pathogenic’ is perhaps preferable terminology to classify novel variants 
lacking further genetic evidence and/or supportive functional studies (MacArthur et 
al., 2014).  Such databases of collated variants will be a powerful resource for 
determining criteria on which to sensitively classify previously unassigned variants 
as performed recently in a large cohort of cystic fibrosis patients and variants in the 
CFTR gene (Sosnay et al., 2013). 
7.1.3 Implications for clinical diagnostics and patient 
management  
Identifying a molecular diagnosis is often of vital importance to the patient and their 
family.  They may desire an explanation for why they or their child is affected in 
such a way and also whether this is likely to occur again in subsequent pregnancies. 
Uncovering the molecular cause can also assist clinical management and potentially 
improve outcomes.  This has been the case in MOPDII where annual screening for 
cerebral vascular malformations in patients lacking PCNT has enabled early 
intervention (Perry et al., 2013).  Additionally, in this study, the discovery of LIG4 
mutations resulted in the detection of previously unrecognised immune dysfunction 
in patients which is now being monitored and managed appropriately (Section 
4.2.2.3).  In several cases the diagnosis has also expedited the consideration of bone 
marrow transplantation enabling early intervention and tailoring of conditioning 
regimes which is associated with improved outcomes in such patients (O'Driscoll et 
al., 2008).  These issues also need to be taken into consideration in the management 
of XRCC4 patients who are likely to share similar characteristics.  Continued follow 
up and data collection of both LIG4 and XRCC4 patients will further improve the 
characterisation of associated phenotypes as well as inform on prognosis and 
malignancy risk hopefully leading to increased diagnosis and improved management 
in these disorders. 
As well as implications for clinical management following molecular diagnosis, 
findings from this study can also be used to inform on the first line investigation of 
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patients presenting to the clinic with severe growth failure.  Given the relatively high 
incidence of LIG4/XRCC4 mutations in the MPD cohort, full blood count, 
immunoglobulin levels and T and B cell subset counts are simple clinical 
investigations in addition to baseline endocrinological testing in newly present 
primordial dwarfism patients.  In addition, following the discovery of causative 
microdeletions in MPD patients in this study (Chapter 6), diagnostic array-CGH 
should also be considered even in the absence of significant malformations or 
intellectual disability.  It would also be important to carefully consider DNA damage 
repair disorders during examination which were identified in 10% of those sequenced 
(Section 3.5.2).  Features which may indicate the presence of such include 
microcephaly disproportionately reduced in comparison to height, abnormalities in 
skin pigmentation, sun-sensitivity, malignancy and immunodeficiency (Weemaes, 
2000, Kaneko et al., 2004, Matsumoto et al., 2011, Murray et al., 2014).  
7.1.4 Identifying a molecular diagnosis in remaining patients 
As the cost of sequencing continues to decline there is an expectation that WES will 
be superseded by WGS which has the advantages of improved uniformity in 
coverage by avoiding capture bias, improved CNV detection including determination 
of breakpoints and sequencing of non-coding genes and regulatory regions (Duan et 
al., 2013, Gilissen et al., 2014).  Although interpreting non-coding variants is 
challenging, focusing on coding variants alone along with CNV analysis in the first 
instance may still result in improved diagnostic yield.  This was recently 
demonstrated in a cohort of patients with severe intellectual disability in which WGS 
following WES and microarray based CNV analysis achieved a diagnosis in a further 
42% of patients (Gilissen et al., 2014).  Furthermore, the generation of larger WGS 
datasets in control populations, for example, the 100,000 genomes project 
(http://www.genomicsengland.co.uk/the-100000-genomes-project/) will assist in the 
filtering of commonly occurring variants.  Other large scale projects are also 
underway sequencing specific subpopulations such as the Born in Bradford study 
(http://www.borninbradford.nhs.uk/) and this will allow improved matching of case 
and control populations in the future.  Interpreting the functional consequence of 
variants out with the exome is also likely to improve with the development of 
241 
 
specific prediction algorithms such as Combined Annotation-Dependent Depletion 
(CADD) (Kircher et al., 2014).  Finally, whole genome genotyping of SNVs, either 
by WGS or SNP array, will enable regions of homozygosity to be more accurately 
defined which can assist in narrowing down candidate variants in consanguineous 
families (Kaasinen et al., 2014).   
Notably, a substantial reduction in variant number was achieved when sequencing 
parents in addition to the affected (Section 3.3.5).  Although at significantly 
increased cost, the benefits of this approach are likely to be particularly important for 
WGS given that each individual genome harbours over 3 million SNVs, at least 100 
times more than in the exome alone (Wheeler et al., 2008, Gilissen et al., 2014).  
Sequencing trios also has the advantage of allowing identification of de novo CNVs.  
This will be particularly beneficial in prioritising candidate disease regions in the 
smaller size range (under 10 Kb) in which the majority of CNVs occur (Mills et al., 
2011b).  Another lower cost alternative to WGS is to perform transcriptome 
sequencing in the remaining patients without a diagnosis which could assist in the 
identification of deleterious variants previously removed on filtering.  However 
variant detection is highly dependent on expression levels of individual genes (Cirulli 
et al., 2010) and thus developmentally relevant genes expressed during 
embryogenesis may not be well represented in an analysis performed in blood or 
tissue obtained in late childhood or early adulthood.   
Lastly, structural variation has also not been fully investigated in this cohort and this 
could be a significant source of pathogenicity in MPD following the identification of 
causal microdeletions in six families, 5% of those sequenced (Chapter 6).  In 
particular, gains in copy number identified by ExomeCNV analysis have not been 
reviewed and the presence of balanced structural rearrangements has not been 
investigated.  In the future it would be worthwhile repeating the CNV analysis using 
another programme(s) with improved performance in CNV detection in a large 
cohort such as ExomeCopy or ExCopyDepth (Love et al., 2011, Samarakoon et al., 
2014).  Cytogenetic techniques including spectral karyotyping and FISH analysis 
(Ried et al., 1998) have previously been the mainstay in the detection of balanced 
structural rearrangements however such aberrations can also now be identified using 
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an NGS-based approach by analysing discordantly mapped paired-end reads 
(Koboldt et al., 2012).  Subsequent de novo assembly of such reads can then be used 
to sensitively detect structural breakpoints (Korbel et al., 2007).  Moving from WES 
to WGS for investigating MPD patients in the future will therefore be preferential as 
it provides greater scope for the analysis of different types of genetic variation within 
one experiment.         
7.1.5 Novel gene discovery in MPD 
Due to the large numbers of candidate disease genes still remaining after filtering 
(Section 3.6), further strategies were used to prioritise novel candidates.  These were 
largely based on researching gene function and identifying a functional link to 
growth (for example, NCAPD3, NCAPD2 and FAT1).  However this approach 
favours genes which have been well characterised and reduces the chance of 
discovering entirely novel disease genes whose function may provide the greatest 
insights into growth regulation.  Additionally, plausible variants may be identified in 
multiple genes within the same patient and assigning causality to one particular 
variant/gene requires supporting evidence.  Discovering additional mutations in other 
similarly affected cases substantially improves confidence that a gene is disease 
causing, for example DONSON and FAT1.  Recently, several new disease genes have 
been identified on the basis of a single mutation identified following WES (Shaheen 
et al., 2014), however, sequencing such as large number of genes substantially 
lowers the prior probability of a gene being disease causing.  Therefore prior to 
assigning causality in such cases it is prudent to determine the functional impact in 
patient cells (or cells engineered to express the mutation) and also confirm the 
phenotypic consequence of each variant in model organisms (MacArthur et al., 
2014).  The question then remains as to how, if at all, the affected gene is involved in 
the disease process.  Addressing this may not be straightforward but is of particular 
importance in genes whose function has not been fully characterised as incorrectly 
assigning causality can have adverse consequences in clinical management.   
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7.2 Insights into cellular mechanisms in MPD 
The majority of genes so far identified in MPD have well defined roles in cell cycle 
regulation leading to the hypothesis that MPD is a disorder of reduced global 
cellularity (Section 1.2.3) (Delaval et al., 2008, Rauch et al., 2008, Klingseisen et al., 
2011).  Additionally, there is also clear genetic overlap with the phenotypically 
related disorder 1° MCPH in which there is an isolated reduction in brain size 
(Verloes et al., 1993, Woods et al., 2005).  Accumulating evidence suggests that a 
key pathogenic mechanism reducing neuronal stem cell population in 1° MPCH is 
the disruption of mitotic spindle orientation in neural progenitors impacting on the 
plane of cell division and consequently stem cell fate (Section 1.3.1.6) (Wang et al., 
2009, Megraw et al., 2011, Chen et al., 2014).  Mutations in three centrosomal genes 
have now been identified in patients with microcephaly and normal stature as well as 
patients with MPD (CEP152, CENPJ and TUBGC6) (Bond et al., 2005, Al-Dosari et 
al., 2010, Guernsey et al., 2010, Kalay et al., 2011, Puffenberger et al., 2012, Martin 
et al., 2014) and thus the two disorders appear to be part of the same clinical 
spectrum with similar underlying pathogenesis.  Why some mutations in these genes 
result in MPD and others in 1° MCPH however is not yet known.  Furthermore, in 
addition to centrosomal proteins and mitotic spindle formation, DNA damage 
response/repair pathways have also been implicated in MPD and 1° MCPH 
(O'Driscoll et al., 2003, Alderton et al., 2006, Qvist et al., 2011, Ogi et al., 2012) 
suggesting increased genome instability in embryogenesis can also result in reduced 
cellularity most likely through increased apoptosis.  Thus global growth failure 
appears to result from a range of aetiologies which perhaps act through their impact 
on all stem cell pool populations, with neural progenitors more sensitive to certain 
cellular defects resulting in a greater impact on brain growth.     
Surprisingly in this study, causal mutations were identified in MPD patients in 
several known disease genes associated with previously distinct disorders such as 
Ligase IV syndrome (Section 3.5.2).  Identifying disorders which overlap with MPD 
can provide insights into other processes which impact on growth.  Many of the 
known disease genes identified in Section 3.5.2 function in well characterised 
cellular mechanisms and detailed review of filtered WES variants in related genes 
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resulted in the identification of the novel disease gene, XRCC4 (Section 4.2.7) 
establishing the role of the LIG4-XRCC4 complex in ensuring normal growth.  In the 
analysis of future exomes/genomes in MPD patients, particular attention should 
therefore be paid to variants in other genes involved in the same mechanisms, such as 
chromatin remodelling and transcriptional activation (SRCAP, MED12) (Wong et al., 
2007, Lai et al., 2013), mRNA processing (RBM10, NSUN2) (Tuorto et al., 2012, 
Inoue et al., 2014) and other DNA damage repair mechanisms (BLM, ERCC6, 
PNKP, SRCAP) (Kaneko et al., 2004, Fousteri et al., 2008, Weinfeld et al., 2011, 
Dong et al., 2014) (Sections 1.3.2.2.4 and 3.5.2).   
7.2.1 NHEJ 
A novel finding of this study was the identification of mutations in two genes 
encoding key components of the NHEJ machinery, LIG4 and XRCC4 as a relatively 
common cause of MPD (4% of total MPD cohort) further emphasising the 
importance of mechanisms which maintain genomic integrity in global 
embryogenesis.  In LIG4- and XRCC4-deficient mice severe p53-mediated apoptosis 
occurs in post-mitotic neurons (Gao et al., 1998b, Orii et al., 2006) suggesting that 
accumulation of DSBs and increased cell death is the primary mechanism of 
hypocellularity in these patients (Gatz et al., 2011).  Additionally, increased DSBs 
and enhanced apoptosis were observed in human induced pluripotent stem (iPS) cells 
derived from LIG4 patient fibroblasts (Tilgner et al., 2013) and stem cell depletion 
was also observed in Lig4 hypomorphic mouse bone marrow (Nijnik et al., 2007).  
Similar to other disorders of DSB repair such as Nijmegen breakage and Nijmegen-
like breakage syndrome (Weemaes, 2000, Waltes et al., 2009, Matsumoto et al., 
2011), head size was more severely affected than body size indicating neurogenesis 
is particularly sensitive to DSBs (Section 4.3.3).  This raises the question of whether 
microcephaly in all disorders of DSB repair arises as a consequence of increased 
apoptosis.  However, the extreme and global growth failure seen in LIG4 and XRCC4 
patients reported here in combination with genotype-phenotype observations from 
this study (Section 4.3.3) suggests an additional mechanism specific to the LIG4-
XRCC4 complex may also be contributing to the severe growth failure in these 
patients.    
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Recently, a reduction in telomere length was observed in lymphocytes from an 
additional patient with biallelic truncating mutations in LIG4 (the sibling of which 
was reported in Yue et al., (2013)) (Stewart et al., 2014).  Although a role of some 
NHEJ components in telomere maintenance has been implied in various organisms 
(Riha et al., 2006), telomere shortening in vertebrates has only previously been 
observed in KU deficient cells and was not apparent in LIG4 or XRCC4 deficient 
mouse embryonic fibroblasts (d'Adda di Fagagna et al., 2001).  Notably in this study, 
predominant features observed in LIG4 deficient patients include pre- and post-natal 
growth failure, progressive bone marrow failure often from early childhood and 
immunodeficiency, all features characteristic of Hoyeraal-Hreidarsson syndrome, a 
severe form of dyskeratosis congenita caused by deficiency in the telomere 
maintenance helicase, RTEL1 (Walne et al., 2013).  The specific role of NHEJ in 
telomere maintenance may therefore be pertinent to other cell populations, not just 
haematopoietic cells, and could be contributing to both bone marrow failure and the 
global failure in growth over time.  Additional signs of a telomere maintenance 
disorder could be specifically reviewed in the further follow up of patients, such as 
premature hair loss/greying and abnormalities in nail growth and skin pigmentation 
(Savage et al., 2010).  Telomere length could also be measured in different patient 
cell lines obtained in this study by flow cytometry with fluorescent in situ 
hybridisation (Baerlocher et al., 2006) however patient derived iPS cells may enable 
more relevant modelling  for telemoric anomalies during development as well as 
enabling investigation of different cellular lineages along with the possibility of 
generating organoids (Fan et al., 2011, Tilgner et al., 2013, Lancaster et al., 2014). 
7.2.2 Condensin complexes 
The identification of mutations in condensin genes in MPD patients provides insight 
into another cellular mechanism which can impact on growth, chromosome 
condensation and segregation.  This is not the first time abnormalities in 
chromosome condensation have been described in relation to growth failure.  
Mutations in the 1° MCPH gene, MCPH1 (microcephalin), result in a characteristic 
cellular phenotype of premature chromosome condensation and perturbed mitosis 
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associated with failure in ATR-checkpoint signalling (Trimborn et al., 2004, 
Alderton et al., 2006).   
As the condensin genes have not been previously implicated in human disease, it is 
important to establish whether the mutations identified are deleterious to condensin 
complex function.  The availability of a patient derived fibroblast line in this study 
allowed demonstration of reduced protein levels and aberrant splicing in the presence 
of compound heterozygous mutations in NCAPD3.  In addition, abnormal 
chromosome morphology and chromosome segregation defects were observed 
similar to findings in previous knockdown studies (Ono et al., 2003, Green et al., 
2012).  This work could be extended by examining chromosome morphology in 
further detail using super-resolution microscopy and quantifying the defect by 
measuring individual chromosomes (Green et al., 2012).  The stability of the 
chromosome structure can also be assessed using a TEEN assay which assesses the 
ability of chromosomes to resume their normal morphology after repeated disruption 
(Hudson et al., 2003).  Chromosomes in cells lacking the condensin subunit SMC2 
fail to recover their normal appearance after exposure to the hypotonic TEEN buffer 
which removes Mg2+ perturbing chromatin higher order structure.  Therefore patient 
cells would be expected to exhibit similar defects.  Additionally, the stability of the 
condensin complexes could be determined by examining condensin localisation at 
chromosomes with immunofluorescent labelling of the various subunits or by co-
immunopreciptation studies in patient cells.  Mutations may also impact on other 
proteins such as TOPII or INCENP whose chromosomal localisation is disrupted in 
SMC2 deficient cells (Hudson et al., 2003).  Live imaging of patient cells could be 
performed to determine whether mitosis is delayed which may possibly explain the 
hypocellularity in these patients (Hirota et al., 2004).  As discussed in Section 5.7.3, 
the observed increase in chromosome segregation defects could result in an increase 
in chromosomal rearrangements and aneuploidy, providing a mechanism for 
increased cell death and consequent dwarfism.  Additionally this might also result in 
cancer predisposition in affected patients.  Various cytogenetic techniques could be 
used to assess the incidence of such aberrations in patient cells including FISH and 
spectral karyotyping (Ried et al., 1998).    
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To determine whether condensin dysfunction impacts on global growth, detailed 
anthropometric measurements could be taken in existing animal models such as the 
nessy mutant mouse which harbours a homozygous non-synonymous coding 
mutation in the condensin II subunit, NCAPH2 (Gosling et al., 2007).  Additionally, 
recently developed genome editing technologies such as transcription activator-like 
effector nucleases (TALEN) and clustered regularly interspaced short palindromic 
repeat (CRISPR)/CAS9 RNA-guided nucleases allows patient mutations to be 
modelled in a variety of different systems including human iPS cells (Li et al., 
2014b), mice (Inui et al., 2014) and zebrafish (Auer et al., 2014).  Establishing 
condensin mutations as a cause of growth failure could enable further exploration of 
condensin function, for example can mutations give further insights into the role of 
condensin at kinetochores or in transcriptional regulation as well as determine 
whether different subunits have specific roles within the protein complex?     
7.3 Physiological relevance to growth 
The overarching question posed by this thesis is can disease causing genes in MPD 
be used to inform on growth regulation?  In MPD all body structures are reduced in 
size with relative preservation of body proportions consistent with a global effect on 
growth.  Accumulating evidence indicates that MPD results from a reduced 
proliferative capacity present in all cell types commencing from early embryogenesis 
indicating that the cells intrinsic ability to divide and survive is critical in attaining a 
normal body size.  A reduced capacity for growth determined by stem cell pools may 
explain why growth is unable to continue over a longer period of time to allow a 
normal size to be achieved in MPD patients.  The recent generation of cerebral 
organoids from patient derived iPS cells has enabled human specific modelling of 
microcephaly demonstrating premature neuronal differentiation (Lancaster et al., 
2013) and thus provides a potential model system by which growth in MPD patients 
can be examined from embryogenesis.   
Somewhat surprisingly, relatively few MPD genes have been identified as key 
components of growth regulatory pathways such as those described in Section 1.2.  
With the exception of IGF1 and IGF1R, mutations in which phenocopy MPD 
(Walenkamp et al., 2013), mutations in genes encoding other components of growth 
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signalling pathways have more distinct developmental phenotypes.  For example, 
mutations in components of the MAPK pathway are associated with neurocognitive 
impairment, pigmentary changes in the skin and cardiac abnormalities (Denayer et 
al., 2008).  Mechanisms controlling growth are clearly complex with cross talk 
occurring between different signalling pathways perhaps allowing for compensation 
to occur and thus preservation of body size when certain components are lacking or 
inadequate.  Alternatively, different signalling pathways may only control growth of 
specific regions and thus global body size is determined by an orchestrated effect of 
the various different regulatory pathways which all ultimately impact on cell 
proliferation, survival and differentiation (Klingseisen et al., 2011).  Perhaps it is 
therefore unsurprising that MPD genes all appear to disrupt this common end point. 
Interestingly in this study, rare deleterious mutations in FAT1 appeared enriched in 
MPD patients compared to control populations (Section 3.6).  In Drosophila, Fat 
functions as a cell surface receptor regulating cell proliferation through the hippo 
pathway (Silva et al., 2006).  Fat1 deficiency in mice results in perinatal lethality 
(Ciani et al., 2003) and mice with reduced expression of fat1 show a distinct 
developmental phenotype similar to patients with facioscapulohumeral dystrophy 
with altered shoulder girdle and facial musculature, retinal vasculopathy, abnormal 
inner ear patterning and kidney defects (Caruso et al., 2013).  Examining the location 
of mutations across the gene in the MPD cohort compared to control populations 
may display a clustering of mutations in a certain region which may have a distinct 
function in growth.  It still remains to be established whether the mutations identified 
in MPD patients have a deleterious effect on protein function however if this proves 
to be the case patient cells could provide valuable insights into the function of such 
atypical protocadherins in development.   
To date MPD genes have provided relatively few new insights into growth regulation 
as most genes discovered so far function in cell cycle machinery or DNA repair 
processes impacting on cell proliferation and cell death thus explaining a reduction in 
global cellularity.  However, the discovery of novel disease genes in MPD patients 
with relatively unknown function may provide significant breakthroughs in 
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understanding growth regulation, for example, the possible identification of FAT1, a 






















Appendix I: Primer sequences 
Genomic DNA primers 
Gene Exon Forward Reverse 
LIG4 1A AAACGAGAAGATTCATCACCG TCCTTTCTGTAAACATCTTGGCT 
1B TGTTGAAGCCAAGATGTTTACAG TGCATTATGAATGAATGGGG 




1E TTGAACCTTGTAATTCTGTCATTG GGCAAAATGTTCTTTGGTTG 
1F CTGTGTAATTGCAGGGTCTGAG TGCAACACGACTATGATCTTCC 
1G ACACCGTTTATTTGGACTCG CCTGCTGCAATGAGTCTGC 
XRCC4 2 TCCTTGGTGTTTGTGTAGCTG TGGAAAAGTATCCCTGAGGAC 
3 CGAGATGTGAGTCTAAATTAATGC CAAGCTTTTGCTTCTGAGGTG 




















































































































































































































































































































































































































































































IGF1R 1 TGAGTTTGAGACTTGTTTCCTTTC GGGTTTCGCAAACAGGG 
2A AGGATTCCTGAAAACCAACTG TCTCAATCCTGATGGCCC 
2B CGGCTGGAAACTCTTCTACAAC AGGTCAAGGAGGAGGAGAGG 
3 AGAGAAGGCGGTGCCTC ACCTTTGTGTGCTAGGGTGG 
4 GGGGTGAGATACCATGTGAC TAGTGGTGACTCAGGGACGG 
5 TCCAAGTATGTCACCCTTACACC CAGCAACACAGTTTCATAAGCAC 
6 AGGCTAGAGGGGACTGTGG AAGCTGCCATCACACATGG 
7 GCAAGACAGGTGCTTTTCAG TCAAGGATCGAAAGACTGGC 
8 AGAAAGTGTGACATGCTGGG ACACCTGGTACAAGCAAGGC 





11 TGTGCCCATTCTGACACTTG GAGAGCGTGGGCTCTGTTC 
12 CTCAGGTCAGCCCAGTGTTG GCATATGCTGTCAATGGATG 
13 AGTTTAGTTGGCAGGCCCC GGGCTGTCCTGATCCTGG 
14 CAGGAATTCTTACTGTATGATGGG TCACCTTCACTCACATTCAAATC 
15  TTCTGATACCGTGTGAGAGAGG GCTCAAAATAATGCAAACCTCC 
16 AAAGCACGTTCTGTCTAAGGG GCCAAGAACATACTGGGAGG 
17 CAGTTCCAGACAACACAGGC TTTAAAGACACAGCATTTCCTTG 
18 CTCGAAAGAAATTGGCATGG TGCCAACAAAGTCCTCAAAAC 
19 GTGTAGGGTCCTCTGCTGTG ACTGAGCTGGTGGAAAGTGC 
20 GCATTGTTCAGTCCATCCC ACAAGGACAAACCTCTTAGCC 
21 CCGCCGTACGCTTGTATG TGAGGTACAGGAGGCTTGTG 




SRCAP 34 GACCTGGAAGCTGCTAATTTC CGGAGCTGAAGCTGGAGTG 
MRE11A 4 CCAGATTGAAAGTCCCTTTG GGAAGGCAAAACAGTTGTGTG 





3 CAGCAGGACAGGAAACACAG CACATCGCTGCTTAACCATTC 
ERCC6 
 
21 TCTTGTGACCCTTCACAGCC AGTGCAGCCAACTTCCATTG 
11 TTAAGGAATGGAAGCAATTGAG CACCAGACTCTCTCATCCGC 
MED12 44 TGGGAAAGGAGGTTGAAGAAG TTTCAGCTACTTTGGCCCAC 
RBM10 8 GACCAGTCGTGGAGCCTTC GTCCTGCTCACTGCCATTTC 










62 TTTTGTTCTGGAACTCTCGTAAG CAATGCAGTGAGACCCTGTC 
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Gene Exon Forward Reverse 
PNKP 
 
9 CCTGATGTGGGGCACAG AACACACGGGACACCCC 
17 GGCTACAGGTACTGTTGGGG TCCATGTAAGAAACTGGCAGG 
TUB-
GCP6 
19 CATCTCCTGTGGATGGGG GGAGCTGGAGTCAGGGC 
FAT1 
 
2A GGACCAAAGGAGGAAATACAGC GGACCAAAGGAGGAAATACAGC 
3 TTCTGAAGCTGGCAGTTTTG AAATGCTAATTCTTACTTTTCCCC 




19 TTCCGTGACTGACATTGAGG AAGGCCGTCTGAAACCATC 
USP2 1 GTCAGCTGGTGCTCACTGC ACTTTCTGAGCTCCAAACCG 


















































3 GGAGCCAGGCTACTCTATTCC TCTCTGCCATGGGTTAGCAC 
4 CATGAAAAGCCTGTGTTTTGC TGCCTATAATCATGATGCCTG 
5-6 CCATGGGACAAAGTGTTTGG TGGTATTTCCATTTCTGCTGG 
7 CATTTAAACATGGCTTGTAGGAC TATGGTTCATGTGCCTTCG 
8 TCTGAGACCCTTGTGTTCTCC CTTAGTGCAGGGCCCAGAG 
9 CCACTCTTATAGCGTGAGGTAGAG AACAATGCACACTCATTCCC 
10 AATATGTTTCAGCCATCCTGC CCAAAGAACCCTCCTCATTC 




14 TGGTGAAATGTTAGCTGCTG ACAACAGGATCAGGGTCAAC 




















24 CTGGGAACAGTGAGGCTTG CCAGCATACATCAGAAATGAGG 
25 TTGGTGTATTCAGAGACTGTTGG AGCCTAACCTCCCCTGATTC 
26 CAGTGTTAAATCCCTTACACCC CTGGGCCATTATCAACACAG 
27 AATTACACCTCCTCTCTGGGC CTTAGGGGAGCAGCACACTC 
28 TGTGGTAGGGTGGCTCTACTC AATCATTCACGGATTGCCTG 
29 TTGTTACACAGGCGAAGGTG GATGACGGAGATCTTGAGAGG 
30 TGATTTGATCATTACGTTGTCC ACAATGACTTTCCTGCCCAC 
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Gene Exon Forward Reverse 
NCAPD3 31 GTGCAGCACTGTCACCTCTG CACCGCTTTGAAAGGAATAAG 
32 TGTGGTTGTTTTGCTCTTCG ACACATCACGAATGCAGGAG 






2 CAGGTCTTGAATATAGACCCTGAC CCATGTGAGATGGTCCTTTG 
3-4 TTTTCTGCCATGGATAGAATTTAC CATGTGGCTGACAAAATGTAGG 
5 TGCTGGGTGTTTTGAAGTTG TGGATCATTGGATTCCCTTC 
6 TGGTACTAGATTGTTTGGGCAC TCAACAGAGCCTCACTCTCAC 








13 AGACAGGCTTCTCCTTGCAG CACCTGGTGGCAGCATATC 
14 TTACAAACGGCTGCAGTGAC AGGCCAATGATGGCATAAAG 
15 GTTGGATTCCCCTGTATCCC GGAAGGCCCCATCTCTATTG 
16 TTCAGAAAGGTTCTGTCGTTAGG GAAGTCCTGTGAGAAGCTGACC 
17 TCCAGATCCATAGGCAGTCC GATCACGAGGTCAAGGGTTC 




21 CACAAAAGGTGAGCTCTCAGG CCTGCAGGGAGAACAGAAG 














32 GTAGATGCTCTGCCCCACTG CTTGGTATCGCAAAGTGCTG 
NCAPH 
  
1 AGGCCCGAGGTGGTCTG AGTACTGCTTCGCTAGGGG 





5 TGAAGCTTGCTGTGTTTTACC TCAAGTAACTACCTGGTATGCCC 
6 CGACAGGTTTTGAAGAACTTGAG TTAGCCCTGCCAAGTCTCAG 
7 TCTTTCCCTTGGCTACATGC TGATGGGCTTATTGTACCCC 
8 TGAAGGGAGTAAGGAATGCAC GCAGGACCACTCTTGAGCC 
9 GTCCCTCCAGTGGTGATTTG AATGCAGTGAGATGCCCG 
10 AATGCAGCTCATTTGCGG ACACAACAGGGCTGTGACTG 
11 CCTTGATAAGGCTGTCAGCAG GGAACAAGGAAGAATGAAACC 
12 AAAGTAAGATGTTTTGCCCACTG GGCACTGCCTAACTGTCATAC 
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Gene Exon Forward Reverse 
NCAPH 
  
13 AGGAGGAGATTGGGCATAGG AATTGCCAACAGTCTCCCAC 
14 GTGTTTCTGAGCTCCTCTGC GCTCAGATTGCGTGACTCTC 
15 AGCTCCTTGGTTGAAACTGG AGACATCAACCACTCCCCTC 




18 CACTACCTTGTGACTGTGATTGG GTCCCGGCAACTGAGTAAGG 
NCAPH2 1 CGCCTACGCATTTTCCTG AGAGCGCCAGATAGCCATAG 
2 AGACCAAAGATGGGTGGGG ACTGTGGTCCCACTGGC 
3-4 ACCGATGGATAGCTGGGAAG GGAGCCCAGGCAAACAC 
5 TGAGTTTCTTTGGCATGTGG CCCAGGGAAAGTGCTGAC 
6-7 ATGTGGGTCCTGTTCTCCAC GTCCAACCAGAAGACCCTCC 
8 GGAGAGGCTTGTTGAACACC CTCCCTGGTCCCCTCTTTG 
9 GGAAGTAGCCATCAGGGTCC CCAGGGTTGCCAGTTCAC 














20 GAGTAGCCTGGGATACGTGG GCCAGCCAGGAGCAGAC 
NCAPG 
 




3 TGTTGTAACTTCTTGCATTCCG TTTTAAGCTGGGTGGTTGC 
4 TGCCCAGCCTATCTTTATCAC AAGAAAATGGCTCCTTGTCC 








































15 AGGACAGGCTACATTGAGAGG CATTTTCATCTAGGAAAGAGCC 
16 GCTCTTTCCTAGATGAAAATGCAC TGCAGTTCCTCAGTATTTCAAGG 


















4 CCCAGGGTGAAGACAATATG AGGCAACAAGAGCGAAACTC 









8 TTCACTATGGTTGGAGAGTAGCTG TGGATCTTAAATAACCCTTCTTTG 
9 TCAGGTCGTCAGTAGGACACAC CCCCTAACTGATGTCTGTGAAAG 
10 CTGTTGCTCTTTCCAAATGC TTTGCTAAATTCAAAAGCACAAG 
11 TTTGGGAACACTGTACTTAAGCC AGTACATGCCACAGCCTGG 
12 TGAAGCAGATGTGGATTTCG TCTTTGTGGAGTAGGATTACAGG 




















22 GTGAGGCTGGATTTACTCCC AGGGAGGGAAGGACTGGTTC 




25 TGTTGAAGAAAACCCAAAGC GCTGAGCGCTTACAGCCAC 
26 GTGGTTGTGGTTGAACCTTG CAGGAGTAGCCAAGTGCAGG 
27 ATAGGGAGGCCCAGCTTAGG CCACCTGGGTGTAAGTAGCAG 
28 GGGGATTCTGACTCCATTTTAC CACCTTCCCACATTCCCAC 
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Gene Exon Forward Reverse 
SMC2 
 
2 TTTGTGGCCTGTTTGATTCC GGGACGTCTCCAAAGTTCAG 




5 TCAGTCTAGATAAACATGAATGGC AATCATTCCCAAATAATGTCTCC 













11 AACCAATCTGAATCTTCGGC AATGTTTCCTACTTGCTTGCG 
12 TGCTTTGGAAATAGTGGTTGC AATTTTCACACTGCTTCCAGC 
13 CAAAAGAGCTCCTGATGAGTAAAG GCACATGACTTTTCAAGCTAACC 










































































11 TGGTTTCATTTCAGTGTAGGTTTG AAATGCTGACCTCATTCTTTTG 
12 CATACAGGTGCTCAGTTTTGG CTTGAAATATGGTTGTCAAGGC 
13 TGAATGAAATGGTCCTGTGC ATGGTGTGAACCCGGGAG 


























Sequencing primers for ASPM and PCNT oligonucleotides 
N13 GTAGCGCGACGGCCAGT CAGGGCGCAGCGATGAC 
Sequencing primers for plasmids 











LIG4 SNPs primers 
dbSNP ID Forward Forward 
rs277812 ATATTTCCCCAATGGGCTTC GGGTAGACATGGTTGAACACAC 




rs551103 CTCCTCAGAAAGGCAGCATC AGGACACTAGTGCTTTGTGGG 
rs980044 AGTTTGCTGGATGAAGAGGC CTCCTCTCTGTGTCTGTCCC 
rs1543004 AAGGAAAATATTGACAGTTTACCCTC TCCAGATGTGCAATTTTAAAGC 
rs1560464 GACAGGTTTTGCCATGTTG TTTCTAGTGGACACAGCCAAG 
rs2030736 AAGCTGAAATCGCACCATTG TGAGATGGGGTTTCTCTCTTG 
rs4300490 TGCTACTGGAAGGGATGTAAAC CTCTTGGAGTGCCCAGTGTC 
rs4772857 TTCCCATAGACCCTCTTCTCC AATTACACAAGCTGGCTCCG 
rs6492171 CAGCAAATAAAAGCACATGGTC CCTAAATATATTGTGGGGAGGAG 
rs7322768 AAACAACAGCTAACCGGAGG CAGCACTTATCACCTGACATCC 
rs7989895 CCGCCTATCTGGCTAAAGTG TGCTACTGAGCATCTTTTGGTATG 
rs9301347 TTTCGCATTTATGACAAAACATC CTGATTTGTGAATGGGACTCTG 












rs61965861 CCATCAGTGTCGTTTTCTCTG TTGGATGGGAAGTTAACCC 
 
cDNA primers 




















Appendix II: Reference sequences 
Genomic DNA 
Gene Reference Gene Reference 
LIG4 NM_002312.3 ORC1 NC_000001.9 
XRCC4 NM_003401.3 CENPJ NG_009165.1 
PCNT NG_008961.1  SRCAP NG_032135.1 
ASPM NG_015867.1 MRE11A NG_007261.1 
IGF1R NG_009492.1  BLM NG_007272.1 
FAT1 NC_000004.11 ERCC6 NG_009442.1 
USP2 NC_018922.1 MED12 NG_012808.1 
DONSON NC_000021.8 RBM10 NG_012548.1 
NCAPD3 NC_000011.9 ESCO2 NG_008117.1 
NCAPD2 NC_000012.11 VPS13B NG_007098.2 
NCAPG2 NC_000007.13 PNKP NG_027717.1 
NCAPG NC_000004.12 TUBGCP6 NG_032160.1 
NCAPH NC_000002.11 SMC2 NC_000009.11 
NCAPH2 NG_021419.1 SMC4 NC_000003.12 
IGF2BP2 NG_011602.1   







Species Gene Reference 
Homo sapiens ORC1 NP_001177747.1 
Pan troglodytes XP_513408.2 
Canis lupus familiaris XP_005629058.1 
Mus musculus NP_035145.2 
Gallus gallus NP_001026457.1 
Danio rerio NP_956227.1 





Canis lupus familiaris XP_005630442.1 
Mus musculus NP_659067.2 
Gallus gallus NP_001244261.1 
Danio rerio NP_001073665.1 
Drosophila melanogaster NP_477106.1 
Schizosaccharomyces pombe NP_587811.1 
Homo sapiens XRCC4 NP_003392.1 
Pan troglodytes NP_001267327.1 
Canis lupus familiaris XP_005618209.1 
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Species Gene Reference 
Bos taurus XRCC4 NP_001075084.1 
Mus musculus NP_082288.1 
Gallus gallus XP_424905.4 
Danio rerio NP_957080.1 
Drosophila melanogaster NP_648316.1 
Saccharomyces cerevisiae NP_011425.1 
Appendix III: Script to align Illumina sequencing reads 
#!/bin/bash -f 
# 
#Align FASTQ file to reference genome using BWA, further align unmapped reads using 
Stampy, create sorted bam, remove duplicates, realign indels and create statistics 
#Output is indexed bam ready for calling variants 
#Fields need to be completed for individual files – add in patient identifier used in FASTQ 
and associated index #sequence 
# 
# -- SGE options : 
#$ -S /bin/bash 
#$ -cwd 
#$ -q serial.q 
#$ -m bea 
#$ -M jennie.murray@igmm.ed.ac.uk 
 
# Configure modules 
. /etc/profile.d/modules.sh 
 
# Load required modules 
module load apps/gcc/BWA/0.6.2 
module load apps/java/hdf_java/2.8 
module load apps/gcc/samtools/0.1.16 
module load apps/gcc/python/2.7.1 
module load apps/gcc/gatk 
module load apps/gcc/BEDTools/2.16.2 
module load apps/gcc/vcftools/0.1.9 
 
#Set variables 
patient="insert patient id" 
RG_Index="insert unique index" 
 








#Use qlogin to login to node and run below commands interactively  
#Merg FASTQ files for each direction and remove individual files 
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gunzip -c "$patient"_TAGCTT_L00*_R1_*.fastq.gz | gzip -c > "$patient"_1.fastq.gz 




# Run below program using qsub 
# 
# Map reads to indexed reference 
#-q10 removes reads at end with quality (PHRED) score less than 10.   
bwa aln -q10 $ref "$patient"_1.fastq.gz > "$patient"_1.sai 
bwa aln -q10 $ref "$patient"_2.fastq.gz > "$patient"_2.sai 
# 
#Unite first and second mapping in SAM format and remove FASTQ and indexes 




java -Xmx4g -jar /mnt/lustre2/jmurray/picard-tools-1.79/CleanSam.jar 
INPUT=$patient.bwa.sam OUTPUT=$patient.bwa.clean.sam 
 
#Add read group  
java -jar /mnt/lustre2/jmurray/picard-tools-1.79/AddOrReplaceReadGroups.jar 
INPUT=$patient.bwa.clean.sam O=$patient.rg.bwa.sam RGID="1" 
RGLB="DENMARK_Ex" RGPL="ILLUMINA" RGPU="insert unique index" 
RGSM="insert patient id" 
 
#Convert sam to bam  
samtools view -hbS -o $patient.rg.bwa.bam $patient.rg.bwa.clean.sam 
 
#Align unmapped reads with stampy  
python ./stampy-1.0.21/stampy.py --solexa --readgroup="ID:1,SM:insert patient 
id,PL:ILLUMINA,PU:insert unique index" --keepreforder -g hg19 -h hg19 --
bamkeepgoodreads -M $patient.rg.bwa.bam > $patient.st.sam 
 
#Convert sam to bam 
samtools view -hbS -o $patient.st.bam $patient.st.sam 
 
#Sort bam file 
samtools sort $patient.st.bam $patient.sorted 
  
#Index bam 
samtools index $patient.sorted.bam 
 
#Mark duplicates with picard 






samtools index $patient.rmdup.bam 
 
#Mapping statistics  
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#bamtools stat -in $patient.rmdup.bam > $patient.markdup.stats.txt 
#java -jar /mnt/lustre2/jmurray/picard-tools-1.79/QualityScoreDistribution.jar 
I=$patient.rmdup.bam O=$patient.rmdup.scores.txt CHART=$patient.rm.scores.pdf 
#java -jar /mnt/lustre2/jmurray/picard-tools-1.79/CollectInsertSizeMetrics.jar 
I=$patient.rmdup.bam O=$patient.rmdup.inserts.txt H=$patient.rm.inserts.pdf 
 
#Mapping coverage statistics 
bedtools coverage -abam $patient.rmdup.bam -b /mnt/lustre2/jmurray/v4.bed > 
$patient.rmdup.targetstats.bed #bait coverage 
bedtools coverage -abam $patient.rmdup.bam -b /mnt/lustre2/jmurray/USCS_all_exons.bed 
> $patient.rmdup.exonstats.bed #Exon coverage 
 
#Order bam file for gatk using correctly ordered reference *only need to do this if not used 
correctly ordered reference in first place 




samtools index $patient.rmdup.order.bam 
 
#Realign indels with gatk *make sure path to correctly ordered reference and indexes 
java -Xmx16g -jar $GATK/GenomeAnalysisTK.jar -l INFO -T RealignerTargetCreator -R 
$ref2 -known $indels_1 -known $indels_2 -o $patient.intervals -I $patient.rmdup.order.bam  
 
#Determining regions to be realigned 
java -Xmx16g -jar $GATK/GenomeAnalysisTK.jar -l INFO -T IndelRealigner -R $ref2 -
known $indels_1 -known $indels_2 -targetIntervals $patient.intervals -I 
$patient.rmdup.order.bam -o $patient.realigned.bam 
 
#Calculate recalibration statistics 
java -Xmx16g -jar $GATK/GenomeAnalysisTK.jar -l INFO -T BaseRecalibrator -R $ref2 -
knownSites $snps -I $patient.realigned.bam -o $patient.recal.grp 
 
#Recalibrate reads in bam 
java -Xmx16g -jar $GATK/GenomeAnalysisTK.jar -l INFO -T PrintReads -R $ref2 -BQSR 
$patient.recal.grp -I $patient.realigned.bam -o $patient.recal.bam 
 









Appendix IV: SQL scripts 
 
SNV and indel filtering 
Prior to filtering, information obtained for every intragenic variant identified was 
collated and uploaded into the following tables in an SQL database named 
`mopd_06_13`.  Each unique variant and patient was given a distinct identification 
number (‘site_id’ and ‘sample_id’ respectively) which was used to link the different 
tables. 
Name of Table Description 
site 
Genomic position, reference and alternate alleles, allele count and 
frequency, quality scores and minor allele frequencies in 1KG and EVS 
databases 
consequence 
Affected gene name and transcript with corresponding cDNA and protein 
change for each unique variant and SnpEff consequence prediction 
genotype 
Genotype of each variant in each individual patient with genotype quality 
scores, total and allele read depths in each patient 
dbnsfp dbNSFP annotation of each unique non-synonymous coding variant 
alamut_output_all 
Output of AlamutHT analysis listing all variants predicted to impact on 
splicing 
GeneDataBiomart 
Gene name, Ensembl ID, gene description, MIM morbid description, gene 
status and chromosome number of all genes downloaded from Ensembl_67 
database 
Pedigree_all 
All sample IDs, pedigree number, mothers ID, fathers ID, siblings ID, sex, 
status, diagnosis and number of family members sequenced in each 
pedigree (ped_count) 
Teir1 List of known disease genes in MPD and 1° MCPH (Appendix V) 
Problem_genes List of noisy genes following NGS as identified by Tennessen et al., (2012) 
 
Stage 1 and 2 filtering 
#Annotate consequence table with consequence score  
  
#add in `Consequence_score` field (double, Nullable) to dbnsfp table using ‘Alter Table’ 
tool in SQLyog and populate with corresponding score 
UPDATE `dbnsfp` SET `Consequence_score`=2  
WHERE (sift_score<0.05 OR `polyphen2_hdiv_pred`='D' OR `polyphen2_hdiv_pred`='P'  
OR `polyphen2_hvar_pred`='D' OR `polyphen2_hvar_pred`='P' 
OR `lrt_pred`='D' OR `mutation_taster_pred`='A' OR `mutation_taster_pred`='D'  
OR `mutation_assessor_pred`='high' OR `mutation_assessor_pred`='medium'); 
 










# add in `type_score` field (double, Nullable) to table ‘consequence’ 
UPDATE `consequence` r, `dbnsfp` d  
SET r.`Type_score`=d.`Consequence_score` WHERE r.site_id=d.`site_id`;  
UPDATE `consequence` SET `Type_score`=1.0   
WHERE (`type`='STOP_GAINED' OR `type`='FRAME_SHIFT' OR  
`type`='SPLICE_SITE_ACCEPTOR' OR `type`='SPLICE_SITE_DONOR' OR 
`type`='START_LOST');  
  
UPDATE `consequence` SET `Type_score`=2.0 
WHERE (`type`='CODON_CHANGE_PLUS_CODON_INSERTION' 
OR `type`='CODON_INSERTION' OR `type`='CODON_DELETION' OR 
`type`='CODON_CHANGE_PLUS_CODON_DELETION')  
  
UPDATE `consequence` SET Type_score=4.0 WHERE ((`type`='INTRON' or 
`type`='STOP_LOST') and type_score is null); 
  
UPDATE `consequence` SET Type_score=5.0  
WHERE ((`type`='SYNONYMOUS_CODING' OR `type`='START_GAINED') and 
type_score is null)); 
  
UPDATE `consequence` SET Type_score=6.0  
WHERE (`type`='UTR_5_PRIME' OR `type`='UTR_3_PRIME'); 
  
UPDATE `consequence` SET Type_score=7.0  
WHERE (`type`='UPSTREAM' OR `type`='DOWNSTREAM' OR 
`type`='SYNONYMOUS_STOP' 
OR `type`='EXON');  
  
#Add in field ‘type2_score’ (double, Nullable) to annotate intronic and synonymous variants 
with splice prediction 
UPDATE `consequence` c, `alamut_output_all` a SET c.`type2_score`=1  
WHERE c.`site_id`=a.`id` AND c.`gene_name`=a.`gene_name`; 
  
UPDATE `consequence` SET type_score=2.5 WHERE type2_score=1 AND (type_score=3 
OR type_score=4 OR type_score=5); 
 
#Filter for rare variants (Stage 1) 
 
#Create table of all rare variants 
CREATE TABLE `Variants_maf_005` SELECT `site_id`, `1kg_maf`, `evs_maf` FROM 
`site` WHERE (`site`.`1kg_maf` <0.005 OR `site`.`1kg_maf` IS NULL) AND 
(`site`.`evs_maf` <0.005 OR `site`.`evs_maf` IS NULL);  
 
#Add in field for gene_name (varchar, 255) to allow counting of genes with rare variants 
UPDATE `Variants_maf_005` v, `consequence` c  
SET v.`gene_name`=c.`gene_name` WHERE v.`site`=c.`site_id`; 







#Create table of all rare variants annotated with associated consequence and consequence 
score 
CREATE TABLE Variants_005_consequence SELECT 
 `Variants_maf_005`.`site_id` 
 , `Variants_maf_005`.`1kg_maf` 
 , `Variants_maf_005`.`evs_maf` 
 , `consequence`.`gene_name` 
 , `consequence`.`transcript` 
 , `consequence`.`type` 
 , `consequence`.`type_score` 
FROM `mopd_06_13`.`Variants_maf_005` 
INNER JOIN `mopd_06_13`.`consequence`  
ON (`Variants_maf_005`.`site_id` = `consequence`.`site_id`); 
  
#Filter for variants occurring in less than 6 families (Stage 1) 
 
#Create table with number of families site_id occurred in  









INNER JOIN `mopd_06_13`.`genotype`  
ON (`genotype`.`site_id` = `Variants_maf_005`.`site_id`) 
INNER JOIN `mopd_06_13`.`Pedigree_all`  
ON (`genotype`.`sample_id` = `Pedigree_all`.`sample_id`); 
  
#Count number of families in which each variant was identified  
CREATE VIEW occurance_count AS (SELECT site_id, COUNT(DISTINCT 
Pedigree_Name)  
FROM Variants_005_genotype GROUP BY site_id);    
  
#Select all rare variants occurring in less than 6 families 
CREATE TABLE occurance_count_under6FN SELECT *  
FROM `occurance_count` WHERE (`count(distinct Pedigree_Name)` <6);   
 
#Add in new field `site_count` (varchar, 5) to `Variants_005_consequence` and 
Variants_005_genotype tables and populate with occurrance scores 
UPDATE `Variants_005_consequence` g, `occurance_count_under6FN` o 
SET g.`site_count`=o.`COUNT(DISTINCT Pedigree_Name)` WHERE 
g.`site_id`=o.`site_id`; 
 
UPDATE `Variants_005_genotype` g, `occurance_count_under6FN` oSET 







#Select those with occurrance score of less than 6  
CREATE TABLE `Variants_005_6FN_consequence` 
SELECT * FROM `Variants_005_consequence` WHERE `site_count` IS NOT NULL; 
 
CREATE TABLE `Variants_005_6FN_genotype` 
SELECT * FROM `Variants_005_genotype` WHERE `site_count` IS NOT NULL; 
# index `site_id` in both tables using ‘Alter Table’ tool in SQLyog 
  
#Merg `Variants_005_6FN_genotype` and `Variants_005_6FN_consequence` tables to 
create table with fields required for further filtering 















INNER JOIN `mopd_06_13`.`Variants_005_6FN_genotype`  
ON (`Variants_005_6FN_consequence`.`site_id` = `Variants_005_6FN_genotype`.`site_id`); 
 
#Identify variants homozygous in unaffected individuals (Stage 1) 
 
#Create table of all homozygous variants occurring in unaffected samples 
CREATE TABLE HOM_variants_unaffected  
SELECT site_id FROM `Variants_005_6FN`  
WHERE `Affection_status`=1 AND genotype='1/1'; 
 
#Add in `Hom_unaffected` field (double, Nullable) to `Variants_005_6FN`  
UPDATE `Variants_005_6FN` h, `Hom_variants_unaffected` v  
SET h.`Hom_unaffected`=2 WHERE h.`site_id`=v.`site_id`; 
   
UPDATE `Variants_005_6FN` SET `Hom_unaffected`=1 WHERE `Hom_unaffected` IS 
NULL 
  
#Select deleterious variants (Stage 2) 
 
CREATE TABLE `Variants_all_deleterious` SELECT * FROM `Variants_005_6FN` 





Identifying mutations in known MPD and 1° MCPH genes 
#Create table of all rare, deleterious variants in known MPD and 1° MCPH genes in 
#affected samples 













    `mopd_06_13`.`Variants_all_deleterious ` 
    INNER JOIN `mopd_06_13`.`Teir1`  
        ON (`Variants_all_deleterious`.`gene_name` = `Teir1`.`Gene_name`) WHERE 
`Variants_all_deleterious`.`Affection_status`=2; 
 
#Manually review variants using IGV and Alamut and manually update diagnosis #field in 
`Pedigree_all` table with gene_name in which causal variants identified #(also insert 
diagnosis for all samples within the same pedigree) 
 
#Add `diagnosis` field (varchar, 255) to `Variants_all_deleterious` table and update #with 
diagnosis  
UPDATE `Variants_all_deleterious` v, `Pedigree_all` p SET v.`diagnosis`=p.`diagnosis` 
WHERE v.`pedigree_name`=p`Pedigree_name`; 
 
#Remove those where diagnosis identified 
CREATE TABLE `Variants_all_deleterious_unknown` SELECT * FROM 
`Variants_all_deleterious` WHERE `diagnosis` IS NULL;  
Mode of inheritance analysis 
#Add field `ped_count` (double, Nullable) to `Variants_all_deleterious_unknown` #and 
update to identify number of family members sequenced 
UPDATE `Variants_all_deleterious_unknown` v, `Pedigree_all` p SET 
v.`ped_count`=p.`ped_count` WHERE v.`pedigree_name`=p.`pedigree_name`; 
 
#Autosomal recessive analysis 
#Create individual tables of heterozygous and homozygous variants in all affected and 
unaffected samples 
CREATE TABLE `JM_Het_affected` SELECT * FROM 
`Variants_all_deleterious_unknown`  





CREATE TABLE `JM_Hom_affected` SELECT * FROM 
`Variants_all_deleterious_unknown` 
WHERE genotype='1/1' AND `Affection_status`=2;  
 
CREATE TABLE `JM_Het_unaffected` SELECT * FROM 
`Variants_all_deleterious_unknown`  
WHERE `genotype`!='1/1' AND `Affection_status`=1 ; 
 
CREATE TABLE `JM_Hom_unaffected` SELECT * FROM 
`Variants_all_deleterious_unknown` 
WHERE `genotype`='1/1' AND `Affection_status`=1;  
#Index all fields in above four tables 
 
#Count number of unique variants per gene per affected sample 
CREATE VIEW `HET_allele_count` AS  
(SELECT `Individual_ID`, gene_name, COUNT(DISTINCT site_id)  
FROM `JM_Het_affected` GROUP BY `Individual_ID`, gene_name ) ; 
 
#Select genes with more than one heterozygous variant present in affected individual 
CREATE TABLE `COMP_HET_allele` SELECT * FROM `HET_allele_count` WHERE 
`COUNT(DISTINCT site_id)`>1; 
  
#Create table of recessive heterozygous variants in affecteds 














FROM `JM_Het_affected`  
JOIN `COMP_HET_allele` ON `JM_Het_affected`.`individual_ID`= 
`COMP_HET_allele`.`Individual_ID`  
AND `JM_Het_affected`.`gene_name`= `COMP_HET_allele`.`gene_name`; 
 
#Create table of all recessive variants in affecteds  
CREATE TABLE `JM_recessive_affected`  
(SELECT * FROM `JM_COMP_HET_affected`)  
UNION ALL (SELECT * FROM `JM_Hom_affected`); 
 
#Create table of all recessive variants in singletons 
CREATE TABLE `JM_recessive_singletons_final` SELECT * FROM 






#Select only variants in common between sib pairs 
#Create table of all homozygous variants in pairs 
CREATE TABLE `JM_hom_sibs` SELECT * FROM `JM_hom_affected` WHERE 
(`ped_count`=2 OR `ped_count`=4); 
 
#Identify shared homozygous variants in pairs 
CREATE VIEW `JM_hom_sib_count` AS (SELECT `site_id`, `pedigree_name`, 
COUNT(DISTINCT `individual_ID`) FROM `JM_hom_sibs` GROUP BY `site_id`, 
`pedigree_name`); 
 
CREATE TABLE `JM_hom_sib_sites` SELECT * FROM `JM_hom_sib_count` WHERE 
`COUNT(DISTINCT `individual_ID`)`=2; 
 
#Create table of shared homozygous variants in pairs 














FROM `JM_hom_sibs`  
JOIN `JM_hom_sibs_sites` ON `JM_hom_sibs`.`site_id`= `JM_hom_sib_sites`.`site_id`  
AND `JM_hom_sibs`.`pedigree_name`= `JM_hom_sib_sites`.`pedigree_name`; 
 
#Create table of all heterozygous variants in pairs 
CREATE TABLE `JM_het_sibs` SELECT * FROM `JM_recessive_affected` WHERE 
(`ped_count`=2 OR `ped_count`=4) AND `genotype`!=’1/1’; 
 
#Identify shared heterozygous variants in pairs 
CREATE VIEW `JM_het_sib_count` AS (SELECT `site_id`, `pedigree_name`, 
`gene_name`, COUNT(DISTINCT `individual_ID`) FROM `JM_het_sibs` GROUP BY 
`site_id`, `pedigree_name`); 
 














#Create table of shared heterozygous variants in pairs 














FROM `JM_het_sibs`  
JOIN `JM_het_sibs_sites` ON `JM_het_sibs`.`site_id`= `JM_het_sib_sites`.`site_id`  
AND `JM_het_sibs`.`pedigree_name`= `JM_het_sib_sites`.`pedigree_name`; 
 
#Identify shared heterozygous variants in pairs where more than one variant per gene 
CREATE VIEW `JM_het_sib_gene_count` AS (SELECT `pedigree_name`, `gene_name`, 
COUNT(DISTINCT `site_id`) FROM `JM_het_sibs_sites` GROUP BY `pedigree_name`, 
`gene_name`); 
 
CREATE TABLE `JM_het_sib_common` SELECT * FROM `JM_het_sib_gene_count` 
WHERE `COUNT(DISTINCT `site_id`)`>1; 
 
#Create table of all shared recessive heterozygous variants in pairs 














FROM `JM_het_shared_pairs`   
JOIN JM_het_sib_common ON `JM_het_shared_pairs`.`pedigree_name`= 
`JM_het_sib_common`.`pedigree_name`  
AND `JM_het_shared_pairs`.`gene_name`= JM_het_sib_common`.`gene_name`; 
 
#Create table of all shared recessive variants in sibling pairs 
CREATE TABLE `JM_biallelic_pairs_final` (SELECT * FROM `JM_het_biallelc_pairs` 






#Identify biallelic homozygous variants in trios 
#Create table of all homozygous variants in affected of trio and heterozygous variants in 
parents 
CREATE TABLE JM_hom_trio (SELECT * FROM `JM_Hom_affected` WHERE 
`ped_count`=3) UNION ALL (SELECT * FROM `JM_Het_unaffected` WHERE 
`ped_count`=3); 
 
#Count number of family members in which each variant occurs and select those occurring 
in all three members 
CREATE VIEW `JM_hom_trio_count` AS (SELECT `site_id`, `pedigree_name`, 
COUNT(DISTINCT `individual_ID`) FROM `JM_hom_trio` GROUP BY `site_id`, 
`pedigree_name`); 
 
CREATE TABLE `JM_hom_trio_sites` SELECT * FROM `JM_hom_trio_count` WHERE 
`COUNT(DISTINCT `individual_ID`)`=3; 
 
#Create table of all homozygous biallelic variants in affected 














FROM `JM_hom_trio`  
JOIN `JM_hom_trio_sites` ON `JM_hom_trio`.`site_id`= `JM_hom_trio_sites`.`site_id`  
AND `JM_hom_trio`.`pedigree_name`= `JM_hom_trio_sites`.`pedigree_name` WHERE 
`JM_hom_trio`.`Affection_status`=2; 
 
#Identify biallelic heterozygous variants in trios 
#Create table of all heterozygous recessive variants in affecteds of trios and heterozygous 
variants in parents of trios 
CREATE TABLE `JM_het_trio` (SELECT * FROM `JM_COMP_HET_affected` WHERE 
`ped_count`=3) UNION ALL (SELECT * FROM `JM_Het_unaffected` WHERE 
`ped_count`=3); 
  
#Count number of family members in which each variant occurs and select those occurring 
in only two members  
CREATE VIEW `JM_het_trio_count` AS (SELECT `site_id`, `pedigree_name`, 
COUNT(DISTINCT `individual_ID`) FROM `JM_het_trio` GROUP BY `site_id`, 
`pedigree_name`); 
 






#Create table of all inherited heterozygous variants  














FROM `JM_het_trio`  
JOIN `JM_het_trio_sites` ON `JM_het_trio`.`site_id`= `JM_het_trio_sites`.`site_id`  
AND `JM_het_trio`.`pedigree_name`= `JM_het_trio_sites`.`pedigree_name`; 
  
#Create table listing genes in which inherited variants occur from both parents 
CREATE VIEW `trio_biallelic_genes` AS (SELECT DISTINCT `pedigree_name`, 
`gene_name`, COUNT(DISTINCT `individual_ID`)  
FROM `JM_het_interim_trio` GROUP BY `pedigree_name`, `gene_name`); 
  
CREATE TABLE `trio_biallelic_genes_t` SELECT * FROM `trio_biallelic_genes` WHERE 
`COUNT(DISTINCT individual_ID)`=3; 
  
#Create table of all heterozygous biallelic variants in affecteds in trios 




















#Create table of all biallelic variants in trios 
CREATE TABLE `JM_biallelic_trios_final` (SELECT * FROM `JM_het_biallelc_trios`) 





#Identify biallelic homozygous variants in quads 
#Create table of all shared homozygous variants in affected sibs of quad and heterozygous 
variants in parents 
CREATE TABLE JM_hom_quad (SELECT * FROM `JM_hom_biallelc_pairs` WHERE 
`ped_count`=4) UNION ALL (SELECT * FROM `JM_Het_unaffected` WHERE 
`ped_count`=4); 
 
#Count number of family members in which each variant occurs and select those occurring 
in all four members 
CREATE VIEW `JM_hom_quad_count` AS (SELECT `site_id`, `pedigree_name`, 
COUNT(DISTINCT `individual_ID`) FROM `JM_hom_quad` GROUP BY `site_id`, 
`pedigree_name`); 
 
CREATE TABLE `JM_hom_quad_sites` SELECT * FROM `JM_hom_quad_count` 
WHERE `COUNT(DISTINCT `individual_ID`)`=4; 
 
#Create table of all homozygous biallelic variants in affected 














FROM `JM_hom_quad`  
JOIN `JM_hom_quad_sites` ON `JM_hom_qad`.`site_id`= `JM_hom_quad_sites`.`site_id`  
AND `JM_hom_quad`.`pedigree_name`= `JM_hom_quad_sites`.`pedigree_name` where 
`JM_hom_quad`.`Affection_status`=2; 
 
#Identify biallelic heterozygous variants in quads 
#Create table of all shared heterozygous recessive variants in affecteds of quads and 
heterozygous variants in parents of quads 
CREATE TABLE `JM_het_quad` (SELECT * FROM `JM_het_biallelc_pairs` WHERE 
`ped_count`=4) UNION ALL (SELECT * FROM `JM_Het_unaffected` WHERE 
`ped_count`=4); 
  
#Count number of family members in which each variant occurs and select those occurring 
in only three members  
CREATE VIEW `JM_het_quad_count` AS (SELECT `site_id`, `pedigree_name`, 
COUNT(DISTINCT `individual_ID`) FROM `JM_het_quad` GROUP BY `site_id`, 
`pedigree_name`); 
 






#Create table of all inherited heterozygous variants  














FROM `JM_het_quad`  
JOIN `JM_het_quad_sites` ON `JM_het_quad`.`site_id`= `JM_het_quad_sites`.`site_id`  
AND `JM_het_quad`.`pedigree_name`= `JM_het_quad_sites`.`pedigree_name`; 
  
#Create table listing genes in which inherited variants occur from both parents 
CREATE VIEW `quad_biallelic_genes` AS (SELECT DISTINCT `pedigree_name`, 
`gene_name`, COUNT(DISTINCT `individual_ID`)  
FROM `JM_het_interim_quad` GROUP BY `pedigree_name`, `gene_name`); 
  
CREATE TABLE `quad_biallelic_genes_t` SELECT * FROM `quad_biallelic_genes` 
WHERE `COUNT(DISTINCT individual_ID)`=4; 
  
#Create table of all heterozygous biallelic variants in affecteds in quads 




















#Create table of all shared biallelic variants in quads 
CREATE TABLE `JM_biallelic_quad_final` (SELECT * FROM `JM_het_biallelc_quad`) 





#Merg all biallelic variant tables 
CREATE TABLE `JM_AR_final` SELECT * FROM 
`JM_recessive_singletons_final`; 
 
INSERT INTO `JM_AR_final` SELECT * FROM `JM_biallelic_pairs_final`; 
 
INSERT INTO `JM_AR_final` SELECT * FROM 
`JM_biallelic_trios_final`; 
 
INSERT INTO `JM_AR_final` SELECT * FROM 
`JM_biallelic_quads_final`; 
 
#Autosomal dominant (de novo) analysis 
 
#Create table of all possible autosomal dominant variants 
CREATE TABLE JM_AD_all_affected SELECT * FROM `JM_Het_affected` WHERE 
`1kg_maf` IS NULL and `evs_maf` IS NULL; 
 
#Create table of all AD variants in singletons 
CREATE TABLE `JM_AD_singletons` SELECT * FROM `JM_AD_all_affected` WHERE 
`ped_count`=1; 
 
#Create table of all AD variants in singletons where consequence score =1 
CREATE TABLE `JM_AD_singletons_1` SELECT * FROM `JM_AD_singletons` 
WHERE `type_score`=1; 
 
#Create table of all AD variants in affecteds in trios 
CREATE TABLE `JM_AD_trios` SELECT * FROM `JM_AD_all_affected` WHERE 
`ped_count`=3; 
 
#Create table of all novel variants in unaffecteds in trios 
CREATE TABLE `Variants_novel_trio_parents` SELECT * FROM 
`Variants_all_deleterious_unknown` WHERE (`1kg_maf` IS NULL AND `evs_maf` IS 
NULL AND `Affection_status`=1 AND `ped_count`=3); 
 
#Merg above two tables 
CREATE TABLE `Variants_all_trio` (SELECT * FROM `Variants_novel_trio_parents`) 
UNION ALL (SELECT * FROM `JM_AD_trios`); 
 
#Count number of family members in which each variant occurs 
CREATE VIEW `Trio_denovo_sites_count` AS 
(SELECT `site_id`, `pedigree_name`, COUNT(DISTINCT `Individual_id`) FROM 
`Variants_all_trio` GROUP BY `site_id`, `pedigree_name`); 
 
#Create table of variants which only occur in one trio member 









#Create table of de novo variants in affecteds of trios  
















INNER JOIN `mopd_06_13`. `Trio_denovo_sites` 
ON (`Variants_all_trio`.`site_id` = ` Trio_denovo_sites`.`site_id`) WHERE 
`Variants_all_trio`.`Affection_status`=2; 
 
#Create final table of all AD variants 
CREATE TABLE `JM_AD_final`  
(SELECT * FROM `JM_denovo`)  
UNION ALL (SELECT * FROM `JM_AD_singletons`)  
 
#X-linked recessive analysis 
 
#Create table of all variants in X chromosome 
CREATE TABLE `chrX_sites` SELECT `site_id` FROM `site` WHERE `chr`='chrX'; 
 
#Select all variants on ChrX present in affected in homozgous state 
















INNER JOIN `mopd_06_13`.`chrX_sites`  




#Add field `sex` (double, Nullable) to `JM_hom_affected_X` and populate with gender for 
each sample  
UPDATE `JM_hom_affected_X` j, `Pedigree_all` p SET j.`sex`=p.`sex` WHERE 
j.individual_ID=p.individual_ID; 
 
#Select all variants in affected males only (`sex`=1) 
DELETE FROM `JM_hom_affected_X` WHERE `sex`=2;  
 
#Select those in common between sib pair 
CREATE VIEW `JMpair_homXcommon` as (SELECT * from `JM_hom_affected_X` 
WHERE `ped_count`=2); 
 
CREATE VIEW `JMpair_homXcommon_count` AS (SELECT `site_id`, 
COUNT(DISTINCT individual_ID) FROM `JMpair_homXcommon` GROUP BY `site_id`); 
 
CREATE TABLE `JM_pairXvariants` SELECT `site_id` FROM 
`JMpair_homXcommon_count` WHERE `count(distinct individual_ID)`=2; 
 

















INNER JOIN `mopd_06_13`.`JM_pairXvariants`  
ON (`JM_hom_affected_X`.`site_id` = `JM_pairXvariants`.`site_id`); 
 
#Select those inherited from mother only in trios 
#Create table of all variants in unaffecteds in trios 
CREATE TABLE `Variants_all_trio_parents` SELECT * FROM 













#Change field names in `Variants_all_trio_parents` from `Individual_ID` to ` 
#Individual_IDp` and from `genotype` to `genotypep` using ‘Alter Table’ tool. 
#Select all variants on X chromosome in affected where also present in a parent 



















INNER JOIN `mopd_06_13`.`Variants_all_trio_parents`  
ON (`JM_hom_affected_X`.`site_id` = `Variants_all_trio_parents`.`site_id`) AND 
(`Variants_all_trio_parents`.`Pedigree_Name` = `JM_hom_affected_X`.`Pedigree_Name`); 
 
#Add in field `sexp` (double, Nullable) to `JM_Xtrios` and populate 
UPDATE `JM_Xtrios` j, `Pedigree_all` p SET j.`sexp`=p.`sex` WHERE 
j.`individual_Idp`=p.`individual_id`; 
 
#Remove all variants in affected present in father 
DELETE FROM `JM_Xtrios` WHERE `sexp`=1; 
 
#Remove all variants in affected where homozygous in the mother 
DELETE FROM `JM_Xtrios` WHERE `sexp`=2 and `genotype`='1/1'; 
 
#Create table of candidate variants in singletons  
CREATE TABLE `JM_Xfinal` SELECT * FROM `JM_hom_affected_X` WHERE 
`ped_count`=1; 
 
#Add results from pair and trio analysis to crate final table of possible X-linked recessive 
variants 
INSERT INTO `JM_Xfinal` SELECT * FROM `JM_pairX_final`; 







Identifying mutations in other known disease genes  
#To tables `JM_Xfinal`, `JM_AD_final` and `JM_AR_final` add in fields 
#`MIM_Morbid_Description` (varchar, 255) and `description` (varchar, 255)  
#Update new fields in each table with gene data and disease association from #ensemble 
database 
UPDATE `JM_AR_final` f, GeneDataBiomart g SET 
f.`MIM_Morbid_Description`=g.`MIM_Morbid_Description` AND 
f. `description`=g.`description` WHERE f.`gene_name`=g.`gene_name`; 
#Repeat for `JM_Xfinal` and `JM_AD_final` 
 
#Manually review variants with relevant disease association using IGV and Alamut #and 
manually update diagnosis field in `Pedigree_all` table with gene_name in #which causal 
variants identified 
 
#Update diagnosis field in final tables 
UPDATE `JM_AR_final` f, `Pedigree_all` p SET f.diagnosis=p.diagnosis WHERE 
f.`pedigree_name`=p.`pedigree_name` 
#Repeat for `JM_Xfinal` and `JM_AD_final` 
 
#Remove variants in families with diagnosis 
DELETE FROM `JM_AR_final` WHERE `diagnosis` IS NOT NULL; 
#Repeat for `JM_Xfinal` and `JM_AD_final` 
 
Prioritising remaining candidate genes 
#Remove variants in poorly mapped genes 
 



















INNER JOIN `mopd_06_13`.`Problem_genes`  
ON (`JM_AR_final`.`gene_name` = `Problem_genes`.`Gene`) WHERE 
`Problem_genes`.`Gene` IS NULL; 
#Repeat for `JM_Xfinal` and `JM_AD_final` 
283 
 
#Manually remove those functionally unrelated to growth 
 
#Select variants occurring in genes present in more than one family 
 
#Count number of families with variants in each gene 
CREATE VIEW JM_gene_pedigree_count AS (SELECT DISTINCT `gene_name, 
COUNT(DISTINCT pedigree_name) FROM JM_AR_minus_noisy_genes GROUP BY 
`gene_name`) 
#Repeat for `JM_X_minus_noisy_genes` and `JM_AD_minus_noisy_genes` 
 


















INNER JOIN `mopd_06_13`.` JM_gene_pedigree_count` ON 
(`JM_AR_minus_noisy_genes`.`gene_name` = `JM_gene_pedigree_count`.`gene_name`) 
WHERE `JM_gene_pedigree_count`.`COUNT(DISTINCT pedigree_name)`>1; 
#Repeat for `JM_X_minus_noisy_genes` and `JM_AD_minus_noisy_genes ` 
 
#Select genes where at least one variant has a consequence score=1. 
 
#Create table of genes from final tables where one variant has consequence score=1 
CREATE TABLE `Novel_AR_genes_1` SELECT DISTINCT `gene_name` FROM 
`JM_AR_minus_noisy_genes` WHERE `type_score`=1; 
















#Select variants in `Novel_AR_genes_1` 


















INNER JOIN `mopd_06_13`.`Novel_AR_genes_1` ON 
(`JM_AR_minus_noisy_genes`.`gene_name` = `Novel_AR_genes_1`.`gene_name`); 
#Repeat for `JM_X_minus_noisy_genes` and `JM_AD_minus_noisy_genes` joining on 
`Novel_X_genes_1` and `Novel_AD_genes_1` respectively 
CNV filtering 
All deleted regions with log2R below -0.7 from ExomeCNV analysis compiled into 
SQL database in table `JM_CNV_all` with the following fields: 
`chr` (varchar, 255) 
`start` (double) 
`end` (double) 
`patient` (varchar, 255) 
`parent` (varchar, 255) 
`diagnosis` (varchar, 255) 
#Index fields `patient`, `chr`, `start`, `end` in `JM_CNV_all` 
 
#Remove regions occurring in more than 3 patients 
 
CREATE VIEW `JM_CNV_count` AS (SELECT DISTINCT chr, `start`, `end`, 
COUNT(DISTINCT patient) FROM `JM_CNV_all` GROUP BY chr, `start`, `end`); 
CREATE TABLE `JM_CNV_count_less4` SELECT * FROM `JM_CNV_count` WHERE 
`count(distinct patient)` <4; 




















INNER JOIN `mopd_06_13`.`JM_CNV_all`  
ON (`JM_CNV_count_less4`.`chr` = `JM_CNV_all`.`chr`) AND 
(`JM_CNV_count_less4`.`start` = `JM_CNV_all`.`start`) AND 
(`JM_CNV_count_less4`.`end` = `JM_CNV_all`.`end`); 
#Select regions in patients without diagnosis 
 
CREATE TABLE `JM_CNV_rare_unknown` SELECT * FROM `JM_CNV_rare` WHERE 
diagnosis IS NULL; 
 
Appendix V: List of known MPD and 1° MCPH 
 









ataxia telangiectasia and Rad3 
related 
210600 
ENSG00000164053 ATRIP ATR interacting protein   
ENSG00000147044 CASK 
calcium/calmodulin-dependent 
serine protein kinase (MAGUK 
family) 
300749 
ENSG00000094804 CDC6 cell division cycle 6 613805 
ENSG00000136861 CDK5RAP2 




chromatin licensing and DNA 
replication factor 1  
613804 
ENSG00000151849 CENPJ centromere protein J  613676/608393 
ENSG00000174799 CEP135 centrosomal protein 135kDa 614673 
ENSG00000103995 CEP152 centrosomal protein 152kDa  614852/613823 
ENSG00000143702 CEP170 centrosomal protein 170kDa   
ENSG00000182923 CEP63 centrosomal protein 63kDa 614728 
ENSG00000149948 HMGA2 high mobility group AT-hook 2  611547 
ENSG00000017427 IGF1 
insulin-like growth factor 1 
(somatomedin C) 
608747 
ENSG00000140443 IGF1R insulin-like growth factor 1 receptor  270450 
ENSG00000167244 IGF2 




insulin-like growth factor 2 mRNA 

























complex component 7  
- 
ENSG00000147316 MCPH1 microcephalin 1 251200 
ENSG00000072864 NDE1 nudE neurodevelopment protein 1 614019 
ENSG00000085840 ORC1 








origin recognition complex, subunit 
6  
613803 
ENSG00000160299 PCNT pericentrin  210720 
ENSG00000142731 PLK4 polo-like kinase 4 - 
ENSG00000101773 RBBP8 retinoblastoma binding protein 8 606744 
ENSG00000264229 RNU4ATAC 
RNA, U4atac small nuclear (U12-
dependent splicing)  
- 
ENSG00000123473 STIL SCL/TAL1 interrupting locus 612703 
ENSG00000183763 TRAIP TRAF interacting protein  - 
ENSG00000075702 WDR62 WD repeat domain 62  604317 
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